{ "last_updated": "2026-10-07T23:43:05.471836+00:00", "count": 605, "agents": [ { "Therapeutic Agent": "140 Ml Per Day Of Beet-It Nitrate Beverage", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Fed, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=140%20Ml%20Per%20Day%20Of%20Beet-It%20Nitrate%20Beverage", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05618574", "title": "Nitrite Supplementation in Long COVID Patients", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-12-01", "completion_date": "2025-02-14", "primary_completion_date": "2025-02-12", "last_updated": "2026-08-26" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Fed", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "7-Day Ambulatory Caloric Restriction Intervention Using The Buchinger-Wilhelmi Method", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06522750", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=7-Day%20Ambulatory%20Caloric%20Restriction%20Intervention%20Using%20The%20Buchinger-Wilhelmi%20Method", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06522750", "title": "Periodic Fasting for Treatment of Long Covid in Adults: a Pilot Study", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-02-19", "completion_date": "2025-09-30", "primary_completion_date": "2025-06-30", "last_updated": "2025-03-30" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "A 3-Day Course", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05236465", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=A%203-Day%20Course", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05236465", "title": "A 3-day Course for CFS/ME", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-03-21", "completion_date": "2028-12-01", "primary_completion_date": "2027-01-01", "last_updated": "2025-11-26" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "A Course Of Individually Tailored Treatment By A Homeopath", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07694232", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=A%20Course%20Of%20Individually%20Tailored%20Treatment%20By%20A%20Homeopath", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07694232", "title": "A Pilot Randomized Controlled Trial of Homeopathic Treatment for Long COVID", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2026-07-15", "completion_date": "2028-12-01", "primary_completion_date": "2028-07-01", "last_updated": "2026-07-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "A.1 - [¹⁸F]F-Arag Pet/Ct", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07076862", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=A.1%20-%20[¹⁸F]F-Arag%20Pet/Ct", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07076862", "title": "Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)", "status": "RECRUITING", "phase": "EARLY_PHASE1", "size_category": "Medium (50-199 participants)", "start_date": "2025-12-04", "completion_date": "2029-12", "primary_completion_date": "2028-12", "last_updated": "2026-05-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "A.2 - [¹⁸F]F-Arag Pet/Ct", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07076862", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=A.2%20-%20[¹⁸F]F-Arag%20Pet/Ct", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07076862", "title": "Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)", "status": "RECRUITING", "phase": "EARLY_PHASE1", "size_category": "Medium (50-199 participants)", "start_date": "2025-12-04", "completion_date": "2029-12", "primary_completion_date": "2028-12", "last_updated": "2026-05-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Abrocitinib", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06597396", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Abrocitinib", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06597396", "title": "Study to Investigate the Efficacy of Abrocitinib in Adult Participants With Severe Fatigue From Post COVID Condition/Long COVID", "status": "ACTIVE_NOT_RECRUITING", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2024-12-27", "completion_date": "2026-09-30", "primary_completion_date": "2026-03-27", "last_updated": "2026-04-20" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Accelerated Intermittent Theta Burst Stimulation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06940609", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Accelerated%20Intermittent%20Theta%20Burst%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06940609", "title": "Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2025-07-07", "completion_date": "2029-06-30", "primary_completion_date": "2029-06-30", "last_updated": "2026-07-15" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Acceptance And Commitment Therapy", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Acceptance%20And%20Commitment%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT03562325", "title": "ACT for ME/CFS - an Open Case Trial", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2012-11-10", "completion_date": "2017-10-31", "primary_completion_date": "2017-10-31", "last_updated": "2018-06-19" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Acceptance Commitment Therapy For Chronic Fatigue", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05168124", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Acceptance%20Commitment%20Therapy%20For%20Chronic%20Fatigue", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05168124", "title": "Effectiveness of Acceptance Commitment Therapy or Micro Breaks in Patients with Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-08-08", "completion_date": "2026-07", "primary_completion_date": "2025-12", "last_updated": "2024-12-16" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Acetyl-L-Carnitine", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Acetyl-L-Carnitine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Scaturro 2022: no effect at 1g/day in PASC; acylcarnitines accumulate in PASC plasma (Guntur 2022) consistent with beta-oxidation transport bottleneck", "pub_date": "", "excerpt": "Scaturro 2022: no effect at 1g/day in PASC; acylcarnitines accumulate in PASC plasma (Guntur 2022) consistent with beta-oxidation transport bottleneck; included at 2g based on dose-response reasoning", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Actigraphy", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Actigraphy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04363606", "title": "Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability", "status": "TERMINATED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2020-05-27", "completion_date": "2022-03-01", "primary_completion_date": "2021-08-26", "last_updated": "2025-03-25" }, { "nct_id": "NCT03849326", "title": "Chronic Fatigue Etiology in Intensive Care Unit Survivors: the Role of Neuromuscular Function", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2023-12", "completion_date": "2025-04", "primary_completion_date": "2025-03", "last_updated": "2023-04-26" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Active", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Active", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04301609", "title": "Clinical Trial to Assess the Improvement of Fatigue, Sleep Problems, Anxiety / Depression, Neurovegetatives Alterations and Quality of Life ", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-11-10", "completion_date": "2023-01-31", "primary_completion_date": "2022-12-30", "last_updated": "2023-03-15" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Active Comparator: Usual Treatment", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Active%20Comparator:%20Usual%20Treatment", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05894629", "title": "Effects of an Active Coping Program in Patients With Persistent Post-Covid Pain.", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-02-20", "completion_date": "2023-09-30", "primary_completion_date": "2023-06-01", "last_updated": "2025-06-04" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Active Kinetic Oscillation Stimulation", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT03502044", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Active%20Kinetic%20Oscillation%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT03502044", "title": "New MRT Imaging Biomarkers and Treatment With Kinetic Oscillatory Stimulation (KOS) in Nasal Cavity for Myalgic Encephalomyelitis/Chronic Fa", "status": "UNKNOWN", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2018-04-17", "completion_date": "2020-06-15", "primary_completion_date": "2019-12-31", "last_updated": "2018-04-19" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Active Smell Training", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05855369", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Active%20Smell%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05855369", "title": "Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2023-10-02", "completion_date": "2028-05-31", "primary_completion_date": "2028-05-31", "last_updated": "2026-04-02" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Active Tdcs", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05092516", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Active%20Tdcs", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05092516", "title": "Home-based Brain Stimulation Treatment for Post-acute Sequelae of COVID-19 (PASC)", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-06-07", "completion_date": "2026-09-15", "primary_completion_date": "2025-03-13", "last_updated": "2026-07-17" }, { "nct_id": "NCT05589272", "title": "TDCS-potentiated Generalization of Cognitive Training in the Rehabilitation of Long COVID Symptoms", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2023-02-01", "completion_date": "2024-09-01", "primary_completion_date": "2023-09-01", "last_updated": "2023-03-13" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise", "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Active Tdcs And Cognitive Training", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Active%20Tdcs%20And%20Cognitive%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05389592", "title": "Treatment of COVID-19 Post-acute Cognitive Impairment Sequelae With tDCS", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-06-30", "completion_date": "2023-03-30", "primary_completion_date": "2022-11-30", "last_updated": "2024-08-27" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Active Transcutaneous Vns", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06170645", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Active%20Transcutaneous%20Vns", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06170645", "title": "Transcutaneous Vagus Nerve Stimulation as a Complementary Therapy to Exercise in Chronic Fatigue", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-10-03", "completion_date": "2028-08", "primary_completion_date": "2028-02", "last_updated": "2026-05-06" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise", "Medical Device" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Activity Pacing", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07697261", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Activity%20Pacing", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07697261", "title": "Fatigue in Long COVID", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2026-11", "completion_date": "2028-12", "primary_completion_date": "2028-12", "last_updated": "2026-07-13" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Acupressure", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Acupressure", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04435002", "title": "The Effect of Acupressure on Fatigue in Individuals With Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2020-05-09", "completion_date": "2021-02-01", "primary_completion_date": "2020-12-09", "last_updated": "2021-08-11" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Acupressure Treatment.", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Acupressure%20Treatment.", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02075489", "title": "Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2012-09", "completion_date": "2017-10", "primary_completion_date": "2017-10", "last_updated": "2017-10-10" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Acupuncture And Tcm-Based Lifestyle Management", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06042777", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Acupuncture%20And%20Tcm-Based%20Lifestyle%20Management", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06042777", "title": "Non-pharmacological and TCM-based Treatment for Long COVID Symptoms", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-09-30", "completion_date": "2024-08-31", "primary_completion_date": "2024-05-31", "last_updated": "2023-09-21" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Acupuncture.", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT01907711", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Acupuncture.", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01907711", "title": "Clinical Trial to Evaluate the Effectiveness of Acupuncture as a Treatment in Patients Diagnosed With CFS.", "status": "UNKNOWN", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2013-02", "completion_date": "2014-10", "primary_completion_date": "2014-01", "last_updated": "2013-08-29" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Acute Intermittent Hypoxia", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06614309", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Acute%20Intermittent%20Hypoxia", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06614309", "title": "Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-09-24", "completion_date": "2026-12", "primary_completion_date": "2026-12", "last_updated": "2026-06-05" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Acute Progressive Carbon Dioxide", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06614309", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Acute%20Progressive%20Carbon%20Dioxide", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06614309", "title": "Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-09-24", "completion_date": "2026-12", "primary_completion_date": "2026-12", "last_updated": "2026-06-05" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Adhera® Fatigue Digital Program", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Adhera®%20Fatigue%20Digital%20Program", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05631171", "title": "Feasibility Study of Adhera® Fatigue Digital Program for Patients With Long COVID-related Fatigue", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-12-13", "completion_date": "2023-06-30", "primary_completion_date": "2023-06-30", "last_updated": "2023-07-20" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Adhera® Fatigue For Long Covid Program", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Adhera®%20Fatigue%20For%20Long%20Covid%20Program", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05483829", "title": "Digital Health Intervention Based on Artificial Intelligence to Support the Personalized Recovery of Long COVID Patients Affected by Fatigue", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-08-01", "completion_date": "2022-08-28", "primary_completion_date": "2022-08-28", "last_updated": "2022-09-22" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Adipose Tissue Biopsy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05833217", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Adipose%20Tissue%20Biopsy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05833217", "title": "Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-06-06", "completion_date": "2025-12-31", "primary_completion_date": "2025-05-02", "last_updated": "2024-12-04" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Adipose Tissue Harvest", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05669261", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Adipose%20Tissue%20Harvest", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05669261", "title": "Treatment of Long COVID Symptoms Utilizing Autologous Stem Cells Following COVID-19 Infection", "status": "UNKNOWN", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2023-08-01", "completion_date": "2024-02-01", "primary_completion_date": "2023-12-31", "last_updated": "2023-06-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Advice Literature With Naturopathy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05289154", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Advice%20Literature%20With%20Naturopathy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05289154", "title": "Acupressure and Qigong in Chronic Fatigue Post COVID-19.", "status": "UNKNOWN", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2022-06-14", "completion_date": "2023-10-01", "primary_completion_date": "2023-09-01", "last_updated": "2023-01-23" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Aer002", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05877508", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Aer002", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05877508", "title": "Anti-SARS-CoV-2 Monoclonal Antibodies for Long COVID (COVID-19)", "status": "ACTIVE_NOT_RECRUITING", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-08-01", "completion_date": "2026-07-31", "primary_completion_date": "2024-07-29", "last_updated": "2025-10-28" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Amantadine", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Amantadine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06055244", "title": "Amantadine Therapy for Cognitive Impairment in Long COVID", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2023-12-07", "completion_date": "2025-12-29", "primary_completion_date": "2025-12-11", "last_updated": "2026-01-27" }, { "nct_id": "NCT06234462", "title": "A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid", "status": "WITHDRAWN", "phase": "PHASE2", "size_category": null, "start_date": "2025-06", "completion_date": "2025-10-01", "primary_completion_date": "2025-09-01", "last_updated": "2025-08-26" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Amphetamine-Dextroamphetamine", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Amphetamine-Dextroamphetamine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05597722", "title": "Addressing Cognitive Fog in Long-COVID-19 Patients", "status": "TERMINATED", "phase": "PHASE4", "size_category": "Small (<50 participants)", "start_date": "2023-04-04", "completion_date": "2023-05-18", "primary_completion_date": "2023-05-18", "last_updated": "2024-07-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Ampion", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ampion", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04880161", "title": "A Study to Evaluate Ampion in Patients With Prolonged Respiratory Symptoms Due to COVID-19 (Long COVID)", "status": "COMPLETED", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2021-07-26", "completion_date": "2022-02-21", "primary_completion_date": "2021-12-22", "last_updated": "2023-09-21" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Ampligen", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Sponsor Type: Industry, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ampligen", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00215800", "title": "The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE3", "size_category": "Large (200-999 participants)", "start_date": "1998-12", "completion_date": "2004-02", "primary_completion_date": "2004-02", "last_updated": "2013-04-17" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Amygdala Insula Retraining", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Fed, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05851846", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Amygdala%20Insula%20Retraining", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05851846", "title": "Amygdala Insula Retraining in the Management of Long COVID Symptoms", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-05-15", "completion_date": "2024-06-15", "primary_completion_date": "2024-05-15", "last_updated": "2023-05-10" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Fed", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Amygdala Retraining Program", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Amygdala%20Retraining%20Program", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01046370", "title": "A Pilot Study of Amygdala Retraining Program in Patients With Chronic Fatigue Syndrome, Chronic Fatigue and Fibromyalgia", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2009-10", "completion_date": "2011-05", "primary_completion_date": "2011-05", "last_updated": "2012-05-03" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Anakinra", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Anakinra", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02108210", "title": "Cytokine Inhibition in Chronic Fatigue Syndrome Patients", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2014-06", "completion_date": "2016-05", "primary_completion_date": "2015-12", "last_updated": "2016-05-25" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Anakinra 149 Mg/Ml Prefilled Syringe [Kineret]", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05926505", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Anakinra%20149%20Mg/Ml%20Prefilled%20Syringe%20[Kineret]", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05926505", "title": "Safety and Efficacy of Anakinra Treatment for Patients With Post Acute Covid Syndrome", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2023-09-06", "completion_date": "2028-03", "primary_completion_date": "2028-03", "last_updated": "2026-01-08" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Angiotensin Converting Enzyme Inhibitor", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Angiotensin%20Converting%20Enzyme%20Inhibitor", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04591210", "title": "The COVID-RASi Trial (COVID-19)", "status": "COMPLETED", "phase": "PHASE3", "size_category": "Large (200-999 participants)", "start_date": "2021-01-27", "completion_date": "2024-12-30", "primary_completion_date": "2024-12-30", "last_updated": "2026-01-28" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Angiotensin Ii Receptor Blockers", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Angiotensin%20Ii%20Receptor%20Blockers", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04591210", "title": "The COVID-RASi Trial (COVID-19)", "status": "COMPLETED", "phase": "PHASE3", "size_category": "Large (200-999 participants)", "start_date": "2021-01-27", "completion_date": "2024-12-30", "primary_completion_date": "2024-12-30", "last_updated": "2026-01-28" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Anhydrous Enol-Oxaloacetate, A \"Medical Food\"", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Anhydrous%20Enol-Oxaloacetate,%20A%20\"Medical%20Food\"", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05840237", "title": "REGAIN: RCT of Oxaloacetate for Fatigue in Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-06-01", "completion_date": "2025-01-30", "primary_completion_date": "2025-01-30", "last_updated": "2025-02-04" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Anktiva", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07123727", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Anktiva", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07123727", "title": "A Study to Examine Anktiva for the Treatment of COVID-19.", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2025-09-04", "completion_date": "2027-03", "primary_completion_date": "2027-03", "last_updated": "2026-09-24" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Antihistamines H1+H2", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 2 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Antihistamines%20H1+H2", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "29% symptom-free at 20 days; fatigue, tachycardia, abdominal symptoms significantly lower in treated group; not statistically significant (underpowere", "pub_date": "", "excerpt": "29% symptom-free at 20 days; fatigue, tachycardia, abdominal symptoms significantly lower in treated group; not statistically significant (underpowered)", "source": "PACVS Evidence Map" }, { "title": "Gradual symptom improvement over 4–16 weeks; gradual response argues against placebo; T cell alterations documented", "pub_date": "", "excerpt": "Gradual symptom improvement over 4–16 weeks; gradual response argues against placebo; T cell alterations documented", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Apa Program", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06170645", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Apa%20Program", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06170645", "title": "Transcutaneous Vagus Nerve Stimulation as a Complementary Therapy to Exercise in Chronic Fatigue", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-10-03", "completion_date": "2028-08", "primary_completion_date": "2028-02", "last_updated": "2026-05-06" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise", "Medical Device" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Applied Relaxation", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06235177", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Applied%20Relaxation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06235177", "title": "Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues", "status": "UNKNOWN", "phase": "EARLY_PHASE1", "size_category": "Small (<50 participants)", "start_date": "2024-10-10", "completion_date": "2025-09-19", "primary_completion_date": "2025-06-29", "last_updated": "2024-08-12" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Aripiprazole", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07714213", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Aripiprazole", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07714213", "title": "Post-acute Infectious Syndrome - Aripiprazole Symptom Evaluation (PAIS-AriSE)", "status": "NOT_YET_RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2026-10-01", "completion_date": "2028-12-31", "primary_completion_date": "2028-05-15", "last_updated": "2026-07-20" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Asarm", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other Gov, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Asarm", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02082730", "title": "The Feasibility, Acceptability and Clinical Utility of a New Remote-mobile Technology Intervention (ASARM) for CFS/ME in a Paediatric Popula", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2013-01", "completion_date": "2014-08-01", "primary_completion_date": "2014-08-01", "last_updated": "2018-12-04" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other Gov", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Aspirin", "Primary Conditions": [ "MCAS" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Aspirin", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "For prostaglandin-mediated MCAS (flushing, hypotension, PGD2 elevation); must be introduced in controlled setting — risk of triggering MC degranulatio", "pub_date": "", "excerpt": "For prostaglandin-mediated MCAS (flushing, hypotension, PGD2 elevation); must be introduced in controlled setting — risk of triggering MC degranulation; 81mg daily typical dose", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Assigned Interventions", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06404411", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Assigned%20Interventions", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06404411", "title": "The Efficacy of Aerobic Exercise in the Rehabilitation of Patients With COVID-19-Related Myocardial Injury", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-06-30", "completion_date": "2025-12-30", "primary_completion_date": "2025-06-30", "last_updated": "2024-05-13" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Atcell", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05669261", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Atcell", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05669261", "title": "Treatment of Long COVID Symptoms Utilizing Autologous Stem Cells Following COVID-19 Infection", "status": "UNKNOWN", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2023-08-01", "completion_date": "2024-02-01", "primary_completion_date": "2023-12-31", "last_updated": "2023-06-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Atorvastatin, 10Mg, 20Mg, 40Mg", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06974084", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Atorvastatin,%2010Mg,%2020Mg,%2040Mg", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06974084", "title": "A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the", "status": "NOT_YET_RECRUITING", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2026-07-15", "completion_date": "2027-05", "primary_completion_date": "2026-12-01", "last_updated": "2026-06-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Attention Training", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Attention%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06503874", "title": "Improving Attention in Individuals With Long COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-03-22", "completion_date": "2026-03-13", "primary_completion_date": "2026-03-13", "last_updated": "2026-04-02" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Auricular Transcutaneous Vagus Nerve Stimulation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Auricular%20Transcutaneous%20Vagus%20Nerve%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05679505", "title": "Vagus Nerve Stimulation for Post-COVID Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-10-27", "completion_date": "2023-01-04", "primary_completion_date": "2023-01-01", "last_updated": "2024-01-05" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Autonomic Function Testing", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Autonomic%20Function%20Testing", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00580619", "title": "Autonomic Nervous System and Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE1", "size_category": "Medium (50-199 participants)", "start_date": "2007-04", "completion_date": "2017-01", "primary_completion_date": "2017-01", "last_updated": "2017-01-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Axa1125", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Axa1125", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Significant improvement in physical and cognitive fatigue vs placebo at 4 weeks; validates beta-oxidation as therapeutic target in long COVID; not com", "pub_date": "", "excerpt": "Significant improvement in physical and cognitive fatigue vs placebo at 4 weeks; validates beta-oxidation as therapeutic target in long COVID; not commercially available", "source": "PACVS Evidence Map" } ], "trials": [ { "nct_id": "NCT05152849", "title": "Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2021-12-15", "completion_date": "2022-06-29", "primary_completion_date": "2022-06-21", "last_updated": "2022-10-20" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "B.1 - [¹⁸F]F-Arag Pet/Ct", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07076862", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=B.1%20-%20[¹⁸F]F-Arag%20Pet/Ct", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07076862", "title": "Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)", "status": "RECRUITING", "phase": "EARLY_PHASE1", "size_category": "Medium (50-199 participants)", "start_date": "2025-12-04", "completion_date": "2029-12", "primary_completion_date": "2028-12", "last_updated": "2026-05-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "B.2 - [¹⁸F]F-Arag Pet/Ct", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07076862", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=B.2%20-%20[¹⁸F]F-Arag%20Pet/Ct", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07076862", "title": "Multiparametric [18F]F-AraG Imaging in Post-Acute Sequelae of COVID-19 (PASC)", "status": "RECRUITING", "phase": "EARLY_PHASE1", "size_category": "Medium (50-199 participants)", "start_date": "2025-12-04", "completion_date": "2029-12", "primary_completion_date": "2028-12", "last_updated": "2026-05-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Balance Acceptance And Commitment Therapy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06231238", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Balance%20Acceptance%20And%20Commitment%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06231238", "title": "Balance Acceptance and Commitment Therapy for Long COVID", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-06-04", "completion_date": "2026-08-01", "primary_completion_date": "2026-05-30", "last_updated": "2026-07-02" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Baricitinib", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06631287", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Baricitinib", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06631287", "title": "Randomized Double-Blind Placebo-Controlled Trial EValuating Baricitinib on PERSistent NEurologic and Cardiopulmonary Symptoms of Long COVID", "status": "RECRUITING", "phase": "PHASE3", "size_category": "Large (200-999 participants)", "start_date": "2024-10-21", "completion_date": "2027-07-01", "primary_completion_date": "2026-11-01", "last_updated": "2026-09-25" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Baricitinib 4 Mg", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Baricitinib%204%20Mg", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05858515", "title": "REVERSE-Long COVID-19 With Baricitinib Study", "status": "WITHDRAWN", "phase": "PHASE3", "size_category": null, "start_date": "2024-10-21", "completion_date": "2029-12-30", "primary_completion_date": "2027-12-31", "last_updated": "2026-09-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [] }, { "Therapeutic Agent": "Basic/Low Tech Telerehabilitation Decision Support System", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06534164", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Basic/Low%20Tech%20Telerehabilitation%20Decision%20Support%20System", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06534164", "title": "Telerehabilitation of Balance Clinical and Economic Decision Support System", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2025-09-01", "completion_date": "2026-08-31", "primary_completion_date": "2026-06-30", "last_updated": "2025-07-10" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Behavioral", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Network, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06441955", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Behavioral", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06441955", "title": "Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.", "status": "RECRUITING", "phase": "PHASE4", "size_category": "Medium (50-199 participants)", "start_date": "2024-03-01", "completion_date": "2030-09-30", "primary_completion_date": "2030-09-30", "last_updated": "2024-11-27" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Network", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Bio 300 Oral Suspension", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT04482595", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Bio%20300%20Oral%20Suspension", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04482595", "title": "BIO 300 Oral Suspension in Previously Hospitalized Long COVID Patients", "status": "UNKNOWN", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2020-11-11", "completion_date": "2025-04-30", "primary_completion_date": "2024-07-31", "last_updated": "2024-10-01" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Bioarginina C", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT04947488", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Bioarginina%20C", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04947488", "title": "Evaluation of the Effects of Treatment With Bioarginin C in Adult Subjects Belonging to the Post-Covid Day Hospital", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-06-18", "completion_date": "2022-11-18", "primary_completion_date": "2022-09-18", "last_updated": "2022-05-17" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Biofeedback Training", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Biofeedback%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05793736", "title": "Prevention of Long Covid Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-02-02", "completion_date": "2023-10-30", "primary_completion_date": "2023-10-30", "last_updated": "2024-05-13" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Biopsychological", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Network, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06441955", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Biopsychological", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06441955", "title": "Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.", "status": "RECRUITING", "phase": "PHASE4", "size_category": "Medium (50-199 participants)", "start_date": "2024-03-01", "completion_date": "2030-09-30", "primary_completion_date": "2030-09-30", "last_updated": "2024-11-27" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Network", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Biopsychological Intervention", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Biopsychological%20Intervention", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02336126", "title": "Biopsychological Intervention in Chronic Fatigue Syndrome - a Pilot Study", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2014-10", "completion_date": "2015-01", "primary_completion_date": "2015-01", "last_updated": "2016-04-18" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Biosound Therapy System", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Biosound%20Therapy%20System", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05848401", "title": "Biosound Therapy as a Treatment for Long COVID Patients", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2021-04-29", "completion_date": "2022-01-19", "primary_completion_date": "2022-01-05", "last_updated": "2023-05-08" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Blood Collection", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Blood%20Collection", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05543590", "title": "Effect of Plasmapheresis on Clinical Improvement and Biological Parameters of Patients With Long-haul COVID", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2023-02", "completion_date": "2025-10", "primary_completion_date": "2025-02", "last_updated": "2023-08-14" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Blood Test", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Blood%20Test", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04363606", "title": "Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability", "status": "TERMINATED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2020-05-27", "completion_date": "2022-03-01", "primary_completion_date": "2021-08-26", "last_updated": "2025-03-25" }, { "nct_id": "NCT03849326", "title": "Chronic Fatigue Etiology in Intensive Care Unit Survivors: the Role of Neuromuscular Function", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2023-12", "completion_date": "2025-04", "primary_completion_date": "2025-03", "last_updated": "2023-04-26" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Brainhq", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Brainhq", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05965739", "title": "RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2023-09-01", "completion_date": "2024-12-17", "primary_completion_date": "2024-09-19", "last_updated": "2026-08-11" }, { "nct_id": "NCT05965752", "title": "RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2023-09-01", "completion_date": "2024-06-10", "primary_completion_date": "2024-06-10", "last_updated": "2025-07-18" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Brainhq/Active Comparator Activity", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Brainhq/Active%20Comparator%20Activity", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05965739", "title": "RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2023-09-01", "completion_date": "2024-12-17", "primary_completion_date": "2024-09-19", "last_updated": "2026-08-11" }, { "nct_id": "NCT05965752", "title": "RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2023-09-01", "completion_date": "2024-06-10", "primary_completion_date": "2024-06-10", "last_updated": "2025-07-18" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Breathe", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Breathe", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05107440", "title": "BREATHE: Virtual Self-management for Long COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-01-03", "completion_date": "2022-10-13", "primary_completion_date": "2022-06-20", "last_updated": "2022-12-14" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Breathing And Wellness Webinar", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Breathing%20And%20Wellness%20Webinar", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05139979", "title": "Yogic Breathing and Guided Meditation for Long Covid Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-09-15", "completion_date": "2024-02-07", "primary_completion_date": "2024-02-07", "last_updated": "2025-02-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Breathing Visualisation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Breathing%20Visualisation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06503913", "title": "Cognitive Muscular Therapy for Patients With Long-COVID and Breathing Pattern Disorder", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-08-01", "completion_date": "2026-03-01", "primary_completion_date": "2026-03-01", "last_updated": "2026-05-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Bright Light Therapy", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Bright%20Light%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06635928", "title": "Bright Light Therapy in ME/CFS Patients", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2021-01-01", "completion_date": "2024-03-25", "primary_completion_date": "2024-03-25", "last_updated": "2024-10-10" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Budesonide/Formoterol", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Immunomodulatory, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06597682", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Budesonide/Formoterol", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06597682", "title": "Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2025-03", "completion_date": "2027-07", "primary_completion_date": "2027-07", "last_updated": "2025-03-06" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Immunomodulatory", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Bupivacaine Injection", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Bupivacaine%20Injection", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05664711", "title": "Effect of Stellate Ganglion Block on ME/CFS", "status": "COMPLETED", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2023-03-15", "completion_date": "2024-01-15", "primary_completion_date": "2023-12-21", "last_updated": "2024-12-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Cardiac Coherence", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05851859", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cardiac%20Coherence", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05851859", "title": "Evaluation of the Effectiveness of Breathing Control Technique on Long COVID Symptoms at the Reunion University Hospital", "status": "RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2025-05-05", "completion_date": "2027-04", "primary_completion_date": "2026-11", "last_updated": "2026-09-14" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Cardiac Rehabilitation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cardiac%20Rehabilitation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05530317", "title": "CArdiac REhabilitation for Building Exertional heArt Rate for Chronotropic Incompetence in Long COVID-19", "status": "TERMINATED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-12-21", "completion_date": "2026-07-31", "primary_completion_date": "2026-07-31", "last_updated": "2026-08-13" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Cardio-Pulmonary Exercise Test", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cardio-Pulmonary%20Exercise%20Test", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06933017", "title": "Feasibility of an Augmented Two-Day Step Test and Causal Modeling for Post-Exertional Symptom Exacerbation in Post Covid-19 Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-03-20", "completion_date": "2025-07-03", "primary_completion_date": "2025-07-03", "last_updated": "2025-07-08" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Cardiopulmonary Exercise Test", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Nih, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cardiopulmonary%20Exercise%20Test", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02669212", "title": "Myalgic Encephalomyelitis Chronic Fatigue at the National Institutes of Health", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2016-10-10", "completion_date": "2022-01-11", "primary_completion_date": "2022-01-11", "last_updated": "2023-04-18" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Nih", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Cardiopulmonary Exercise Training", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cardiopulmonary%20Exercise%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05035628", "title": "Cardiopulmonary Rehabilitation in Long COVID-19 Patients With Persistent Breathlessness and Fatigue", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2021-09-15", "completion_date": "2023-05-31", "primary_completion_date": "2023-05-31", "last_updated": "2024-11-05" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Cardiopulmonary Rehabilitation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cardiopulmonary%20Rehabilitation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05539950", "title": "Cardiopulmonary Rehabilitation in Post-acute COVID-19 Syndrome", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2022-10-01", "completion_date": "2024-12-31", "primary_completion_date": "2024-10-31", "last_updated": "2025-03-26" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Care As Usual", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Care%20As%20Usual", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05703074", "title": "Mental Intervention and Nicotinamide Riboside Supplementation in Long Covid", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2023-01-30", "completion_date": "2025-06-23", "primary_completion_date": "2024-09-23", "last_updated": "2026-08-25" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Case Formulation With Web-Program", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT04532827", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Case%20Formulation%20With%20Web-Program", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04532827", "title": "Web-based Rehabilitation for Persistent Physical Symptoms.", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2020-08-18", "completion_date": "2023-09-30", "primary_completion_date": "2023-07-01", "last_updated": "2023-01-04" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Cbt", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cbt", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00920777", "title": "Survey and Cognitive Behavior Therapy for Chronic Fatigue Syndrome/Myalgic Encephalomyelitis", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2009-05", "completion_date": "2015-05", "primary_completion_date": "2014-07", "last_updated": "2020-06-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Cct Long Covid", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05582603", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cct%20Long%20Covid", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05582603", "title": "Safety and Dosage of a Computerized Cognitive Training Program for Cognitive Dysfunction After COVID-19", "status": "UNKNOWN", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2022-10-18", "completion_date": "2022-11-30", "primary_completion_date": "2022-11-30", "last_updated": "2022-10-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Celecoxib", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07597902", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Celecoxib", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07597902", "title": "SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction", "status": "NOT_YET_RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2026-06-01", "completion_date": "2028-06-30", "primary_completion_date": "2028-06-30", "last_updated": "2026-05-19" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Chinese Medicine Nutritional Supplement Cs4", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Chinese%20Medicine%20Nutritional%20Supplement%20Cs4", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06054438", "title": "Examining the Function of Cs4 on Post-COVID-19 Disorders", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-04-17", "completion_date": "2024-03-31", "primary_completion_date": "2024-03-31", "last_updated": "2024-07-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Chiropractic Adjustments", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Chiropractic%20Adjustments", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05693064", "title": "The Impact of Chiropractic on Long COVID-19", "status": "SUSPENDED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-01-15", "completion_date": "2025-08-01", "primary_completion_date": "2025-06-15", "last_updated": "2024-08-28" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Chlorella Pyrenoidosa", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06255600", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Chlorella%20Pyrenoidosa", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06255600", "title": "High-definition Transcranial Direct Current Stimulation and Chlorella Pyrenoidosa to Reduce Cardiovascular Risk", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-08-10", "completion_date": "2024-06-28", "primary_completion_date": "2024-06-28", "last_updated": "2024-03-05" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Ci-581A", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05690503", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ci-581A", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05690503", "title": "Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial", "status": "ACTIVE_NOT_RECRUITING", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-03-20", "completion_date": "2025-12-31", "primary_completion_date": "2025-06-30", "last_updated": "2024-07-16" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Ci-581B", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05690503", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ci-581B", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05690503", "title": "Glutamatergic Modulation as a Treatment for Depressive Symptoms Among Patients With Post-acute Sequelae of COVID (PASC): A Pilot Trial", "status": "ACTIVE_NOT_RECRUITING", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-03-20", "completion_date": "2025-12-31", "primary_completion_date": "2025-06-30", "last_updated": "2024-07-16" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Cicr-Nam", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07798570", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cicr-Nam", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07798570", "title": "Observational Study With CICR-NAM as a Food for Special Medicinal Purposes in Post-COVID Syndrome (PCS)", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2026-09-06", "completion_date": "2028-06-30", "primary_completion_date": "2028-06-30", "last_updated": "2026-09-01" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Citalopram", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT01154647", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Citalopram", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01154647", "title": "Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2010-09", "completion_date": "Unknown", "primary_completion_date": "2012-09", "last_updated": "2010-07-01" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Clinical Yoga", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06235177", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Clinical%20Yoga", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06235177", "title": "Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues", "status": "UNKNOWN", "phase": "EARLY_PHASE1", "size_category": "Small (<50 participants)", "start_date": "2024-10-10", "completion_date": "2025-09-19", "primary_completion_date": "2025-06-29", "last_updated": "2024-08-12" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Clonidine", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Clonidine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01040429", "title": "The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2010-02", "completion_date": "2012-11", "primary_completion_date": "2012-06", "last_updated": "2012-11-20" }, { "nct_id": "NCT01507701", "title": "Pilot Study for the NorCAPITAL Trial", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2010-01", "completion_date": "Unknown", "primary_completion_date": "2010-03", "last_updated": "2012-01-13" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise", "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA", "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)", "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Coenzyme Q10 (CoQ10)", "Primary Conditions": [ "Gulf War Illness", "Long COVID", "ME/CFS", "Other Post-Viral (Post-infectious cough, Q-fever fatigue syndrome, Post-dengue fatigue, Chikungunya post-infectious, Parvovirus B19 GBS, Mycoplasma pneumoniae neurological, Herpes encephalitis sequelae, RIME, etc.)", "POTS" ], "Proposed Mechanism": "Anti-inflammatory, Enrollment: Actual, Enrollment: Estimated, Immunomodulatory", "Evidence Level": "Preliminary", "Key Studies / References": [ "PMID:41009608", "PMID:41640426" ], "Ongoing Research": "NCT06597682", "Clinical Notes": "Mitochondrial support, fatigue data in ME/CFS. 100-300mg ubiquinol. Very safe; consider with statins or low intake. Common in supportive regimens.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/compound/5281915", "Safety": "Very safe; mild GI upset rare. May interact with warfarin (monitor INR). Ubiquinol form preferred for absorption.", "Dosing": "100–300 mg/day (often 200 mg); 8–12+ weeks in fatigue studies.", "aliases": [ "Coenzyme Q10 (CoQ10)" ], "studies": [ { "pmid": "41009608", "title": "Gulf War Illness, Fibromyalgia, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID Overlap in Common Symptoms and Underlying ", "pub_date": "2025-09-27", "excerpt": "Although Gulf War Illness (GWI), fibromyalgia (FM), myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and long COVID have distinct origins, in this article we have reviewed evidence that these disorders comprise a group of so-called low-energy associated disorders with overlapping common s...", "source_page": "gulf-war-illness" }, { "pmid": "41640426", "title": "Case Report: A case of post-viral inflammatory insomnia: observed sleep restoration associated with histamine-targeted interventions and imp", "pub_date": "2026-02-05", "excerpt": "Mast cell-mediated inflammation has been proposed as a potential contributor to neuroinflammatory insomnia and dysautonomia, but objective clinical documentation remains limited. Histamine and related immune mediators can disrupt circadian rhythm, arousal systems, and autonomic stability. Convention...", "source_page": "other-post-viral" } ], "trials": [ { "nct_id": "NCT06597682", "title": "Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2025-03", "completion_date": "2027-07", "primary_completion_date": "2027-07", "last_updated": "2025-03-06" }, { "nct_id": "NCT03186027", "title": "Coenzyme Q10 Plus NADH Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2017-06-28", "completion_date": "2021-09-01", "primary_completion_date": "2020-05-28", "last_updated": "2022-09-21" }, { "nct_id": "NCT05128292", "title": "Effect of CoQ10 Plus Selenium Supplementation on Clinical Outcomes and Biochemical Markers in ME/CFS (CoSeME Study)", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2018-01-01", "completion_date": "2018-11-30", "primary_completion_date": "2018-09-01", "last_updated": "2021-11-19" }, { "nct_id": "NCT02063126", "title": "Clinical Trial to Measure the Maximun HR After ReConnect ® Supplementation vs. Placebo in CFS.", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2013-01", "completion_date": "2013-12", "primary_completion_date": "2013-01", "last_updated": "2015-02-19" } ], "total_mentions": 6, "types": [ "Behavioral / Protocol / Exercise", "Supplement / Nutraceutical" ], "mechanisms": [ "Anti-inflammatory", "Enrollment: Actual", "Enrollment: Estimated", "Immunomodulatory", "Metabolic / Mitochondrial", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA", "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)", "Medium (50-199 participants)", "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Cognifit'S Cct Post Covid-19", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cognifit'S%20Cct%20Post%20Covid-19", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05571852", "title": "Personalized Computerized Training Program for Cognitive Dysfunction After COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-12-01", "completion_date": "2022-02-28", "primary_completion_date": "2022-02-28", "last_updated": "2022-10-07" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Cognitive Behavior Therapy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cognitive%20Behavior%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05770193", "title": "Effect of Kinesio Tape Versus Diaphragmatic Breathing Exercise In Post COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-03-11", "completion_date": "2023-11-30", "primary_completion_date": "2023-08-30", "last_updated": "2023-12-05" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Cognitive Behavioral Therapy", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cognitive%20Behavioral%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00540254", "title": "Behavioral Insomnia Therapy With Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2007-09", "completion_date": "2010-07", "primary_completion_date": "2010-07", "last_updated": "2013-03-01" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Cognitive Behavioural Therapy", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cognitive%20Behavioural%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00860236", "title": "Giardia Induced Fatigue and Functional Gastrointestinal Diseases", "status": "COMPLETED", "phase": "PHASE4", "size_category": "Small (<50 participants)", "start_date": "2009-03", "completion_date": "2010-06", "primary_completion_date": "2010-06", "last_updated": "2017-03-03" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Cognitive Muscular Therapy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cognitive%20Muscular%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06503913", "title": "Cognitive Muscular Therapy for Patients With Long-COVID and Breathing Pattern Disorder", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-08-01", "completion_date": "2026-03-01", "primary_completion_date": "2026-03-01", "last_updated": "2026-05-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Cognitive Rehabilitation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05731570", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cognitive%20Rehabilitation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05676047", "title": "Cognitive Rehabilitation for Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-05-01", "completion_date": "2025-01-21", "primary_completion_date": "2025-01-21", "last_updated": "2025-01-23" }, { "nct_id": "NCT05731570", "title": "Cognitive Rehabilitation for People With Cognitive Covid19", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-02-14", "completion_date": "2024-09", "primary_completion_date": "2024-07", "last_updated": "2024-06-21" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Cognitive Rehabilitation Workshops", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cognitive%20Rehabilitation%20Workshops", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07184398", "title": "Use of a Cysteine-rich Whey Protein Isolate in Post COVID-19 Cognitive Impairment", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-07-01", "completion_date": "2025-01-01", "primary_completion_date": "2024-09-30", "last_updated": "2025-09-24" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Cognitive Screening", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other Gov", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06391970", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cognitive%20Screening", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06391970", "title": "Digital Cognition Study During Long-COVID", "status": "UNKNOWN", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2023-04-15", "completion_date": "2025-09-30", "primary_completion_date": "2024-08-01", "last_updated": "2024-04-30" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other Gov" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Cognitive Training", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06074848", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cognitive%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06074848", "title": "tDCS in the Management of Post-COVID Disorders", "status": "UNKNOWN", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-08-25", "completion_date": "2024-09-28", "primary_completion_date": "2024-07-01", "last_updated": "2024-04-24" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Cognitive-Behavioral Self-Management", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cognitive-Behavioral%20Self-Management", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00997451", "title": "Fatigue Self-Management in Primary Care", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2009-02", "completion_date": "2011-12", "primary_completion_date": "2011-12", "last_updated": "2012-10-01" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Cold Water Hydrotherapy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07110714", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cold%20Water%20Hydrotherapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07110714", "title": "Effects of Kneipp Hydrotherapy in Post-COVID-19 Patients", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-12-01", "completion_date": "2027-10-31", "primary_completion_date": "2027-01-31", "last_updated": "2025-12-02" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Combined Metabolic Modulator", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Metabolic / Mitochondrial, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06967428", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Combined%20Metabolic%20Modulator", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06967428", "title": "Effect of Metabolic Modulation on a Post-acute COVID-19 Vaccination Syndrome (PACVS) Cohort", "status": "NOT_YET_RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2025-09-01", "completion_date": "2026-01", "primary_completion_date": "2026-01", "last_updated": "2025-05-13" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Metabolic / Mitochondrial", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Combined Treatment: Heart Rhythm Biofeedback Plus Hydrogen Water", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05397626", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Combined%20Treatment:%20Heart%20Rhythm%20Biofeedback%20Plus%20Hydrogen%20Water", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05397626", "title": "Biofeedback and Hydrogen Water as Treatments for Chronic Fatigue Syndrome", "status": "UNKNOWN", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2022-05-23", "completion_date": "2023-05-23", "primary_completion_date": "2023-05-23", "last_updated": "2022-05-31" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Common Moxa-Stick Moxibustion", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT02964533", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Common%20Moxa-Stick%20Moxibustion", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02964533", "title": "Thunder-Fire Moxibustion Therapy for Chronic Fatigue Syndrome on Shenque Acupoint: a Randomized Controlled Trial", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2016-11", "completion_date": "Unknown", "primary_completion_date": "2017-02", "last_updated": "2016-11-16" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Compensatory Cognitive Training For Covid-19", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Fed", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06086379", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Compensatory%20Cognitive%20Training%20For%20Covid-19", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06086379", "title": "Cognitive Rehabilitation Therapy for COVID-19", "status": "ENROLLING_BY_INVITATION", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-07-01", "completion_date": "2029-03-31", "primary_completion_date": "2027-06-30", "last_updated": "2026-07-15" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Fed" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Compound Ciwujia Granules, Guipi Granules", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Compound%20Ciwujia%20Granules,%20Guipi%20Granules", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06245642", "title": "Compound Ciwujia Granules Treat Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE4", "size_category": "Large (200-999 participants)", "start_date": "2024-03-19", "completion_date": "2025-01-16", "primary_completion_date": "2025-01-16", "last_updated": "2025-09-23" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Comprehensive Rehabilitation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Comprehensive%20Rehabilitation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06156202", "title": "Evaluating a Comprehensive Multimodal Outpatient Rehabilitation Program for PASC Program to Improve Functioning of Persons Suffering From Po", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-11-15", "completion_date": "2025-11-30", "primary_completion_date": "2025-11-30", "last_updated": "2026-01-20" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Comprehensive Theocentric Psychological Assessment", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06235177", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Comprehensive%20Theocentric%20Psychological%20Assessment", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06235177", "title": "Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues", "status": "UNKNOWN", "phase": "EARLY_PHASE1", "size_category": "Small (<50 participants)", "start_date": "2024-10-10", "completion_date": "2025-09-19", "primary_completion_date": "2025-06-29", "last_updated": "2024-08-12" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Concurrent Training", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Concurrent%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05204511", "title": "Exercise and Post-COVID/ Long-COVID: Effects of Different Training Modalities on Various Parameters in People Affected by the Sequelae of CO", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-02-10", "completion_date": "2023-05-31", "primary_completion_date": "2023-05-31", "last_updated": "2023-07-19" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Conventional Exercise", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06978582", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Conventional%20Exercise", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06978582", "title": "Effectiveness and Safety of a Tele-Rehabilitation Program on Fatigue and Related Variables in Chronic Fatigue Syndrome and Post COVID Syndro", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-10-01", "completion_date": "2027-03-30", "primary_completion_date": "2026-12-30", "last_updated": "2026-04-28" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Conventional Physiotherapy", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Network, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07242573", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Conventional%20Physiotherapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07242573", "title": "Effect of Physical Exercise and Neuromodulation on Pain, Sleep and Fatigue in Patients With Fibromyalgia", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-11-01", "completion_date": "2027-12-15", "primary_completion_date": "2027-02-20", "last_updated": "2026-02-24" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Network", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Conventional Rehabilitation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06404411", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Conventional%20Rehabilitation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06404411", "title": "The Efficacy of Aerobic Exercise in the Rehabilitation of Patients With COVID-19-Related Myocardial Injury", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-06-30", "completion_date": "2025-12-30", "primary_completion_date": "2025-06-30", "last_updated": "2024-05-13" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Coordinated Care", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Immunomodulatory, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Coordinated%20Care", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06305793", "title": "RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2024-05-08", "completion_date": "2026-06-22", "primary_completion_date": "2026-03-23", "last_updated": "2026-07-31" }, { "nct_id": "NCT06305806", "title": "RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2024-03-11", "completion_date": "2025-12-17", "primary_completion_date": "2025-10-13", "last_updated": "2026-02-20" } ], "total_mentions": 2, "types": [ "Biologic / Immunotherapy", "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Immunomodulatory", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)", "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Coperia-Rehab", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05629884", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Coperia-Rehab", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05629884", "title": "Efficacy of a Physical and Respiratory Rehabilitation Program for Patients With Persistent COVID-19 (SARS-CoV-2).", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-12-14", "completion_date": "2023-11-14", "primary_completion_date": "2023-11-14", "last_updated": "2022-11-29" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Coronary Functional Test", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07559994", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Coronary%20Functional%20Test", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07559994", "title": "Diagnostic and Clinical Management of Non-Obstructive Myocardial Ischemia in Patients With Long Covid-19 Syndrome and New Onset Chest Pain", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-09-02", "completion_date": "2026-06-30", "primary_completion_date": "2025-04-30", "last_updated": "2026-05-28" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Covid Rehab Formula Granules", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Covid%20Rehab%20Formula%20Granules", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04924881", "title": "Chinese Medicine for Patients With LCOVID-19 Symptoms", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2021-07-02", "completion_date": "2022-10-03", "primary_completion_date": "2022-10-03", "last_updated": "2026-07-27" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Covidex", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06156176", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Covidex", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06156176", "title": "Pursuing Reduction in Fatigue After COVID-19 Via Exercise and Rehabilitation (PREFACER): A Randomized Feasibility Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-04-01", "completion_date": "2026-04-01", "primary_completion_date": "2026-04-01", "last_updated": "2025-08-01" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Covidreapp Group", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05725538", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Covidreapp%20Group", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05725538", "title": "Exercise Intervention Using mHealth in Patients With Post-Acute COVID-19 Syndrome: a Randomized Clinical Trial", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-03-15", "completion_date": "2024-09-15", "primary_completion_date": "2024-03-15", "last_updated": "2023-02-13" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Creatine", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT02374112", "Clinical Notes": "Creatine monohydrate 5g daily. RCT evidence (d~1) for mental fatigue and concentration in PASC. Mitochondrial support. Safe for most; monitor renal and fluid retention.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Creatine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02374112", "title": "Creatine Supplementation in Chronic Fatigue Syndrome", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2016-01", "completion_date": "2025-12", "primary_completion_date": "2025-12", "last_updated": "2025-05-23" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Creatine Monohydrate", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06992414", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Creatine%20Monohydrate", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Mental fatigue d=1.02 (6mo); concentration d=1.19–2.46 (note: n=6 inflates effect sizes); 2026 RCT: fatigue −2.05 points p=0.005; ATP buffering + neur", "pub_date": "", "excerpt": "Mental fatigue d=1.02 (6mo); concentration d=1.19–2.46 (note: n=6 inflates effect sizes); 2026 RCT: fatigue −2.05 points p=0.005; ATP buffering + neuroprotection mechanism", "source": "PACVS Evidence Map" } ], "trials": [ { "nct_id": "NCT06992414", "title": "Exploring the Therapeutic Effects of Creatine Supplementation for Long COVID-19", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-07-02", "completion_date": "2026-10-31", "primary_completion_date": "2026-06-30", "last_updated": "2025-05-31" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Cromolyn Sodium", "Primary Conditions": [ "MCAS" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cromolyn%20Sodium", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Primarily for GI symptoms; mast cell stabiliser; 200mg 4x daily before meals; 4–8 week onset before judging effect; poor systemic absorption but GI be", "pub_date": "", "excerpt": "Primarily for GI symptoms; mast cell stabiliser; 200mg 4x daily before meals; 4–8 week onset before judging effect; poor systemic absorption but GI benefit reported", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Ct38", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ct38", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT03613129", "title": "Clinical Trial to Investigate CT38 in the Treatment of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2018-07-23", "completion_date": "2019-04-30", "primary_completion_date": "2019-04-30", "last_updated": "2020-05-12" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Curcumin", "Primary Conditions": [ "Gulf War Illness" ], "Proposed Mechanism": "Unknown / General", "Evidence Level": "Anecdotal", "Key Studies / References": [ "PMID:42347851" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Curcumin", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [ "Curcumin" ], "studies": [ { "pmid": "42347851", "title": "The comparative ameliorating effects of an amorphous formula of curcumin and α-glycosyl isoquercitrin on hippocampal dysfunction in a rat gu", "pub_date": "2026-06-25", "excerpt": "Brain dysfunction is a primary symptom of Gulf War illness (GWI). The present study investigated the effects of an amorphous formula of curcumin (CUR) and α-glycosyl isoquercitrin (AGIQ) on neurobehaviors and adult neurogenesis and following synaptic plasticity of produced neurons in the hippocampal...", "source_page": "gulf-war-illness" } ], "trials": [], "total_mentions": 1, "types": [ "Supplement / Nutraceutical" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Cycle Ergometer Stress Test", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cycle%20Ergometer%20Stress%20Test", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05543590", "title": "Effect of Plasmapheresis on Clinical Improvement and Biological Parameters of Patients With Long-haul COVID", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2023-02", "completion_date": "2025-10", "primary_completion_date": "2025-02", "last_updated": "2023-08-14" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Cycling", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cycling", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07454395", "title": "Is Swimming a More Tolerable Form of Movement for Individuals With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome?", "status": "SUSPENDED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2026-02-20", "completion_date": "2027-06", "primary_completion_date": "2027-01", "last_updated": "2026-03-30" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Cyclophosphamide", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Cyclophosphamide", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02444091", "title": "Cyclophosphamide in Myalgic Encephalopathy/ Chronic Fatigue Syndrome (ME/CFS)", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2015-03", "completion_date": "2019-12-06", "primary_completion_date": "2019-12-06", "last_updated": "2021-05-11" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Daoib", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05764538", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Daoib", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05764538", "title": "DAOIB for the Treatment of Brain Fog", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-02-27", "completion_date": "2026-06", "primary_completion_date": "2026-06", "last_updated": "2026-03-19" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Dapagliflozin", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06907251", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Dapagliflozin", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06907251", "title": "Dapagliflozin for Long COVID Syndrome", "status": "NOT_YET_RECRUITING", "phase": "PHASE3", "size_category": "Medium (50-199 participants)", "start_date": "2026-09-01", "completion_date": "2029-06-30", "primary_completion_date": "2028-06-30", "last_updated": "2026-07-01" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Decompartmentalization Framework", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06235177", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Decompartmentalization%20Framework", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06235177", "title": "Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues", "status": "UNKNOWN", "phase": "EARLY_PHASE1", "size_category": "Small (<50 participants)", "start_date": "2024-10-10", "completion_date": "2025-09-19", "primary_completion_date": "2025-06-29", "last_updated": "2024-08-12" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Delayed Cbt", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT01096641", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Delayed%20Cbt", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01096641", "title": "An Explorative Study on Physiological and Neurophysiological Determinants of Fatigue in Cancer Survivors", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2010-04", "completion_date": "2012-10", "primary_completion_date": "2012-09", "last_updated": "2012-06-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Desmopressin", "Primary Conditions": [ "POTS" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Crossover RCT n=30: no HR change but reduced symptom score. Risk of hyponatremia/nocturia. Limited role for select POTS.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Desmopressin", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Did not change HR increment but significantly reduced symptom burden score (VOSS 13 vs 19; p=0.009); nocturia risk at higher doses", "pub_date": "", "excerpt": "Did not change HR increment but significantly reduced symptom burden score (VOSS 13 vs 19; p=0.009); nocturia risk at higher doses", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Device", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Device", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05817006", "title": "Research of the Long-COVID-19 Syndrome in the Children", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-04-16", "completion_date": "2024-12-31", "primary_completion_date": "2024-04-30", "last_updated": "2025-01-23" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Diaphragmatic Breathing Exercise", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Diaphragmatic%20Breathing%20Exercise", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05770193", "title": "Effect of Kinesio Tape Versus Diaphragmatic Breathing Exercise In Post COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-03-11", "completion_date": "2023-11-30", "primary_completion_date": "2023-08-30", "last_updated": "2023-12-05" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Diaphragmatic Breathing Exercises", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Diaphragmatic%20Breathing%20Exercises", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07621588", "title": "Diaphragmatic Breathing Exercises With KOTS Currents in Patients With Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-06-14", "completion_date": "2026-08-07", "primary_completion_date": "2026-07-31", "last_updated": "2026-09-29" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Diaphragmatic Electrostimulation Using Kots Currents", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Diaphragmatic%20Electrostimulation%20Using%20Kots%20Currents", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07621588", "title": "Diaphragmatic Breathing Exercises With KOTS Currents in Patients With Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-06-14", "completion_date": "2026-08-07", "primary_completion_date": "2026-07-31", "last_updated": "2026-09-29" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Dietary And Lifestyle Recommendations", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07627815", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Dietary%20And%20Lifestyle%20Recommendations", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07627815", "title": "Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2026-05-20", "completion_date": "2026-12-26", "primary_completion_date": "2026-08-26", "last_updated": "2026-06-04" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Dietary Intervention To Mitigate Post-Acute Covid-19 Syndrome", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05977179", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Dietary%20Intervention%20To%20Mitigate%20Post-Acute%20Covid-19%20Syndrome", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05977179", "title": "Dietary Intervention to Mitigate Post-Acute COVID-19 Syndrome", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-05-12", "completion_date": "2028-09-30", "primary_completion_date": "2028-06-30", "last_updated": "2026-06-23" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Dietary Supplement: Experimental", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Dietary%20Supplement:%20Experimental", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06013072", "title": "Pre-probiotic Supplementation for Post-covid Fatigue Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-10-01", "completion_date": "2024-01-15", "primary_completion_date": "2023-12-31", "last_updated": "2024-02-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Dietary Supplements", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06235177", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Dietary%20Supplements", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06235177", "title": "Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues", "status": "UNKNOWN", "phase": "EARLY_PHASE1", "size_category": "Small (<50 participants)", "start_date": "2024-10-10", "completion_date": "2025-09-19", "primary_completion_date": "2025-06-29", "last_updated": "2024-08-12" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Digital Cognitive Behavioral Intervention-Rxwell", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Digital%20Cognitive%20Behavioral%20Intervention-Rxwell", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05597722", "title": "Addressing Cognitive Fog in Long-COVID-19 Patients", "status": "TERMINATED", "phase": "PHASE4", "size_category": "Small (<50 participants)", "start_date": "2023-04-04", "completion_date": "2023-05-18", "primary_completion_date": "2023-05-18", "last_updated": "2024-07-22" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Digital Physiotherapy Practice", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT04742946", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Digital%20Physiotherapy%20Practice", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04742946", "title": "Digital Physiotherapy Practice in Long Covid-19 Patients", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2021-12-15", "completion_date": "2022-12-30", "primary_completion_date": "2022-12-30", "last_updated": "2022-11-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Dpa-714 Pet/Mri", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Anti-inflammatory, Enrollment: Estimated, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT03759522", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Dpa-714%20Pet/Mri", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT03759522", "title": "Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714.", "status": "RECRUITING", "phase": "PHASE1", "size_category": "Medium (50-199 participants)", "start_date": "2019-02-03", "completion_date": "2028-04", "primary_completion_date": "2028-04", "last_updated": "2026-06-02" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Anti-inflammatory", "Enrollment: Estimated", "Sponsor Type: Other" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Droxidopa", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Droxidopa", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00977171", "title": "Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome", "status": "TERMINATED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2010-07", "completion_date": "2011-10", "primary_completion_date": "2011-10", "last_updated": "2014-06-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Dual Task Exercise", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07254377", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Dual%20Task%20Exercise", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07254377", "title": "Design and Validation of Innovative Strategies Based on Dual-Task Approach", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-11-01", "completion_date": "2027-02-28", "primary_completion_date": "2026-03-30", "last_updated": "2025-12-11" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Duloxetine", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Duloxetine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00375973", "title": "Double Blind Trial of Duloxetine in Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2006-09", "completion_date": "2014-03", "primary_completion_date": "2012-06", "last_updated": "2015-08-21" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Dynamic Neural Retraining System", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06933173", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Dynamic%20Neural%20Retraining%20System", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06933173", "title": "RCT of Mind-body in Long COVID and Myalgic Encephalomyelitis", "status": "RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2025-07-10", "completion_date": "2028-03", "primary_completion_date": "2027-12-31", "last_updated": "2026-09-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "E-Cograt", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05863897", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=E-Cograt", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05863897", "title": "e-COGRAT: A Blended eHealth Intervention for Fatigue Following Acquired Brain Injury", "status": "ENROLLING_BY_INVITATION", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-09-01", "completion_date": "2026-09", "primary_completion_date": "2026-09", "last_updated": "2025-04-03" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Echinochrome A", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Echinochrome%20A", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05531019", "title": "COVID-19 Sequelae: Treatment and Monitoring. A Dietary Supplement Based on Sea Urchin Eggs With Echinochroma A", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-09-22", "completion_date": "2022-12-18", "primary_completion_date": "2022-12-08", "last_updated": "2023-02-28" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Effect On Inflammation After Chronic Pns Stimulation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Anti-inflammatory, Enrollment: Actual, Immunomodulatory, Neurological / Autonomic", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05421208", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Effect%20On%20Inflammation%20After%20Chronic%20Pns%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05421208", "title": "Cardiovascular Autonomic and Immune Mechanism of Post COVID-19 Tachycardia Syndrome", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-06-01", "completion_date": "2027-06-30", "primary_completion_date": "2026-07-13", "last_updated": "2026-07-15" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Anti-inflammatory", "Enrollment: Actual", "Immunomodulatory", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Efgartigimod", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Industry", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Efgartigimod", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05918978", "title": "Open Label Extension of Efgartigimod in Adults With Post-COVID-19 POTS", "status": "TERMINATED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-06-20", "completion_date": "2024-08-15", "primary_completion_date": "2024-08-15", "last_updated": "2025-10-23" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Industry" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Eicosapentaenoic Acid", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other Gov, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Eicosapentaenoic%20Acid", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07711444", "title": "The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID N", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-06-01", "completion_date": "2026-06-01", "primary_completion_date": "2025-12-01", "last_updated": "2026-07-21" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other Gov", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Electrodiagnostic Bioelectrical Assessment", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07343856", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Electrodiagnostic%20Bioelectrical%20Assessment", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07343856", "title": "Long COVID Diagnostic Reactivity Assesment Test", "status": "ENROLLING_BY_INVITATION", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-12-05", "completion_date": "2027-01-01", "primary_completion_date": "2026-12-30", "last_updated": "2026-01-15" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Endurance Training", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Endurance%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05204511", "title": "Exercise and Post-COVID/ Long-COVID: Effects of Different Training Modalities on Various Parameters in People Affected by the Sequelae of CO", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-02-10", "completion_date": "2023-05-31", "primary_completion_date": "2023-05-31", "last_updated": "2023-07-19" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Enhanced External Counterpulsation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other, Sponsor Type: Other Gov", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05668039", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Enhanced%20External%20Counterpulsation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07492953", "title": "Using Enhanced External Counterpulsation to Recover Cardiovascular Function for Patient of Chronic Diseases", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-12-25", "completion_date": "2024-06-24", "primary_completion_date": "2024-06-24", "last_updated": "2026-03-25" }, { "nct_id": "NCT05668039", "title": "Enhanced External Counterpulsation to Treat Long COVID-19 Fatigue", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-04-01", "completion_date": "2024-07", "primary_completion_date": "2024-04-01", "last_updated": "2023-11-30" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Sponsor Type: Other", "Sponsor Type: Other Gov", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Ensitrelvir", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Anti-inflammatory, Antiviral / Persistence, Enrollment: Actual, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06161688", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ensitrelvir", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06161688", "title": "Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID", "status": "ACTIVE_NOT_RECRUITING", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2024-04-09", "completion_date": "2026-12-31", "primary_completion_date": "2024-12-20", "last_updated": "2026-04-02" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Anti-inflammatory", "Antiviral / Persistence", "Enrollment: Actual", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Etanercept", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Etanercept", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01730495", "title": "Tumor Necrosis Factor-alpha Inhibition Using Etanercept in Chronic Fatigue Syndrome", "status": "TERMINATED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2012-10", "completion_date": "2014-08", "primary_completion_date": "2014-08", "last_updated": "2015-12-02" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Evidence-Based Informational Support", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06871293", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Evidence-Based%20Informational%20Support", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06871293", "title": "Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19", "status": "RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2025-10-30", "completion_date": "2027-01-01", "primary_completion_date": "2026-12-31", "last_updated": "2026-04-13" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Exercise Programe", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06142240", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Exercise%20Programe", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06142240", "title": "Efficacy of Two Therapeutic Exercise Modalities for Patients With Persistent COVID", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-06-01", "completion_date": "2025-09-01", "primary_completion_date": "2025-04-01", "last_updated": "2023-11-21" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Exercise Test On Ergocycle", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07491315", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Exercise%20Test%20On%20Ergocycle", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07491315", "title": "Is Post-exertional Symptom Exacerbation Specific to Patients With Myalgic Encephalomyelitis / Chronic Fatigue Syndrome? A Study Comparing Pa", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-06-24", "completion_date": "2026-12-24", "primary_completion_date": "2026-12-24", "last_updated": "2026-06-08" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Exercise Therapy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Exercise%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04958161", "title": "Reconditioning Exercise for COVID-19 Patients Experiencing Residual sYmptoms", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2022-01", "completion_date": "2023-05", "primary_completion_date": "2022-12", "last_updated": "2022-02-24" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Exercise Training", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Exercise%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06251011", "title": "Effects of Physiotherapy Via Telerehabilitation in Patients With COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-02-09", "completion_date": "2024-06-04", "primary_completion_date": "2024-06-01", "last_updated": "2024-06-05" }, { "nct_id": "NCT05961462", "title": "Effects of Exercise Training on Patients With Long COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-01-10", "completion_date": "2023-08-30", "primary_completion_date": "2023-07-30", "last_updated": "2023-09-06" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Experimental Product", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Anti-inflammatory, Enrollment: Estimated, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07397910", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Experimental%20Product", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07397910", "title": "Clinical Trial on a Natural Compound to Improve Chronic Inflammation After SARS-CoV-2 Infection", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-02-23", "completion_date": "2026-08-03", "primary_completion_date": "2026-07-06", "last_updated": "2026-02-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Anti-inflammatory", "Enrollment: Estimated", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Experimental Tests", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05629793", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Experimental%20Tests", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05629793", "title": "Differential Diagnosis of Persistent COVID-19 by Artificial Intelligence", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-12-14", "completion_date": "2023-11", "primary_completion_date": "2023-11", "last_updated": "2022-11-29" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Experimental: Nutrilite® High Dose", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Experimental:%20Nutrilite®%20High%20Dose", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02807649", "title": "Effect of Ginko and Cistanche Against Fatigue Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2015-05", "completion_date": "2015-12", "primary_completion_date": "2015-10", "last_updated": "2016-06-21" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Experimental: Nutrilite® Low Dose", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Experimental:%20Nutrilite®%20Low%20Dose", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02807649", "title": "Effect of Ginko and Cistanche Against Fatigue Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2015-05", "completion_date": "2015-12", "primary_completion_date": "2015-10", "last_updated": "2016-06-21" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Extension For Community Healthcare Outcomes", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05167227", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Extension%20For%20Community%20Healthcare%20Outcomes", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05167227", "title": "Does a Technology Enabled Multi-disciplinary Team-based Care Model for the Management of Long COVID and Other Fatiguing Illnesses Improve Cl", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2021-11-30", "completion_date": "2025-11-28", "primary_completion_date": "2024-11-20", "last_updated": "2025-08-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Faecal Microbiota Transplantation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05556733", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Faecal%20Microbiota%20Transplantation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05556733", "title": "FMT for Post-acute COVID-19 Syndrome", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-09-28", "completion_date": "2024-06-30", "primary_completion_date": "2023-09-13", "last_updated": "2023-10-31" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Faecal Transplantation", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Faecal%20Transplantation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04158427", "title": "Intestinal Microbiota and Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2020-01-01", "completion_date": "2022-03-31", "primary_completion_date": "2021-12-31", "last_updated": "2022-04-28" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Fermented Foods", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06560554", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Fermented%20Foods", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06560554", "title": "Evaluating the Effects of a Fermented Diet on Microbiome Diversity in Individuals With Long COVID", "status": "ENROLLING_BY_INVITATION", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-09-05", "completion_date": "2026-12-30", "primary_completion_date": "2025-09-30", "last_updated": "2026-06-03" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Fermented Velvet Antler Extract", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Fermented%20Velvet%20Antler%20Extract", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01689467", "title": "Efficacy and Safety of Fermented Velvet Antler Extract on Fatigue Recovery After Exercise", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2013-04-25", "completion_date": "2014-06-26", "primary_completion_date": "2014-06-26", "last_updated": "2019-08-26" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Fitnet Treatment", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Fitnet%20Treatment", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00893438", "title": "Efficacy of Web-based Cognitive Behavioural Treatment for Adolescents With Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2008-01", "completion_date": "2011-11", "primary_completion_date": "2011-11", "last_updated": "2013-05-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Flavonoids", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Flavonoids", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06064838", "title": "Effects of Cacao Flavonoids in Long COVID-19 Patients (FLALOC)", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-08-01", "completion_date": "2024-09-30", "primary_completion_date": "2024-08-01", "last_updated": "2024-10-01" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Floradapt Intensive Gi", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06211062", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Floradapt%20Intensive%20Gi", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06211062", "title": "The Use of Directed Probiotics in ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2022-12-20", "completion_date": "2026-02-24", "primary_completion_date": "2026-02-24", "last_updated": "2025-03-04" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Fludrocortisone", "Primary Conditions": [ "POTS" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Observational + guideline support for volume expansion in low-BP POTS. ~43% success obs. Low evidence per guidelines. Monitor electrolytes, supine HTN. For hypovolemic phenotype.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Fludrocortisone", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Blood volume expansion; 42.8% success in observational data; low evidence per VA Long COVID guidelines; used for low blood pressure phenotype", "pub_date": "", "excerpt": "Blood volume expansion; 42.8% success in observational data; low evidence per VA Long COVID guidelines; used for low blood pressure phenotype", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Fluvoxamine", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Anti-inflammatory, Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07359482", "Clinical Notes": "Sigma-1 + SSRI; early COVID + some Long COVID data. 50-100mg. CYP interactions, GI/insomnia. Preliminary for select symptoms; not core fatigue/autonomic first choice.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/compound/3406", "Safety": "Nausea, insomnia, somnolence; significant CYP1A2 and CYP2C19 interactions. Avoid in combination with thioridazine, pimozide. Monitor for serotonin syndrome if combined with other serotonergics.", "Dosing": "50–100 mg/day (often 100 mg); short courses (10–15 days) in early studies; some PASC protocols 4–8 weeks.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05874037", "title": "Fluvoxamine for Long COVID-19", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2023-05-15", "completion_date": "2025-03-15", "primary_completion_date": "2025-03-15", "last_updated": "2026-10-07" }, { "nct_id": "NCT07359482", "title": "sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19", "status": "RECRUITING", "phase": "PHASE3", "size_category": "Medium (50-199 participants)", "start_date": "2026-06-04", "completion_date": "2028-05-01", "primary_completion_date": "2027-12-31", "last_updated": "2026-06-09" }, { "nct_id": "NCT04510194", "title": "COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)", "status": "COMPLETED", "phase": "PHASE3", "size_category": "Very Large (1000+ participants)", "start_date": "2021-01-01", "completion_date": "2022-12-14", "primary_completion_date": "2022-12-14", "last_updated": "2026-04-24" }, { "nct_id": "NCT06128967", "title": "A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial", "status": "COMPLETED", "phase": "PHASE3", "size_category": "Large (200-999 participants)", "start_date": "2023-10-18", "completion_date": "2025-08-01", "primary_completion_date": "2025-07-01", "last_updated": "2026-04-13" } ], "total_mentions": 4, "types": [ "Drug (Pharmaceutical)" ], "mechanisms": [ "Anti-inflammatory", "Enrollment: Actual", "Enrollment: Estimated", "Sponsor Type: Other" ], "trial_types": [ "PHASE2", "PHASE3" ], "trial_sizes": [ "Large (200-999 participants)", "Medium (50-199 participants)", "Very Large (1000+ participants)" ] }, { "Therapeutic Agent": "Fmg", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Fmg", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06393790", "title": "Strength Training Protocol in Fibromyalgia Women", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-04-01", "completion_date": "2025-01-01", "primary_completion_date": "2024-07-30", "last_updated": "2025-02-13" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Follow Up Phone Calls", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06095297, NCT07523113", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Follow%20Up%20Phone%20Calls", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06095297", "title": "Long COVID Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-04-25", "completion_date": "2027-12", "primary_completion_date": "2026-12", "last_updated": "2026-04-13" }, { "nct_id": "NCT07523113", "title": "ME/CFS Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-06-23", "completion_date": "2028-06", "primary_completion_date": "2027-06", "last_updated": "2026-08-14" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Food Diary", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Food%20Diary", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04363606", "title": "Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability", "status": "TERMINATED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2020-05-27", "completion_date": "2022-03-01", "primary_completion_date": "2021-08-26", "last_updated": "2025-03-25" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Full/High Tech Telerehabilitation Decision Support System", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06534164", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Full/High%20Tech%20Telerehabilitation%20Decision%20Support%20System", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06534164", "title": "Telerehabilitation of Balance Clinical and Economic Decision Support System", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2025-09-01", "completion_date": "2026-08-31", "primary_completion_date": "2026-06-30", "last_updated": "2025-07-10" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Functional And Cognitive Rehabilitation Strategy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06871293", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Functional%20And%20Cognitive%20Rehabilitation%20Strategy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06871293", "title": "Evaluating the Impact of a Functional and Cognitive Strategy in Patients With Long Covid-19", "status": "RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2025-10-30", "completion_date": "2027-01-01", "primary_completion_date": "2026-12-31", "last_updated": "2026-04-13" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Gcjbp Laennec Inj.", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Gcjbp%20Laennec%20Inj.", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01742013", "title": "Investigator Initiated Clinical Study to Explore the Efficacy and Safety of Human Placenta Hydrolysate in the Chronic Fatigue Patients", "status": "COMPLETED", "phase": "PHASE3", "size_category": "Medium (50-199 participants)", "start_date": "2013-01", "completion_date": "2013-09", "primary_completion_date": "2013-08", "last_updated": "2013-09-26" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Genetic", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Network, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06441955", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Genetic", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06441955", "title": "Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.", "status": "RECRUITING", "phase": "PHASE4", "size_category": "Medium (50-199 participants)", "start_date": "2024-03-01", "completion_date": "2030-09-30", "primary_completion_date": "2030-09-30", "last_updated": "2024-11-27" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Network", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Graded Dobutamine Infusions", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Sponsor Type: Fed, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Graded%20Dobutamine%20Infusions", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00100412", "title": "Hyporeactivity and Gulf War Illness", "status": "COMPLETED", "phase": "NA", "size_category": null, "start_date": "1999-10", "completion_date": "2002-09", "primary_completion_date": "Unknown", "last_updated": "2009-01-21" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Sponsor Type: Fed", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Graded Phenylephrine Injections", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Sponsor Type: Fed, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Graded%20Phenylephrine%20Injections", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00100412", "title": "Hyporeactivity and Gulf War Illness", "status": "COMPLETED", "phase": "NA", "size_category": null, "start_date": "1999-10", "completion_date": "2002-09", "primary_completion_date": "Unknown", "last_updated": "2009-01-21" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Sponsor Type: Fed", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Gradual Movement Therapy In The Ward", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Network, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Gradual%20Movement%20Therapy%20In%20The%20Ward", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05967052", "title": "Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation", "status": "TERMINATED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-10-24", "completion_date": "2025-09-11", "primary_completion_date": "2025-09-11", "last_updated": "2026-06-17" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Network", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Group Psychotherapy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Group%20Psychotherapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06726772", "title": "Group Psychotherapy in Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-11-01", "completion_date": "2024-01-31", "primary_completion_date": "2024-01-31", "last_updated": "2025-02-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Guanidinoacetic Acid", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Guanidinoacetic%20Acid", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02213679", "title": "Guanidinoacetic Acid Loading for Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2014-08", "completion_date": "2015-07", "primary_completion_date": "2015-06", "last_updated": "2017-02-01" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Guidebook", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06348186", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Guidebook", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06348186", "title": "Fascial Tissue Response to Manual Therapy: Implications in Long COVID-19", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-02-01", "completion_date": "2025-08-31", "primary_completion_date": "2024-04-01", "last_updated": "2024-11-20" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Guidebook And Myofascial Reorganization® (Rmf).", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06348186", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Guidebook%20And%20Myofascial%20Reorganization®", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06348186", "title": "Fascial Tissue Response to Manual Therapy: Implications in Long COVID-19", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-02-01", "completion_date": "2025-08-31", "primary_completion_date": "2024-04-01", "last_updated": "2024-11-20" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Gutmagnific™ H.", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Gutmagnific™%20H.", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04741841", "title": "Effect of Probiotics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2020-03-30", "completion_date": "2021-06-30", "primary_completion_date": "2021-03-30", "last_updated": "2021-10-14" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Gutmagnific™ L.", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Gutmagnific™%20L.", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04741841", "title": "Effect of Probiotics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2020-03-30", "completion_date": "2021-06-30", "primary_completion_date": "2021-03-30", "last_updated": "2021-10-14" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Health Promoting Dialogue", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Health%20Promoting%20Dialogue", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04177459", "title": "Rehabilitation of Adolescents Living With Chronic Fatigue", "status": "TERMINATED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2019-12-06", "completion_date": "2020-04-30", "primary_completion_date": "2020-04-30", "last_updated": "2020-06-25" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Healthy Consulation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Healthy%20Consulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06840873", "title": "Tele-Rehabilitative Exercise Training Program in Nurses With Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-11-02", "completion_date": "2024-11-01", "primary_completion_date": "2024-06-30", "last_updated": "2025-10-07" }, { "nct_id": "NCT05922865", "title": "The Effect of Smart Sensor Combined With APP for Individualized Precise Exercise Training in Long Covid-19", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-07-11", "completion_date": "2024-03-15", "primary_completion_date": "2024-02-27", "last_updated": "2025-04-27" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Heart Rate Variability Biofeedback", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05228665", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Heart%20Rate%20Variability%20Biofeedback", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05228665", "title": "HEART Rate Variability Biofeedback in LOng COVID-19 (HEARTLOC)", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-01-24", "completion_date": "2024-03-31", "primary_completion_date": "2023-12-31", "last_updated": "2022-10-24" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Heart Rhythm Biofeedback", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05397626", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Heart%20Rhythm%20Biofeedback", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05397626", "title": "Biofeedback and Hydrogen Water as Treatments for Chronic Fatigue Syndrome", "status": "UNKNOWN", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2022-05-23", "completion_date": "2023-05-23", "primary_completion_date": "2023-05-23", "last_updated": "2022-05-31" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Heat Therapy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06928116", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Heat%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06928116", "title": "Heat thErapy And mobiLity in COVID-19 Survivors", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-01-16", "completion_date": "2029-08", "primary_completion_date": "2028-08-31", "last_updated": "2026-09-28" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Hg", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Hg", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06393790", "title": "Strength Training Protocol in Fibromyalgia Women", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-04-01", "completion_date": "2025-01-01", "primary_completion_date": "2024-07-30", "last_updated": "2025-02-13" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Hi-Ox Device", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06928506", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Hi-Ox%20Device", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06928506", "title": "Effect of Hi-OxSR for the Treatment of Post COVID Condition", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-08-01", "completion_date": "2028-12", "primary_completion_date": "2027-12", "last_updated": "2025-09-15" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Hi-Oxsr Device", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06928506", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Hi-Oxsr%20Device", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06928506", "title": "Effect of Hi-OxSR for the Treatment of Post COVID Condition", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-08-01", "completion_date": "2028-12", "primary_completion_date": "2027-12", "last_updated": "2025-09-15" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "High Definition-Transcranial Direct Current Stimulation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06255600", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=High%20Definition-Transcranial%20Direct%20Current%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06255600", "title": "High-definition Transcranial Direct Current Stimulation and Chlorella Pyrenoidosa to Reduce Cardiovascular Risk", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-08-10", "completion_date": "2024-06-28", "primary_completion_date": "2024-06-28", "last_updated": "2024-03-05" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Hobscotch-Pacs", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06391489", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Hobscotch-Pacs", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06391489", "title": "HOBSCOTCH for People With Post Acute COVID-19 Syndrome (PACS)", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-05-14", "completion_date": "2026-12", "primary_completion_date": "2026-12", "last_updated": "2026-02-20" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Home-Based Concurrent Exercise", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06073002", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Home-Based%20Concurrent%20Exercise", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06073002", "title": "Effects of a Home-Based Exercise Intervention in Subjects with Long COVID", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-09-04", "completion_date": "2025-02-28", "primary_completion_date": "2025-02-28", "last_updated": "2024-12-11" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Home-Based Telerehabilitation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Home-Based%20Telerehabilitation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05205460", "title": "Telerehabilitation in People With Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-10-12", "completion_date": "2023-05-20", "primary_completion_date": "2023-04-30", "last_updated": "2025-03-11" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Home-Based Transcranial Direct Current Stimulation", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05791812", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Home-Based%20Transcranial%20Direct%20Current%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05791812", "title": "Application of Direct Current Transcranial stImulation, Remotely superVised in Chronic fATiguE", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-03-16", "completion_date": "2026-03-31", "primary_completion_date": "2025-11-30", "last_updated": "2025-09-19" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Hope-Lc~Espanol", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07216040", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Hope-Lc~Espanol", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07216040", "title": "Harnessing Optimism and Perseverance in the Face of Long COVID-Español", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-05", "completion_date": "2026-08-31", "primary_completion_date": "2026-08-31", "last_updated": "2026-04-23" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Hydrogen Water", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06227273, NCT05397626", "Clinical Notes": "Investigational for listed conditions. 3 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Hydrogen%20Water", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06227273", "title": "Hydrogen Water Dosing Study for ME/CFS", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-12-01", "completion_date": "2024-11-30", "primary_completion_date": "2024-11-01", "last_updated": "2024-01-26" }, { "nct_id": "NCT05397626", "title": "Biofeedback and Hydrogen Water as Treatments for Chronic Fatigue Syndrome", "status": "UNKNOWN", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2022-05-23", "completion_date": "2023-05-23", "primary_completion_date": "2023-05-23", "last_updated": "2022-05-31" }, { "nct_id": "NCT05013606", "title": "Hydrogen Water Treatment for Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2019-04-01", "completion_date": "2021-06-01", "primary_completion_date": "2021-04-01", "last_updated": "2021-08-19" } ], "total_mentions": 3, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA", "PHASE1" ], "trial_sizes": [ "Medium (50-199 participants)", "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Hydrogen Water Which Is Prepared From An Otc Supplement.", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07009691", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Hydrogen%20Water%20Which%20Is%20Prepared%20From%20An%20Otc%20Supplement.", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07009691", "title": "Hydrogen Water Intervention With Heart Rate Variability as an Outcome Biomarker in ME/CFS", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-06-09", "completion_date": "2026-05-31", "primary_completion_date": "2026-05-31", "last_updated": "2025-06-08" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Hydroxy Gas", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06159296", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Hydroxy%20Gas", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06159296", "title": "Effect of Inhaled Hydroxy Gas on Long COVID Symptoms", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-09-25", "completion_date": "2024-05-31", "primary_completion_date": "2024-05-31", "last_updated": "2023-12-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Hydroxychloroquine", "Primary Conditions": [ "Lyme" ], "Proposed Mechanism": "Unknown / General", "Evidence Level": "Anecdotal", "Key Studies / References": [ "PMID:41421419" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Hydroxychloroquine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [ "Hydroxychloroquine" ], "studies": [ { "pmid": "41421419", "title": "Methemoglobinemia induced by dapsone, hydroxychloroquine, and rifampin combination for post-treatment Lyme disease syndrome: A case report.", "pub_date": "2025-12-21", "excerpt": "A patient presented to the emergency department with drug-induced methemoglobinemia due to a combination of medications prescribed for post-treatment Lyme disease syndrome (PTLDS). This case highlights the potential risks of dapsone, hydroxychloroquine (HCQ), and rifampin for the management of PTLDS...", "source_page": "lyme" } ], "trials": [], "total_mentions": 1, "types": [ "Drug (Pharmaceutical)" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Hyperbaric", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Neurological / Autonomic", "Evidence Level": "Anecdotal", "Key Studies / References": [ "PMID:42249466" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Hyperbaric", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [ "Hyperbaric" ], "studies": [ { "pmid": "42249466", "title": "Hyperbaric oxygen therapy improves clinical symptoms and functional capacity and modulates thalamic connectivity in ME/CFS: a prospective co", "pub_date": "2026-06-06", "excerpt": "Hyperbaric oxygen therapy (HBOT) has been proposed as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), but evidence remains limited. This study evaluated its clinical effectiveness and feasibility, as well as associated functional brain changes. Thirty patients with ME/CF...", "source_page": "me-cfs" } ], "trials": [], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise", "Medical Device" ], "mechanisms": [ "Neurological / Autonomic" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Hyperbaric Oxygen Therapy (HBOT)", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Moderate", "Key Studies / References": [ "PMID:42249466" ], "Ongoing Research": "NCT06452095, NCT06267300, NCT07621068", "Clinical Notes": "Investigational for listed conditions. 5 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Hyperbaric%20Oxygen%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [ "Hyperbaric Oxygen Therapy (HBOT)" ], "studies": [ { "pmid": "42249466", "title": "Hyperbaric oxygen therapy improves clinical symptoms and functional capacity and modulates thalamic connectivity in ME/CFS: a prospective co", "pub_date": "2026-06-06", "excerpt": "Hyperbaric oxygen therapy (HBOT) has been proposed as a treatment for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), but evidence remains limited. This study evaluated its clinical effectiveness and feasibility, as well as associated functional brain changes. Thirty patients with ME/CF...", "source_page": "me-cfs" } ], "trials": [ { "nct_id": "NCT06452095", "title": "Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine Trial - Effect of Hyperbaric Oxygen Therapy for the Treatment of P", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2026-01-01", "completion_date": "2029-12-31", "primary_completion_date": "2029-12-31", "last_updated": "2026-02-23" }, { "nct_id": "NCT04842448", "title": "Safety and Efficacy of Hyperbaric Oxygen Therapy for Long COVID Syndrome", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2021-09-15", "completion_date": "2024-06-17", "primary_completion_date": "2023-09-27", "last_updated": "2024-08-22" }, { "nct_id": "NCT06267300", "title": "Treatment of Post-COVID-19 With Hyperbaric Oxygen Therapy: a Randomized, Controlled Trial", "status": "UNKNOWN", "phase": "PHASE3", "size_category": "Medium (50-199 participants)", "start_date": "2024-10-01", "completion_date": "2026-04-01", "primary_completion_date": "2025-10-01", "last_updated": "2024-02-28" }, { "nct_id": "NCT04905888", "title": "Hyperbaric Oxygen for Long COVID-19 Pulmonary Sequela", "status": "WITHDRAWN", "phase": "PHASE2", "size_category": null, "start_date": "2021-11-08", "completion_date": "2023-12-31", "primary_completion_date": "2022-12-31", "last_updated": "2024-01-23" }, { "nct_id": "NCT07621068", "title": "Hyperbaric Oxygen Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2026-07-19", "completion_date": "2027-06", "primary_completion_date": "2027-06", "last_updated": "2026-08-21" } ], "total_mentions": 6, "types": [ "Behavioral / Protocol / Exercise", "Medical Device" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other", "Sponsor Type: Other Gov", "Unknown / General" ], "trial_types": [ "NA", "PHASE2", "PHASE3" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Ibudilast", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ibudilast", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05513560", "title": "RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2023-05-31", "completion_date": "2025-12-31", "primary_completion_date": "2025-03-31", "last_updated": "2026-02-23" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Iendure", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05616806", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Iendure", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05616806", "title": "Long COVID-19 Intervention Using Digital Health & Technology", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-07-01", "completion_date": "2025-01-01", "primary_completion_date": "2024-07-01", "last_updated": "2023-04-04" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Igpro20", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Industry", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Igpro20", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06524739", "title": "Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in Post-COVID-19 POTS", "status": "TERMINATED", "phase": "PHASE3", "size_category": "Small (<50 participants)", "start_date": "2024-08-28", "completion_date": "2025-07-11", "primary_completion_date": "2025-06-20", "last_updated": "2026-04-13" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Industry" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Immediate Cbt", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT01096641", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Immediate%20Cbt", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01096641", "title": "An Explorative Study on Physiological and Neurophysiological Determinants of Fatigue in Cancer Survivors", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2010-04", "completion_date": "2012-10", "primary_completion_date": "2012-09", "last_updated": "2012-06-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Immulina Tm", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Immulina%20Tm", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05524532", "title": "Effects of Immulina TM Supplements With PASC Patients", "status": "COMPLETED", "phase": "PHASE3", "size_category": "Medium (50-199 participants)", "start_date": "2023-07-20", "completion_date": "2025-07-29", "primary_completion_date": "2025-07-29", "last_updated": "2026-07-31" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Immunoadsorption", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Immunomodulatory, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07316127", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Immunoadsorption", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05710770", "title": "Immunoadsorption in Patients With Chronic Fatigue Syndrome Including Patients With Post-COVID-19 CFS", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-10-01", "completion_date": "2025-10-08", "primary_completion_date": "2025-08-04", "last_updated": "2026-01-16" }, { "nct_id": "NCT07316127", "title": "Immunoadsorption in Autoimmune Long COVID", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2026-01-01", "completion_date": "2028-03-12", "primary_completion_date": "2027-12-12", "last_updated": "2026-01-05" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Immunomodulatory", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA", "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "In-Lab Brain Health Training", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06095297", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=In-Lab%20Brain%20Health%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06095297", "title": "Long COVID Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-04-25", "completion_date": "2027-12", "primary_completion_date": "2026-12", "last_updated": "2026-04-13" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "In-Lab Instrumental Activities Of Daily Living Training", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06095297", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=In-Lab%20Instrumental%20Activities%20Of%20Daily%20Living%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06095297", "title": "Long COVID Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-04-25", "completion_date": "2027-12", "primary_completion_date": "2026-12", "last_updated": "2026-04-13" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "In-Session Brain Health Training", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07523113", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=In-Session%20Brain%20Health%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07523113", "title": "ME/CFS Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-06-23", "completion_date": "2028-06", "primary_completion_date": "2027-06", "last_updated": "2026-08-14" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "In-Session Instrumental Activities Of Daily Living Training", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07523113", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=In-Session%20Instrumental%20Activities%20Of%20Daily%20Living%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07523113", "title": "ME/CFS Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-06-23", "completion_date": "2028-06", "primary_completion_date": "2027-06", "last_updated": "2026-08-14" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Incentive Spirometer Respiratory Training", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06231225", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Incentive%20Spirometer%20Respiratory%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06231225", "title": "Study on the Effect of Incentive Spirometer-based Respiratory Training on the Long COVID-19", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-07-01", "completion_date": "2026-08-01", "primary_completion_date": "2025-06-30", "last_updated": "2024-01-30" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Increased Salt And Fluid Intake", "Primary Conditions": [ "POTS" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Increased%20Salt%20And%20Fluid%20Intake", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Standard POTS supportive measure; 2–3L fluid/day + 3–5g sodium/day; minimally adequate evidence per guidelines; widely recommended as first-line non-p", "pub_date": "", "excerpt": "Standard POTS supportive measure; 2–3L fluid/day + 3–5g sodium/day; minimally adequate evidence per guidelines; widely recommended as first-line non-pharmacological", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Independent Walking Training", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Network, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Independent%20Walking%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05967052", "title": "Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation", "status": "TERMINATED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-10-24", "completion_date": "2025-09-11", "primary_completion_date": "2025-09-11", "last_updated": "2026-06-17" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Network", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Individual Follow-Ups", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06085911", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Individual%20Follow-Ups", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06085911", "title": "RCT Long COVID-19 Rehabilitation", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-11-03", "completion_date": "2025-11", "primary_completion_date": "2025-02", "last_updated": "2024-06-11" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Individual Tailored Exercise", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05877534", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Individual%20Tailored%20Exercise", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05877534", "title": "Effects of Individual Tailored Physical Exercise in Patients With POTS After COVID-19 - a Randomized Controlled Study", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-05-25", "completion_date": "2026-11-01", "primary_completion_date": "2025-10-01", "last_updated": "2026-07-15" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Inebilizumab", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07724834", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Inebilizumab", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07724834", "title": "CD19-B Cell Depletion in PAIS-ME/CFS Patients", "status": "NOT_YET_RECRUITING", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2026-12-01", "completion_date": "2029-03-01", "primary_completion_date": "2029-02-01", "last_updated": "2026-07-24" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Inhalation Of Sterile Distilled Non-Pyrogenic Water", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Inhalation%20Of%20Sterile%20Distilled%20Non-Pyrogenic%20Water", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06294756", "title": "Sulfureous Water Therapy in Viral Respiratory Diseases", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-05-30", "completion_date": "2023-09-30", "primary_completion_date": "2023-08-01", "last_updated": "2024-03-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Inhalation Of Sulfurous Thermal Water", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Inhalation%20Of%20Sulfurous%20Thermal%20Water", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06294756", "title": "Sulfureous Water Therapy in Viral Respiratory Diseases", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-05-30", "completion_date": "2023-09-30", "primary_completion_date": "2023-08-01", "last_updated": "2024-03-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Inspiratory Muscle Training", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Inspiratory%20Muscle%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05196529", "title": "Inspiratory Muscle Training in ME/CFS and COVID-19 Survivors", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-05-09", "completion_date": "2023-01-31", "primary_completion_date": "2023-01-31", "last_updated": "2023-04-12" }, { "nct_id": "NCT05279430", "title": "Effects of IMT on Functional Capacity in Patients With Chronic COVID After Hospital Discharge", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-01-30", "completion_date": "2022-08-01", "primary_completion_date": "2022-07-31", "last_updated": "2022-12-13" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Institutional Standard Treatment For Xerostomia And Long Covid", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Institutional%20Standard%20Treatment%20For%20Xerostomia%20And%20Long%20Covid", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05760092", "title": "The Use of Photobiomodulation in the Treatment of Oral Complaints of Long COVID-19.A Randomized Controlled Trial.", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-03-01", "completion_date": "2024-03-08", "primary_completion_date": "2024-02-01", "last_updated": "2024-03-12" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Integrative Rehabilitation Program", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Integrative%20Rehabilitation%20Program", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01806246", "title": "A Rehabilitation Program for Adolescents With Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2013-02", "completion_date": "2015-09", "primary_completion_date": "2015-09", "last_updated": "2015-10-23" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Intensive Combined Rehabilitation Therapy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05534997", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Intensive%20Combined%20Rehabilitation%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05534997", "title": "Rehabilitation Therapy for Post COVID 19 Chronic Fatigue Syndrome", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-10-01", "completion_date": "2023-10-01", "primary_completion_date": "2023-09-01", "last_updated": "2022-09-10" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Interdisciplinary Complex Intervention", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05130099", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Interdisciplinary%20Complex%20Intervention", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05130099", "title": "A Complex Intervention for Chronically Fatigued Lymphoma Survivors", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-11-20", "completion_date": "2025-06-30", "primary_completion_date": "2023-06-30", "last_updated": "2024-04-08" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Intermittent Hypoxia-Hyperoxia Treatment", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Metabolic / Mitochondrial, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07317401", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Intermittent%20Hypoxia-Hyperoxia%20Treatment", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07317401", "title": "Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Myalgic Encephalomyelitis/Chronic Fatigue Syndro", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2026-06-01", "completion_date": "2029-01-01", "primary_completion_date": "2027-06-01", "last_updated": "2026-05-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Metabolic / Mitochondrial", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Interrupting Sitting With Physical Activity", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Interrupting%20Sitting%20With%20Physical%20Activity", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05453175", "title": "Uninterrupted and Interrupted Sitting in Long COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-10-07", "completion_date": "2024-07-30", "primary_completion_date": "2024-07-30", "last_updated": "2024-10-03" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Intervention Group", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Metabolic / Mitochondrial, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06765421", "Clinical Notes": "Investigational for listed conditions. 3 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Intervention%20Group", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06765421", "title": "Optimising General Practice Long COVID Care - an Educational Intervention.", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-03", "completion_date": "2025-04", "primary_completion_date": "2025-04", "last_updated": "2025-01-09" }, { "nct_id": "NCT05254301", "title": "Nutrition and LOComotoric Rehabilitation in Long COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-04-24", "completion_date": "2024-01-30", "primary_completion_date": "2024-01-30", "last_updated": "2024-05-08" }, { "nct_id": "NCT07363655", "title": "Effects of a Rehabilitation Programme Focused on Energy Management in People With Myalgic Encephalomyelitis / Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-10-09", "completion_date": "2025-03-09", "primary_completion_date": "2025-02-23", "last_updated": "2026-01-28" } ], "total_mentions": 3, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Metabolic / Mitochondrial", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Intervention Group: Virtual Home-Based Rehabilitation Plus Usual Outpatient Care", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Intervention%20Group:%20Virtual%20Home-Based%20Rehabilitation%20Plus%20Usual%20Outpatient%20Care", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05298878", "title": "Virtual Physical Rehabilitation for Patients Living with Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-08-01", "completion_date": "2024-03-28", "primary_completion_date": "2023-09-22", "last_updated": "2024-11-27" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Intervention With Consolidated Cysteine (Immunocal) 20 G Per Day", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Intervention%20With%20Consolidated%20Cysteine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07184398", "title": "Use of a Cysteine-rich Whey Protein Isolate in Post COVID-19 Cognitive Impairment", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-07-01", "completion_date": "2025-01-01", "primary_completion_date": "2024-09-30", "last_updated": "2025-09-24" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Intravenous Immunoglobulin (IVIG)", "Primary Conditions": [ "Long COVID", "Lyme", "ME/CFS", "Other Post-Viral (Post-infectious cough, Q-fever fatigue syndrome, Post-dengue fatigue, Chikungunya post-infectious, Parvovirus B19 GBS, Mycoplasma pneumoniae neurological, Herpes encephalitis sequelae, RIME, etc.)", "PACVS", "POTS" ], "Proposed Mechanism": "Anti-inflammatory, Enrollment: Actual, Immunomodulatory, Neurological / Autonomic", "Evidence Level": "Moderate", "Key Studies / References": [ "PMID:42391726", "PMID:42391726", "PMID:42243711" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 5 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Intravenous%20Immunoglobulin", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [ "Intravenous Immunoglobulin (IVIG)" ], "studies": [ { "pmid": "42391726", "title": "Therapeutic plasma exchange and immunomodulatory strategies in post-infectious syndromes: A review of immune dysregulation in PTLDS, long CO", "pub_date": "2026-07-03", "excerpt": "Post-infectious syndromes including post-treatment Lyme disease syndrome (PTLDS), long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and pediatric acute-onset neuropsychiatric syndrome (PANS)/pediatric autoimmune neuropsychiatric disorders associated with streptococcal infectio...", "source_page": "lyme" }, { "pmid": "42391726", "title": "Therapeutic plasma exchange and immunomodulatory strategies in post-infectious syndromes: A review of immune dysregulation in PTLDS, long CO", "pub_date": "2026-07-03", "excerpt": "Post-infectious syndromes including post-treatment Lyme disease syndrome (PTLDS), long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and pediatric acute-onset neuropsychiatric syndrome (PANS)/pediatric autoimmune neuropsychiatric disorders associated with streptococcal infectio...", "source_page": "long-covid" }, { "pmid": "42243711", "title": "Human parvovirus B19-associated Guillain-Barré syndrome diagnosed by cerebrospinal fluid targeted next-generation sequencing: a case report ", "pub_date": "2026-06-05", "excerpt": "Guillain-Barré syndrome (GBS) is a post-infectious autoimmune disorder of the peripheral nerves. While human parvovirus B19 (B19V) is a recognized rare trigger, its diagnosis can be challenging without advanced molecular techniques. A 24-year-old male presented with acute symmetrical limb weakness a...", "source_page": "other-post-viral" }, { "pmid": "42137701", "title": "Isolated Arterial Hypertension as a Rare Early Manifestation of Guillain-Barré Syndrome: A Case Report.", "pub_date": "2026-05-15", "excerpt": "Guillain-Barré syndrome (GBS) is a well-known post-infectious acute polyradiculoneuritis, classically characterized by ascending muscle weakness. While dysautonomia affects up to two-thirds of patients, it almost always follows the onset of motor deficits. Arterial hypertension, when presenting as a...", "source_page": "other-post-viral" }, { "pmid": "42093930", "title": "A unified spectrum model for the anti-GQ1b antibody syndromes: from pathophysiology to a new diagnostic framework.", "pub_date": "2026-05-07", "excerpt": "Bickerstaff Brainstem Encephalitis (BBE) is a rare, post-infectious autoimmune disorder characterized by ophthalmoplegia, ataxia, and altered consciousness. Its significant clinical and serological overlap with Miller Fisher syndrome (MFS) and Guillain-Barré syndrome (GBS) creates diagnostic challen...", "source_page": "other-post-viral" } ], "trials": [ { "nct_id": "NCT06305780", "title": "RECOVER-AUTONOMIC Platform Protocol", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2024-03-11", "completion_date": "2025-07-09", "primary_completion_date": "2025-07-09", "last_updated": "2026-08-03" }, { "nct_id": "NCT06305793", "title": "RECOVER-AUTONOMIC: Platform Protocol, Appendix A (IVIG)", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2024-05-08", "completion_date": "2026-06-22", "primary_completion_date": "2026-03-23", "last_updated": "2026-07-31" } ], "total_mentions": 16, "types": [ "Behavioral / Protocol / Exercise", "Biologic / Immunotherapy" ], "mechanisms": [ "Anti-inflammatory", "Enrollment: Actual", "Immunomodulatory", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Iodocarb", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT01793415", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Iodocarb", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01793415", "title": "Treatment of Chronic Fatigue Syndrome (CFS) With Iodinated Activated Charcoal (IodoCarb®)", "status": "UNKNOWN", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2013-02", "completion_date": "2013-12", "primary_completion_date": "2013-12", "last_updated": "2013-02-15" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Isomaltose And Magnesium Stearate", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05454683", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Isomaltose%20And%20Magnesium%20Stearate", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05454683", "title": "Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-09-05", "completion_date": "2024-12-31", "primary_completion_date": "2024-09-30", "last_updated": "2022-07-12" } ], "total_mentions": 1, "types": [ "Supplement / Nutraceutical" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Ivabradine", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Fed", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05481177", "Clinical Notes": "Observational success ~55% + nested COVIVA RCT. Selective HR reduction without beta effects. 2.5-7.5mg BID. Visual side effects possible. Strong for hyperadrenergic POTS/IST phenotypes.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/compound/132999", "Safety": "Bradycardia, visual phosphenes (luminous phenomena), headache. Contraindicated in sick sinus, severe hypotension, acute decompensated HF. Monitor HR.", "Dosing": "2.5–7.5 mg twice daily; titrate to HR; durations in POTS/autonomic studies 4–12 weeks or longer.", "aliases": [], "studies": [ { "title": "Consistent HR reduction across studies; selective If channel blocker — HR reduction without other cardiovascular effects; COVIVA published Frontiers N", "pub_date": "", "excerpt": "Consistent HR reduction across studies; selective If channel blocker — HR reduction without other cardiovascular effects; COVIVA published Frontiers Neurol July 2025", "source": "PACVS Evidence Map" } ], "trials": [ { "nct_id": "NCT06305806", "title": "RECOVER-AUTONOMIC: Platform Protocol, Appendix B (Ivabradine)", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2024-03-11", "completion_date": "2025-12-17", "primary_completion_date": "2025-10-13", "last_updated": "2026-02-20" }, { "nct_id": "NCT05481177", "title": "Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort", "status": "UNKNOWN", "phase": "PHASE4", "size_category": "Large (200-999 participants)", "start_date": "2023-06-14", "completion_date": "2024-09-01", "primary_completion_date": "2024-09-01", "last_updated": "2023-11-29" } ], "total_mentions": 3, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Fed", "Sponsor Type: Other" ], "trial_types": [ "PHASE2", "PHASE4" ], "trial_sizes": [ "Large (200-999 participants)", "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Ivabradine + Coordinated Care", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Ivabradine + pacing/PT/autonomic rehab. Synergistic for POTS recovery. Multidisciplinary approach important.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ivabradine%20+%20Coordinated%20Care", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06305780", "title": "RECOVER-AUTONOMIC Platform Protocol", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2024-03-11", "completion_date": "2025-07-09", "primary_completion_date": "2025-07-09", "last_updated": "2026-08-03" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Ivermectin", "Primary Conditions": [ "Long COVID", "Lyme" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "PMID:41421419" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ivermectin", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [ "Ivermectin" ], "studies": [ { "pmid": "41421419", "title": "Methemoglobinemia induced by dapsone, hydroxychloroquine, and rifampin combination for post-treatment Lyme disease syndrome: A case report.", "pub_date": "2025-12-21", "excerpt": "A patient presented to the emergency department with drug-induced methemoglobinemia due to a combination of medications prescribed for post-treatment Lyme disease syndrome (PTLDS). This case highlights the potential risks of dapsone, hydroxychloroquine (HCQ), and rifampin for the management of PTLDS...", "source_page": "lyme" } ], "trials": [ { "nct_id": "NCT04510194", "title": "COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)", "status": "COMPLETED", "phase": "PHASE3", "size_category": "Very Large (1000+ participants)", "start_date": "2021-01-01", "completion_date": "2022-12-14", "primary_completion_date": "2022-12-14", "last_updated": "2026-04-24" } ], "total_mentions": 2, "types": [ "Drug (Pharmaceutical)" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Very Large (1000+ participants)" ] }, { "Therapeutic Agent": "Journaling", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Journaling", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00468013", "title": "A Computer-Based Intervention for Medically Unexplained Physical Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2007-03", "completion_date": "2010-03", "primary_completion_date": "2010-03", "last_updated": "2015-02-09" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Ketamine", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Nih, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ketamine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04141696", "title": "A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue", "status": "COMPLETED", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2021-07-26", "completion_date": "2024-03-21", "primary_completion_date": "2024-03-21", "last_updated": "2025-04-15" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Nih", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Ketamine Only", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ketamine%20Only", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06821087", "title": "Evaluating the Neuromodulatory Effect of Ketamine in Long COVID-19", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2025-06-05", "completion_date": "2026-06-22", "primary_completion_date": "2026-06-22", "last_updated": "2026-09-17" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Ketogenic Metabolic Therapy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Metabolic / Mitochondrial, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ketogenic%20Metabolic%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07745699", "title": "Fully Remote, Telehealth-based Ketogenic Metabolic Therapy for Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-12-10", "completion_date": "2025-06-01", "primary_completion_date": "2025-06-01", "last_updated": "2026-08-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Metabolic / Mitochondrial", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Ketotifen", "Primary Conditions": [ "MCAS" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Dual H1 + mast cell stabilizer. Long track record; obs MCAS series. 1-2mg BID. 4-8wk to effect. When H1 alone insufficient.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ketotifen", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Dual H1 blocker + mast cell stabiliser; 1–2mg twice daily; 4–8 weeks to full effect; used when antihistamines alone insufficient; no MCAS-specific RCT", "pub_date": "", "excerpt": "Dual H1 blocker + mast cell stabiliser; 1–2mg twice daily; 4–8 weeks to full effect; used when antihistamines alone insufficient; no MCAS-specific RCT", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Keytruda", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Nih, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07388550", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Keytruda", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07388550", "title": "Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)", "status": "NOT_YET_RECRUITING", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2026-10-12", "completion_date": "2028-01-01", "primary_completion_date": "2028-01-01", "last_updated": "2026-10-07" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Nih", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Kinesio Tape", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Kinesio%20Tape", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05770193", "title": "Effect of Kinesio Tape Versus Diaphragmatic Breathing Exercise In Post COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-03-11", "completion_date": "2023-11-30", "primary_completion_date": "2023-08-30", "last_updated": "2023-12-05" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Kisspeptin 112-121", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07224490", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Kisspeptin%20112-121", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07224490", "title": "Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease", "status": "RECRUITING", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2026-03-10", "completion_date": "2030-05", "primary_completion_date": "2030-05", "last_updated": "2026-07-13" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Kneesup Smart Knee Assistive Device + Kneesup Care App", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Kneesup%20Smart%20Knee%20Assistive%20Device%20+%20Kneesup%20Care%20App", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05922865", "title": "The Effect of Smart Sensor Combined With APP for Individualized Precise Exercise Training in Long Covid-19", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-07-11", "completion_date": "2024-03-15", "primary_completion_date": "2024-02-27", "last_updated": "2025-04-27" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise", "Medical Device" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "L-Arginine + Vitamin C", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Single-blind RCT n=56 showed large fatigue reduction (8.7% vs 80.1% placebo) and 6MWT gains; targets documented arginine depletion. Doses studied ~1-2g L-arginine + vit C. Promising for fatigue; OTC, low cost. Replication warranted.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=L-Arginine%20+%20Vitamin%20C", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Fatigue 8.7% vs 80.1% placebo (p<0.0001); 6MWT d=0.56; eNOS/ADMA ratio d=0.72; targets documented arginine depletion in PASC", "pub_date": "", "excerpt": "Fatigue 8.7% vs 80.1% placebo (p<0.0001); 6MWT d=0.56; eNOS/ADMA ratio d=0.72; targets documented arginine depletion in PASC", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "L-Citrulline", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Depletion data + superior plasma arginine raising vs arginine alone. No dedicated PASC RCT. 3-6g/day studied in other contexts. May support nitric oxide / vascular function. Low risk OTC option for POTS/vascular phenotypes.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=L-Citrulline", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Citrulline/ornithine ratio elevated in PASC; bypasses hepatic arginine metabolism to raise plasma arginine more effectively than arginine alone; no PA", "pub_date": "", "excerpt": "Citrulline/ornithine ratio elevated in PASC; bypasses hepatic arginine metabolism to raise plasma arginine more effectively than arginine alone; no PASC-specific RCT", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "L-Glutamine", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Depletion documented; acute COVID RCT benefit on hospital stay. Alternative TCA substrate. 5-10g/day typical. GI tolerance variable. Supportive for gut/immune recovery; limited PASC-specific data.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=L-Glutamine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Depleted in PASC (López-Hernández 2023); acute COVID RCT: reduced hospitalisation duration (Cengiz 2020); TCA cycle alternative substrate when beta-ox", "pub_date": "", "excerpt": "Depleted in PASC (López-Hernández 2023); acute COVID RCT: reduced hospitalisation duration (Cengiz 2020); TCA cycle alternative substrate when beta-oxidation impaired; no PASC-specific RCT", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "L-Nmma Trimethaphan", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=L-Nmma%20Trimethaphan", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00580619", "title": "Autonomic Nervous System and Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE1", "size_category": "Medium (50-199 participants)", "start_date": "2007-04", "completion_date": "2017-01", "primary_completion_date": "2017-01", "last_updated": "2017-01-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "L-Serine", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Depleted in PASC, correlates with neuropsych symptoms; D-serine benefits cognition in healthy. No PASC RCT. 1-3g/day exploratory. Low risk; potential for cognitive phenotypes.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=L-Serine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Saito 2024: depleted in PASC; inversely correlated with neuropsychiatric symptoms; D-serine (NMDA co-agonist) improves cognition in healthy volunteers", "pub_date": "", "excerpt": "Saito 2024: depleted in PASC; inversely correlated with neuropsychiatric symptoms; D-serine (NMDA co-agonist) improves cognition in healthy volunteers; no PASC RCT", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Lactobacillus Paracasei Ps23", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other Gov", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06348212", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Lactobacillus%20Paracasei%20Ps23", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06348212", "title": "Effect of Probiotic Strain Lactobacillus Paracasei PS23 on Brain Fog in People With Long COVID", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-04", "completion_date": "2025-12", "primary_completion_date": "2025-08", "last_updated": "2024-04-04" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other Gov" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Lactose Capsula", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Lactose%20Capsula", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01040429", "title": "The Norwegian Study of Chronic Fatigue Syndrome in Adolescents: Pathophysiology and Intervention Trial", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2010-02", "completion_date": "2012-11", "primary_completion_date": "2012-06", "last_updated": "2012-11-20" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Larazotide Acetate", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Larazotide%20Acetate", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05747534", "title": "AT1001 for the Treatment of Long COVID", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2023-05-31", "completion_date": "2026-06-18", "primary_completion_date": "2026-06-18", "last_updated": "2026-08-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Lau-7B For 3 Cycles", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Lau-7B%20For%203%20Cycles", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05999435", "title": "Study of LAU-7b for the Treatment of Long COVID in Adults", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2023-11-15", "completion_date": "2024-11-30", "primary_completion_date": "2024-08-05", "last_updated": "2026-01-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Lifestyle Intervention", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Metabolic / Mitochondrial, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Lifestyle%20Intervention", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07745699", "title": "Fully Remote, Telehealth-based Ketogenic Metabolic Therapy for Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-12-10", "completion_date": "2025-06-01", "primary_completion_date": "2025-06-01", "last_updated": "2026-08-06" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Metabolic / Mitochondrial", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Light Stretching/Breathing Exercises", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Metabolic / Mitochondrial, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Light%20Stretching/Breathing%20Exercises", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06172803", "title": "Restoring Energy With Sub-symptom Threshold Optimized Rehabilitation Exercise for Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-10-01", "completion_date": "2024-01-15", "primary_completion_date": "2024-01-15", "last_updated": "2024-06-06" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Metabolic / Mitochondrial", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Lightning Process", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07697261", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Lightning%20Process", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07697261", "title": "Fatigue in Long COVID", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2026-11", "completion_date": "2028-12", "primary_completion_date": "2028-12", "last_updated": "2026-07-13" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Lingzhi Capsule", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06739720", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Lingzhi%20Capsule", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06739720", "title": "RCT of Efficacy and Safety of CP003 on CFS/ME or Post COVID-19 Fatigue", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2025-01-02", "completion_date": "2026-12-31", "primary_completion_date": "2026-01-15", "last_updated": "2026-09-21" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Liquid Herbal Tinctures", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06235177", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Liquid%20Herbal%20Tinctures", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06235177", "title": "Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues", "status": "UNKNOWN", "phase": "EARLY_PHASE1", "size_category": "Small (<50 participants)", "start_date": "2024-10-10", "completion_date": "2025-09-19", "primary_completion_date": "2025-06-29", "last_updated": "2024-08-12" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Liraglutide Pen Injector [Saxenda]", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Liraglutide%20Pen%20Injector%20[Saxenda]", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06171152", "title": "Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues", "status": "SUSPENDED", "phase": "EARLY_PHASE1", "size_category": "Small (<50 participants)", "start_date": "2024-01-26", "completion_date": "2027-10-01", "primary_completion_date": "2027-06-01", "last_updated": "2026-03-30" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Lisdexamfetamine Dimesylate", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Lisdexamfetamine%20Dimesylate", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01071044", "title": "Efficacy and Safety of Lisdexamfetamine Dimesylate in Adults With Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE4", "size_category": "Small (<50 participants)", "start_date": "2009-11", "completion_date": "2011-03", "primary_completion_date": "2011-03", "last_updated": "2025-09-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Lithium", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Lithium", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05618587", "title": "Effect of Lithium Therapy on Long COVID Symptoms", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2022-11-28", "completion_date": "2023-07-21", "primary_completion_date": "2023-07-21", "last_updated": "2025-03-05" }, { "nct_id": "NCT06108297", "title": "Lithium Long COVID Dose-finding Study", "status": "COMPLETED", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2023-10-12", "completion_date": "2024-05-02", "primary_completion_date": "2024-03-26", "last_updated": "2024-10-22" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE1", "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Long Covid Coping And Recovery (Lccr) Intervention", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Fed, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Long%20Covid%20Coping%20And%20Recovery", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05453201", "title": "Developing an Integrative, Recovery-Based, Post-Acute COVID-19 Syndrome (PACS) Psychotherapeutic Intervention", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-10-01", "completion_date": "2024-09-30", "primary_completion_date": "2024-02-01", "last_updated": "2025-04-02" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Fed", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Losartan", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05619653", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Losartan", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05619653", "title": "Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19", "status": "ACTIVE_NOT_RECRUITING", "phase": "PHASE3", "size_category": "Large (200-999 participants)", "start_date": "2022-12-12", "completion_date": "2026-03-31", "primary_completion_date": "2025-08-08", "last_updated": "2025-12-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Low Carbohydrate Diet Intervention", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Low%20Carbohydrate%20Diet%20Intervention", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05836402", "title": "Long COVID-19 Syndrome Lifestyle Intervention Study", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-09-14", "completion_date": "2025-08-04", "primary_completion_date": "2025-08-04", "last_updated": "2025-08-07" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Low Sugar Diet And 10-12 Hour Eating Window", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Low%20Sugar%20Diet%20And%2010-12%20Hour%20Eating%20Window", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06214455", "title": "Intermittent Fasting and a No-Sugar Diet for Long COVID Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-11-04", "completion_date": "2024-09-10", "primary_completion_date": "2024-07-01", "last_updated": "2026-05-14" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Low Sugar Diet, 8 Hour Eating Window And Fasting", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Low%20Sugar%20Diet,%208%20Hour%20Eating%20Window%20And%20Fasting", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06214455", "title": "Intermittent Fasting and a No-Sugar Diet for Long COVID Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-11-04", "completion_date": "2024-09-10", "primary_completion_date": "2024-07-01", "last_updated": "2026-05-14" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Low-Dose Naltrexone (LDN)", "Primary Conditions": [ "Long COVID", "ME/CFS", "Other Post-Viral (Post-infectious cough, Q-fever fatigue syndrome, Post-dengue fatigue, Chikungunya post-infectious, Parvovirus B19 GBS, Mycoplasma pneumoniae neurological, Herpes encephalitis sequelae, RIME, etc.)" ], "Proposed Mechanism": "Enrollment: Estimated, Immunomodulatory, Repurposed Drug, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "PMID:42060160" ], "Ongoing Research": "NCT06366724, NCT07285473", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 2 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Low-Dose%20Naltrexone", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [ "Low-Dose Naltrexone (LDN)" ], "studies": [ { "pmid": "42060160", "title": "Low-Dose Naltrexone: What is the Evidence? A Narrative Review.", "pub_date": "2026-04-30", "excerpt": "Naltrexone is prescribed off-label at low doses, typically 0.5-6.0 mg, for a variety of therapeutic indications. This review evaluates the clinical evidence for low-dose naltrexone (LDN). A literature search was conducted in February 2026 across PubMed, Embase and CINAHL for studies published from 1...", "source_page": "other-post-viral" }, { "title": "Hedges' g = −0.74 on fatigue (p<0.001); no RCTs published to date; TRPM3 ion channel restoration in NK cells proposed mechanism; BC RCT (n=160) expect", "pub_date": "", "excerpt": "Hedges' g = −0.74 on fatigue (p<0.001); no RCTs published to date; TRPM3 ion channel restoration in NK cells proposed mechanism; BC RCT (n=160) expected soon", "source": "PACVS Evidence Map" } ], "trials": [ { "nct_id": "NCT06366724", "title": "LIFT: Life Improvement Trial", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2024-09-10", "completion_date": "2026-11", "primary_completion_date": "2026-09", "last_updated": "2025-10-22" }, { "nct_id": "NCT07285473", "title": "Low-Dose Naltrexone For ME/CFS: Dose-Finding", "status": "NOT_YET_RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2026-10-01", "completion_date": "2028-04-01", "primary_completion_date": "2028-04-01", "last_updated": "2026-08-21" } ], "total_mentions": 4, "types": [ "Drug (Pharmaceutical)" ], "mechanisms": [ "Enrollment: Estimated", "Immunomodulatory", "Repurposed Drug", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Low-Intensity Laser Treatment", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06423495", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Low-Intensity%20Laser%20Treatment", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06423495", "title": "Efficacy of Photobiomodulation in the Rehabilitation of Olfactory Dysfunctions Induced by Long COVID-19", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-06-05", "completion_date": "2024-12-22", "primary_completion_date": "2023-12-22", "last_updated": "2024-05-21" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Lumbrokinase", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06511050", "Clinical Notes": "Mount Sinai RCT recruiting (NCT06511050) for microclots in Long COVID/ME-CFS. Fibrinolytic. 20-40mg 2-3x/day protocols. Low bleeding risk but caution with anticoagulants. Rigorous trial underway; currently research-only.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Lumbrokinase", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Fibrinolytic enzyme trial for microclot dissolution; no results yet; most rigorous fibrinolytic trial in long COVID to date; PolyBio Research Foundati", "pub_date": "", "excerpt": "Fibrinolytic enzyme trial for microclot dissolution; no results yet; most rigorous fibrinolytic trial in long COVID to date; PolyBio Research Foundation", "source": "PACVS Evidence Map" } ], "trials": [ { "nct_id": "NCT06511050", "title": "Lumbrokinase for Adults With Long Covid, Post-treatment Lyme Disease Syndrome, and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome", "status": "RECRUITING", "phase": "PHASE1", "size_category": "Medium (50-199 participants)", "start_date": "2024-10-09", "completion_date": "2026-12", "primary_completion_date": "2026-12", "last_updated": "2026-03-13" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Magnesium Chloride", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other Gov, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Magnesium%20Chloride", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05630339", "title": "Magnesium and Vitamin D Combination for Post-COVID Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-01-30", "completion_date": "2023-09-01", "primary_completion_date": "2023-05-01", "last_updated": "2023-09-28" } ], "total_mentions": 1, "types": [ "Supplement / Nutraceutical" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other Gov", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Maltodextrin", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Maltodextrin", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06620406", "title": "Synbiotic Therapy for NP-PASC", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-12-09", "completion_date": "2025-08-06", "primary_completion_date": "2025-08-06", "last_updated": "2025-08-26" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Manual Therapy", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Manual%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04174300", "title": "Molecular Response to Custom Manual Physiotherapy Treatment of Fibromyalgia & Chronic Fatigue Syndrome (CFS)", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2019-03-20", "completion_date": "2020-03-10", "primary_completion_date": "2020-03-10", "last_updated": "2020-08-27" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Maraviroc", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06974084", "Clinical Notes": "CCR5 antagonist studied for persistent immune activation (often + statin). 300mg BID; LFT monitoring. Very early/experimental for these conditions.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Maraviroc", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06974084", "title": "A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the", "status": "NOT_YET_RECRUITING", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2026-07-15", "completion_date": "2027-05", "primary_completion_date": "2026-12-01", "last_updated": "2026-06-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Maraviroc + Pravastatin", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Maraviroc%20+%20Pravastatin", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Biomarker normalisation (CD16+ monocytes) + subjective symptom improvement; critical selection bias — responders only enrolled", "pub_date": "", "excerpt": "Biomarker normalisation (CD16+ monocytes) + subjective symptom improvement; critical selection bias — responders only enrolled", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Maximal Effort Test", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Maximal%20Effort%20Test", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04363606", "title": "Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability", "status": "TERMINATED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2020-05-27", "completion_date": "2022-03-01", "primary_completion_date": "2021-08-26", "last_updated": "2025-03-25" }, { "nct_id": "NCT03849326", "title": "Chronic Fatigue Etiology in Intensive Care Unit Survivors: the Role of Neuromuscular Function", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2023-12", "completion_date": "2025-04", "primary_completion_date": "2025-03", "last_updated": "2023-04-26" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Medicabilis Cannabis Sativa 50", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Medicabilis%20Cannabis%20Sativa%2050", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04997395", "title": "Feasibility of Cannabidiol for the Treatment of Long COVID", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2022-04-14", "completion_date": "2023-01-06", "primary_completion_date": "2023-01-06", "last_updated": "2023-01-19" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Medical Consultations", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Medical%20Consultations", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05543590", "title": "Effect of Plasmapheresis on Clinical Improvement and Biological Parameters of Patients With Long-haul COVID", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2023-02", "completion_date": "2025-10", "primary_completion_date": "2025-02", "last_updated": "2023-08-14" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Medical Food - Anhydrous Enol-Oxaloacetate", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Medical%20Food%20-%20Anhydrous%20Enol-Oxaloacetate", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05273372", "title": "RESTORE ME -- RCT of Oxaloacetate on Improving Fatigue in ME/CFS", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-03-15", "completion_date": "2024-11-15", "primary_completion_date": "2024-06-15", "last_updated": "2025-02-04" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Medication Diary", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Medication%20Diary", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06171152", "title": "Study of Liraglutide (A Weight Loss Drug) in High Risk Obese Participants With Cognitive and Memory Issues", "status": "SUSPENDED", "phase": "EARLY_PHASE1", "size_category": "Small (<50 participants)", "start_date": "2024-01-26", "completion_date": "2027-10-01", "primary_completion_date": "2027-06-01", "last_updated": "2026-03-30" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Medications For Symptoms Management", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Medications%20For%20Symptoms%20Management", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06234462", "title": "A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid", "status": "WITHDRAWN", "phase": "PHASE2", "size_category": null, "start_date": "2025-06", "completion_date": "2025-10-01", "primary_completion_date": "2025-09-01", "last_updated": "2025-08-26" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [] }, { "Therapeutic Agent": "Medium Chain Triglyceride Oil", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05705648", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Medium%20Chain%20Triglyceride%20Oil", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05705648", "title": "Nutritional Management of Post COVID-19 Cognitive Symptoms", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-10-01", "completion_date": "2027-03-01", "primary_completion_date": "2026-06-24", "last_updated": "2026-07-17" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Melatonin", "Primary Conditions": [ "Long COVID", "POTS" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "PMID:42254140" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Melatonin", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [ "Melatonin" ], "studies": [ { "pmid": "42254140", "title": "Diet and environment: unexplored influences on sleep quality in postural orthostatic tachycardia syndrome (POTS).", "pub_date": "2026-06-08", "excerpt": "Postural orthostatic tachycardia syndrome (POTS) is a chronic autonomic disorder characterized by an excessive increase in heart rate upon standing, accompanied by symptoms such as dizziness, fatigue, palpitations, cognitive impairment, and sleep disturbances. Sleep dysfunction is increasingly recog...", "source_page": "pots" } ], "trials": [ { "nct_id": "NCT06404112", "title": "RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2024-07-31", "completion_date": "2026-04-01", "primary_completion_date": "2026-02-26", "last_updated": "2026-07-08" }, { "nct_id": "NCT06404086", "title": "RECOVER-SLEEP: Platform Protocol", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2024-07-31", "completion_date": "2025-12-31", "primary_completion_date": "2025-12-31", "last_updated": "2026-01-22" } ], "total_mentions": 3, "types": [ "Behavioral / Protocol / Exercise", "Supplement / Nutraceutical" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Melatonin Plus Zinc", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05454683", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Melatonin%20Plus%20Zinc", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05454683", "title": "Melatonin and Zinc Administration on Cardinal Symptoms in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-09-05", "completion_date": "2024-12-31", "primary_completion_date": "2024-09-30", "last_updated": "2022-07-12" }, { "nct_id": "NCT03000777", "title": "Oral Melatonin Plus Zinc Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME)", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2016-02", "completion_date": "2017-09", "primary_completion_date": "2017-07", "last_updated": "2018-08-09" } ], "total_mentions": 2, "types": [ "Supplement / Nutraceutical" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Mental Imagery", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06235177", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Mental%20Imagery", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06235177", "title": "Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues", "status": "UNKNOWN", "phase": "EARLY_PHASE1", "size_category": "Small (<50 participants)", "start_date": "2024-10-10", "completion_date": "2025-09-19", "primary_completion_date": "2025-06-29", "last_updated": "2024-08-12" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Mental Stress Test", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Mental%20Stress%20Test", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04378634", "title": "Epigenetics of Post-exertional Malaise in Patients With ME/CFS", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-04-01", "completion_date": "2023-04-30", "primary_completion_date": "2023-04-30", "last_updated": "2023-11-07" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Mental Training", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Mental%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02499302", "title": "Mental Training for CFS Following EBV Infection in Adolescents", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2015-10", "completion_date": "2018-10", "primary_completion_date": "2017-10", "last_updated": "2022-02-16" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Metformin", "Primary Conditions": [ "Gulf War Illness", "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Anti-inflammatory, Enrollment: Actual, Enrollment: Estimated, Metabolic / Mitochondrial", "Evidence Level": "Moderate", "Key Studies / References": [ "PMID:40544605" ], "Ongoing Research": "NCT06147050", "Clinical Notes": "Prevention signal strong; treatment data mixed/preliminary. 500-2000mg. GI effects, B12. Reasonable metabolic adjunct in overweight PASC patients.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/compound/4091", "Safety": "GI side effects (diarrhea, nausea) common initially. Risk of B12 deficiency long-term; lactic acidosis rare (avoid in severe renal/hepatic disease, contrast).", "Dosing": "500–2000 mg/day (extended release often better tolerated); prevention trials used during acute infection ~14 days; treatment studies 8–12+ weeks.", "aliases": [ "Metformin" ], "studies": [ { "pmid": "40544605", "title": "Mitochondria-targeted therapy with metformin and MitoQ reduces oxidative stress, improves mitochondrial function, and restores metabolic hom", "pub_date": "2025-06-23", "excerpt": "Gulf War Illness (GWI) is a cluster of medically unexplained chronic symptoms, including neurological and gastrointestinal impairments, and muscle fatigue, suffered by veterans of the Persian Gulf War. A GWI model in C57BL/6 mice exposed to the nerve gas prophylactic pyridostigmine-bromide (PB) and ...", "source_page": "gulf-war-illness" }, { "title": "Clinician-diagnosed long COVID halved at 6 months (RR 0.495; 95% CI 0.155–0.995); prevention not treatment; concordance across two independent trials ", "pub_date": "", "excerpt": "Clinician-diagnosed long COVID halved at 6 months (RR 0.495; 95% CI 0.155–0.995); prevention not treatment; concordance across two independent trials strengthens signal", "source": "PACVS Evidence Map" } ], "trials": [ { "nct_id": "NCT04510194", "title": "COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)", "status": "COMPLETED", "phase": "PHASE3", "size_category": "Very Large (1000+ participants)", "start_date": "2021-01-01", "completion_date": "2022-12-14", "primary_completion_date": "2022-12-14", "last_updated": "2026-04-24" }, { "nct_id": "NCT06128967", "title": "A Multicenter, Adaptive, Randomized, doublE-blinded, Placebo-controlled Study in Participants With Long COVID-19: The REVIVE Trial", "status": "COMPLETED", "phase": "PHASE3", "size_category": "Large (200-999 participants)", "start_date": "2023-10-18", "completion_date": "2025-08-01", "primary_completion_date": "2025-07-01", "last_updated": "2026-04-13" }, { "nct_id": "NCT06147050", "title": "Effect of Metformin in Reducing Fatigue in Long COVID in Adolescents", "status": "UNKNOWN", "phase": "PHASE3", "size_category": "Small (<50 participants)", "start_date": "2024-04", "completion_date": "2024-12", "primary_completion_date": "2024-10", "last_updated": "2024-03-04" } ], "total_mentions": 5, "types": [ "Drug (Pharmaceutical)" ], "mechanisms": [ "Anti-inflammatory", "Enrollment: Actual", "Enrollment: Estimated", "Metabolic / Mitochondrial", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Large (200-999 participants)", "Small (<50 participants)", "Very Large (1000+ participants)" ] }, { "Therapeutic Agent": "Methyl-P Plus Nutrient Formula", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT01966276", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Methyl-P%20Plus%20Nutrient%20Formula", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01966276", "title": "The Synergy Trial: Methylphenidate Plus a CFS-Specific Nutrient Formula as a Treatment for Chronic Fatigue Syndrome", "status": "UNKNOWN", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2013-11", "completion_date": "2014-12", "primary_completion_date": "2014-12", "last_updated": "2014-09-25" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Methyldopa", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Methyldopa", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00580619", "title": "Autonomic Nervous System and Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE1", "size_category": "Medium (50-199 participants)", "start_date": "2007-04", "completion_date": "2017-01", "primary_completion_date": "2017-01", "last_updated": "2017-01-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Metoprolol Succinate", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Metoprolol%20Succinate", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05096884", "title": "Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study", "status": "TERMINATED", "phase": "EARLY_PHASE1", "size_category": "Small (<50 participants)", "start_date": "2022-03-23", "completion_date": "2023-09-12", "primary_completion_date": "2023-09-12", "last_updated": "2024-12-03" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Micro Breaks In Everyday Life For Chronic Fatigue", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05168124", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Micro%20Breaks%20In%20Everyday%20Life%20For%20Chronic%20Fatigue", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05168124", "title": "Effectiveness of Acceptance Commitment Therapy or Micro Breaks in Patients with Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-08-08", "completion_date": "2026-07", "primary_completion_date": "2025-12", "last_updated": "2024-12-16" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Micro-Choice-Based Intervention", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07726082", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Micro-Choice-Based%20Intervention", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07726082", "title": "Micro-choice-based Intervention for Multicausal Fatigue", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-08-13", "completion_date": "2027-08", "primary_completion_date": "2027-08", "last_updated": "2026-08-18" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Microcrystalline Cellulose", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Industry", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06348212", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Microcrystalline%20Cellulose", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05795816", "title": "Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms", "status": "COMPLETED", "phase": "PHASE3", "size_category": "Medium (50-199 participants)", "start_date": "2023-10-25", "completion_date": "2025-01-31", "primary_completion_date": "2025-01-30", "last_updated": "2025-03-10" }, { "nct_id": "NCT06348212", "title": "Effect of Probiotic Strain Lactobacillus Paracasei PS23 on Brain Fog in People With Long COVID", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-04", "completion_date": "2025-12", "primary_completion_date": "2025-08", "last_updated": "2024-04-04" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Industry", "Sponsor Type: Other Gov", "Unknown / General" ], "trial_types": [ "NA", "PHASE3" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Microdosing Of Mindfulness", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05676008", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Microdosing%20Of%20Mindfulness", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05676008", "title": "A Study of Positive Emotions With Long COVID-19", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2023-01-12", "completion_date": "2027-04", "primary_completion_date": "2027-04", "last_updated": "2026-05-29" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Midazolam", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Nih, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Midazolam", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04141696", "title": "A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue", "status": "COMPLETED", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2021-07-26", "completion_date": "2024-03-21", "primary_completion_date": "2024-03-21", "last_updated": "2025-04-15" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Nih", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Midodrine", "Primary Conditions": [ "POTS" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Systematic review + obs data ~34% success for hemodynamic benefit. VA guideline moderate evidence. 2.5-10mg TID. Vasopressor; supine hypertension risk. Useful for hypotensive POTS.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Midodrine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "33.9% treatment success in observational data; adequate evidence for hemodynamic benefit; moderate evidence per VA Long COVID guidelines", "pub_date": "", "excerpt": "33.9% treatment success in observational data; adequate evidence for hemodynamic benefit; moderate evidence per VA Long COVID guidelines", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Mind Body Intervention #1", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06045338", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Mind%20Body%20Intervention%20#1", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06045338", "title": "Mind Body Intervention for Long COVID-19", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-11-09", "completion_date": "2026-12", "primary_completion_date": "2026-09", "last_updated": "2026-02-18" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Mind-Body Reprocessing Therapy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Mind-Body%20Reprocessing%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05703074", "title": "Mental Intervention and Nicotinamide Riboside Supplementation in Long Covid", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2023-01-30", "completion_date": "2025-06-23", "primary_completion_date": "2024-09-23", "last_updated": "2026-08-25" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Mindful And Conscious Movement-Based Exercise", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06978582", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Mindful%20And%20Conscious%20Movement-Based%20Exercise", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06978582", "title": "Effectiveness and Safety of a Tele-Rehabilitation Program on Fatigue and Related Variables in Chronic Fatigue Syndrome and Post COVID Syndro", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-10-01", "completion_date": "2027-03-30", "primary_completion_date": "2026-12-30", "last_updated": "2026-04-28" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Mindfulness - Mindful Awareness Practices", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Mindfulness%20-%20Mindful%20Awareness%20Practices", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05566379", "title": "Mindfulness in Post Acute Sequelae of SARS-CoV-2 Infection (PASC) Dysautonomia", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-02-28", "completion_date": "2023-07-29", "primary_completion_date": "2023-07-29", "last_updated": "2024-06-14" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Mindfulness-Based Stress Reduction", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05815693", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Mindfulness-Based%20Stress%20Reduction", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05815693", "title": "Cognitive-behavioral Therapy for Mental Disorder in COVID-19 Survivors", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-04-13", "completion_date": "2023-11-30", "primary_completion_date": "2023-11-30", "last_updated": "2023-06-29" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Minimal-Dose Home-Based Resistance Exercise", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Fed, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Minimal-Dose%20Home-Based%20Resistance%20Exercise", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05699538", "title": "Fatigability in Long COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-07-31", "completion_date": "2025-09-30", "primary_completion_date": "2025-07-04", "last_updated": "2026-05-18" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Fed", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Modafinil", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Modafinil", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06404099", "title": "RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2024-08-12", "completion_date": "2026-04-20", "primary_completion_date": "2026-03-24", "last_updated": "2026-06-03" }, { "nct_id": "NCT06404086", "title": "RECOVER-SLEEP: Platform Protocol", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2024-07-31", "completion_date": "2025-12-31", "primary_completion_date": "2025-12-31", "last_updated": "2026-01-22" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Moderna Covid-19 Vaccine", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Network, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06441955", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Moderna%20Covid-19%20Vaccine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06441955", "title": "Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.", "status": "RECRUITING", "phase": "PHASE4", "size_category": "Medium (50-199 participants)", "start_date": "2024-03-01", "completion_date": "2030-09-30", "primary_completion_date": "2030-09-30", "last_updated": "2024-11-27" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Network", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Moderna Mrna Covid-19 Vaccine", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Moderna%20Mrna%20Covid-19%20Vaccine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05212610", "title": "Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reacti", "status": "COMPLETED", "phase": "PHASE4", "size_category": "Medium (50-199 participants)", "start_date": "2022-03-21", "completion_date": "2025-03-07", "primary_completion_date": "2025-03-07", "last_updated": "2026-03-27" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Molecular Hydrogen Produced By A Metallic Magnesium Tablet, Consumed 3X A Day Dissolved In Water. Treatment Duration Is 16 Weeks.", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07753122", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Molecular%20Hydrogen%20Produced%20By%20A%20Metallic%20Magnesium%20Tablet,%20Consumed%203X%20A%20Day%20Dissolved%20In%20Water.%20Treatment%20Duration%20Is%2016%20Weeks.", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07753122", "title": "Controlled Trial of Hydrogen Water as a Treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2026-08-15", "completion_date": "2027-07", "primary_completion_date": "2027-07", "last_updated": "2026-08-07" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Montelukast", "Primary Conditions": [ "Long COVID", "MCAS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Leukotriene receptor antagonist used as add-on in MCAS and sometimes respiratory phenotypes in long COVID. 10mg daily. Supported by observational MCAS data and urticaria RCTs. Low risk; consider for MCAS-overlap with incomplete antihistamine response.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Montelukast", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "2nd most commonly used drug after antihistamines in idiopathic MCAS; RCT evidence from urticaria (34 RCTs) shows modest benefit of adding LTRA to anti", "pub_date": "", "excerpt": "2nd most commonly used drug after antihistamines in idiopathic MCAS; RCT evidence from urticaria (34 RCTs) shows modest benefit of adding LTRA to anti-H1; cysteinyl leukotriene elevation documented during MCAS episodes", "source": "PACVS Evidence Map" } ], "trials": [ { "nct_id": "NCT04695704", "title": "Efficacy of Montelukast in Mild-moderate Respiratory Symptoms in Patients With Long-COVID-19:", "status": "TERMINATED", "phase": "PHASE3", "size_category": "Medium (50-199 participants)", "start_date": "2021-08-11", "completion_date": "2023-08-28", "primary_completion_date": "2023-07-24", "last_updated": "2024-07-03" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Montelukast Tablets Oral Treatment", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Immunomodulatory, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06597682", "Clinical Notes": "Leukotriene antagonist (10mg daily) for MCAS/inflammatory overlap. Supported by MCAS obs + urticaria RCTs. Low-risk add-on.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Montelukast%20Tablets%20Oral%20Treatment", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06597682", "title": "Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2025-03", "completion_date": "2027-07", "primary_completion_date": "2027-07", "last_updated": "2025-03-06" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Immunomodulatory", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Motor Training", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06074848", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Motor%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06074848", "title": "tDCS in the Management of Post-COVID Disorders", "status": "UNKNOWN", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-08-25", "completion_date": "2024-09-28", "primary_completion_date": "2024-07-01", "last_updated": "2024-04-24" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Movement To Rhythm", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Movement%20To%20Rhythm", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01873482", "title": "Traditional African Healing Ceremony in a U.S. Population", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2014-05", "completion_date": "Unknown", "primary_completion_date": "2014-05", "last_updated": "2014-11-03" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Moxibustion", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT02924831", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Moxibustion", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02924831", "title": "High-tech Acupuncture for Treatment of Chronic Fatigue Syndrome", "status": "UNKNOWN", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2016-11", "completion_date": "2018-07", "primary_completion_date": "2018-05", "last_updated": "2016-10-05" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Msc-Derived Exosomes", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05808400", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Msc-Derived%20Exosomes", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05808400", "title": "Safety and Efficacy of Umbilical Cord Mesenchymal Stem Cell Exosomes in Treating Chronic Cough After COVID-19", "status": "UNKNOWN", "phase": "EARLY_PHASE1", "size_category": "Medium (50-199 participants)", "start_date": "2023-02-15", "completion_date": "2025-02-15", "primary_completion_date": "2024-02-15", "last_updated": "2023-04-14" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Multi-Systemic Rehabilitation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Multi-Systemic%20Rehabilitation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06379737", "title": "Multi-systemic Rehabilitative Interventions in Long COVID-19 Patients in Two Different Settings: a Randomized Controlled Trial", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-01-01", "completion_date": "2023-12-20", "primary_completion_date": "2023-12-20", "last_updated": "2024-04-23" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Multicomponent Intervention", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Multicomponent%20Intervention", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06492590", "title": "Long COVID-19 Intervention (COVIDL/MIQoL)", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-01-17", "completion_date": "2025-11-30", "primary_completion_date": "2025-09-30", "last_updated": "2026-01-16" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Multicomponent Treatment", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05719493", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Multicomponent%20Treatment", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05719493", "title": "Effectiveness and Health Benefits of a Nutritional, Chronobiological and Physical Exercise Intervention in Fibromyalgia and Chronic Fatigue ", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-10-04", "completion_date": "2025-12", "primary_completion_date": "2024-05-31", "last_updated": "2024-12-18" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Multidisciplinary Approach", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Network, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06441955", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Multidisciplinary%20Approach", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06441955", "title": "Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.", "status": "RECRUITING", "phase": "PHASE4", "size_category": "Medium (50-199 participants)", "start_date": "2024-03-01", "completion_date": "2030-09-30", "primary_completion_date": "2030-09-30", "last_updated": "2024-11-27" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Network", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Multimodal Intervention In Long Covid19", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05932797", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Multimodal%20Intervention%20In%20Long%20Covid19", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05932797", "title": "Multimodal Long Covid19", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-05-03", "completion_date": "2024-11-18", "primary_completion_date": "2024-11-18", "last_updated": "2023-07-06" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Music Group", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Music%20Group", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06503874", "title": "Improving Attention in Individuals With Long COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-03-22", "completion_date": "2026-03-13", "primary_completion_date": "2026-03-13", "last_updated": "2026-04-02" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "My-Skills For Long Covid", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=My-Skills%20For%20Long%20Covid", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05697042", "title": "Merging Yoga and Self-Management Skills for Symptoms of Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-02-01", "completion_date": "2023-12-30", "primary_completion_date": "2023-12-30", "last_updated": "2024-05-13" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "N-803", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07108036", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=N-803", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07108036", "title": "A Study to Assess Anktiva in Patients With Long Covid-19.", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2025-11-14", "completion_date": "2026-10", "primary_completion_date": "2026-10", "last_updated": "2026-05-11" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "N-Acetylcysteine (NAC)", "Primary Conditions": [ "Long COVID", "Lyme", "ME/CFS", "Other Post-Viral (Post-infectious cough, Q-fever fatigue syndrome, Post-dengue fatigue, Chikungunya post-infectious, Parvovirus B19 GBS, Mycoplasma pneumoniae neurological, Herpes encephalitis sequelae, RIME, etc.)", "POTS" ], "Proposed Mechanism": "Anti-inflammatory, Enrollment: Actual, Enrollment: Estimated, Immunomodulatory", "Evidence Level": "Moderate", "Key Studies / References": [ "PMID:41042957", "PMID:41835354", "PMID:42119693" ], "Ongoing Research": "NCT04542161, NCT03502044, NCT01154647", "Clinical Notes": "NAC 600-1800mg/day. Glutathione/antioxidant support; studied for fatigue/oxidative stress in Long COVID/ME-CFS. Good safety profile; small positive studies.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/compound/12035", "Safety": "Excellent safety profile. GI upset (nausea, vomiting, diarrhea) at high doses. Rare bronchospasm with inhalation. Safe in pregnancy at standard doses.", "Dosing": "600–1800 mg/day divided doses (e.g. 600 mg TID); durations in studies 4–12 weeks.", "aliases": [ "N-Acetylcysteine (NAC)" ], "studies": [ { "pmid": "41042957", "title": "Assessment of the accuracy of initial diagnoses and the frequency of clinical forms of Lyme disease among hospitalized patients: a single-ce", "pub_date": "2025-10-03", "excerpt": "Lyme borreliosis (LB) is one of the most commonly diagnosed tick-borne diseases globally, caused by Borrelia spirochetes. Despite advances in laboratory diagnostics, both overdiagnosis and underdiagnosis of LB remain significant issues. Nonspecific symptoms such as chronic fatigue or musculoskeletal...", "source_page": "lyme" }, { "pmid": "41835354", "title": "Mechanistic Insights and Emerging Therapeutic Strategies in Recurrent Pericarditis.", "pub_date": "2026-03-16", "excerpt": "Recurrent pericarditis is a heterogeneous and often debilitating inflammatory disorder characterized by recurrent flares following a symptom-free interval of at least 4 to 6 weeks. Although most cases in developed countries are idiopathic or post-viral, the condition may arise from autoimmune diseas...", "source_page": "other-post-viral" }, { "pmid": "42119693", "title": "What is the Role of \"the Psyche\"? Long COVID and ME/CFS as Test Cases for Evidence-Based and Patient-Centered Psychiatry and Psychotherapy.", "pub_date": "2026-05-13", "excerpt": "The role of psychological factors in the development and course of Long Covid (LC) and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) remains a subject of controversial debate. We argue that psychologizing LC and ME/CFS carries significant risks: it leads to potentially harmful therapie...", "source_page": "me-cfs" }, { "pmid": "41991875", "title": "[Post-COVID: An inventory focusing on the key complaints PEM and POTS].", "pub_date": "2026-04-17", "excerpt": "More than five years after the start of the COVID-19 pandemic, its long-term effects are increasingly coming into focus. Post-COVID disease poses a significant challenge, - not only for the individuals affected, but also for healthcare providers and society as a whole. In order to improve care for p...", "source_page": "pots" }, { "title": "Yale: vWF normalised 3/3 NAC vs 0/6 controls (p=0.0119); primary mechanism is lipid metabolism restoration (beta-oxidation protection) not spike prote", "pub_date": "", "excerpt": "Yale: vWF normalised 3/3 NAC vs 0/6 controls (p=0.0119); primary mechanism is lipid metabolism restoration (beta-oxidation protection) not spike protein", "source": "PACVS Evidence Map" } ], "trials": [ { "nct_id": "NCT05371288", "title": "The Role of Glutathione Deficiency and MSIDS Variables in Long COVID-19", "status": "WITHDRAWN", "phase": "EARLY_PHASE1", "size_category": null, "start_date": "2025-06", "completion_date": "2025-11", "primary_completion_date": "2025-09", "last_updated": "2024-11-05" }, { "nct_id": "NCT04542161", "title": "Assessment of N-Acetylcysteine as Therapy for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome", "status": "ACTIVE_NOT_RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2020-09-01", "completion_date": "2027-04-30", "primary_completion_date": "2027-04-30", "last_updated": "2026-06-22" }, { "nct_id": "NCT03502044", "title": "New MRT Imaging Biomarkers and Treatment With Kinetic Oscillatory Stimulation (KOS) in Nasal Cavity for Myalgic Encephalomyelitis/Chronic Fa", "status": "UNKNOWN", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2018-04-17", "completion_date": "2020-06-15", "primary_completion_date": "2019-12-31", "last_updated": "2018-04-19" }, { "nct_id": "NCT01154647", "title": "Pain Inhibition in Patients With Rheumatoid Arthritis and Central Sensitivity Syndromes", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2010-09", "completion_date": "Unknown", "primary_completion_date": "2012-09", "last_updated": "2010-07-01" } ], "total_mentions": 9, "types": [ "Behavioral / Protocol / Exercise", "Supplement / Nutraceutical" ], "mechanisms": [ "Anti-inflammatory", "Enrollment: Actual", "Enrollment: Estimated", "Immunomodulatory", "Neurological / Autonomic", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1", "NA", "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)", "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Nad+", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Immunomodulatory, Sponsor Type: Industry", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Nad+", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04604704", "title": "Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2021-01-28", "completion_date": "2023-01-23", "primary_completion_date": "2023-01-23", "last_updated": "2023-01-25" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Immunomodulatory", "Sponsor Type: Industry" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Naltrexone", "Primary Conditions": [ "Long COVID", "Other Post-Viral (Post-infectious cough, Q-fever fatigue syndrome, Post-dengue fatigue, Chikungunya post-infectious, Parvovirus B19 GBS, Mycoplasma pneumoniae neurological, Herpes encephalitis sequelae, RIME, etc.)" ], "Proposed Mechanism": "Enrollment: Actual, Immunomodulatory, Repurposed Drug, Sponsor Type: Industry", "Evidence Level": "Preliminary", "Key Studies / References": [ "PMID:42060160" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Naltrexone", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [ "Naltrexone" ], "studies": [ { "pmid": "42060160", "title": "Low-Dose Naltrexone: What is the Evidence? A Narrative Review.", "pub_date": "2026-04-30", "excerpt": "Naltrexone is prescribed off-label at low doses, typically 0.5-6.0 mg, for a variety of therapeutic indications. This review evaluates the clinical evidence for low-dose naltrexone (LDN). A literature search was conducted in February 2026 across PubMed, Embase and CINAHL for studies published from 1...", "source_page": "other-post-viral" } ], "trials": [ { "nct_id": "NCT04604704", "title": "Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2021-01-28", "completion_date": "2023-01-23", "primary_completion_date": "2023-01-23", "last_updated": "2023-01-25" } ], "total_mentions": 2, "types": [ "Drug (Pharmaceutical)" ], "mechanisms": [ "Enrollment: Actual", "Immunomodulatory", "Repurposed Drug", "Sponsor Type: Industry" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Naltrexone Hcl", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Immunomodulatory, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Naltrexone%20Hcl", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02965768", "title": "Immune Effects of Low-dose Naltrexone in ME/CFS", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2016-01", "completion_date": "2022-08-25", "primary_completion_date": "2022-08-25", "last_updated": "2022-09-02" } ], "total_mentions": 1, "types": [ "Drug (Pharmaceutical)" ], "mechanisms": [ "Enrollment: Actual", "Immunomodulatory", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Narrative Intervention For Long Covid-19", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Narrative%20Intervention%20For%20Long%20Covid-19", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06091293", "title": "Narrative Intervention for Long COVID-19 (NICO)", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-10-01", "completion_date": "2022-12-01", "primary_completion_date": "2022-12-01", "last_updated": "2024-12-10" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Nasafytol®", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Nasafytol®", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06974058", "title": "Study to Investigate the Health Benefits of a Quercetin/Curcumin-Based Supplement for Mild to Moderate Long COVID-19 Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-07-22", "completion_date": "2025-12-14", "primary_completion_date": "2025-11-18", "last_updated": "2025-12-19" } ], "total_mentions": 1, "types": [ "Supplement / Nutraceutical" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Nasal Cpap Treatment During Sleep", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Fed, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Nasal%20Cpap%20Treatment%20During%20Sleep", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00252629", "title": "Sleep Disordered Breathing in Gulf War Illness and the Effect of Nasal CPAP Treatment", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2005-11", "completion_date": "2010-11", "primary_completion_date": "2008-10", "last_updated": "2014-12-11" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Fed", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Nattokinase + Bromelain + Curcumin", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Nattokinase%20+%20Bromelain%20+%20Curcumin", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Hulscher/McCullough 2023: proposed spike protein degradation via fibrinolysis and proteolysis; no published clinical trial in PASC/PACVS; widely promo", "pub_date": "", "excerpt": "Hulscher/McCullough 2023: proposed spike protein degradation via fibrinolysis and proteolysis; no published clinical trial in PASC/PACVS; widely promoted in medical freedom communities — evidence significantly overstated", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Ne3107", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ne3107", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06847191", "title": "NE3107 in Adults With Neurological Symptoms of Long COVID", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2025-04-29", "completion_date": "2026-09-02", "primary_completion_date": "2026-08-06", "last_updated": "2026-09-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Near Infrared Spectroscopy", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07491315", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Near%20Infrared%20Spectroscopy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07491315", "title": "Is Post-exertional Symptom Exacerbation Specific to Patients With Myalgic Encephalomyelitis / Chronic Fatigue Syndrome? A Study Comparing Pa", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-06-24", "completion_date": "2026-12-24", "primary_completion_date": "2026-12-24", "last_updated": "2026-06-08" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Nesa X-Signal", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Network, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07242573", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Nesa%20X-Signal", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07242573", "title": "Effect of Physical Exercise and Neuromodulation on Pain, Sleep and Fatigue in Patients With Fibromyalgia", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-11-01", "completion_date": "2027-12-15", "primary_completion_date": "2027-02-20", "last_updated": "2026-02-24" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Network", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Neural Therapy", "Primary Conditions": [ "PACVS" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Neural%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Single neuraltherapeutic stimulus sufficient to completely reverse persistent post-vaccination musculoskeletal pain", "pub_date": "", "excerpt": "Single neuraltherapeutic stimulus sufficient to completely reverse persistent post-vaccination musculoskeletal pain", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Neuroflex", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Neuroflex", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05705193", "title": "Brain-Training Treatment for Long COVID in Older Adults", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-04-07", "completion_date": "2025-12-13", "primary_completion_date": "2025-12-13", "last_updated": "2026-08-14" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Neuromodulation Nesa Nxsignal® Device", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05681455", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Neuromodulation%20Nesa%20Nxsignal®%20Device", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05681455", "title": "Physiotherapy for Persistent Function by Superficial Neuromodulation", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-06-15", "completion_date": "2023-07-30", "primary_completion_date": "2023-06-15", "last_updated": "2023-06-06" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Neuromuscular Evaluation", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Neuromuscular%20Evaluation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04363606", "title": "Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability", "status": "TERMINATED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2020-05-27", "completion_date": "2022-03-01", "primary_completion_date": "2021-08-26", "last_updated": "2025-03-25" }, { "nct_id": "NCT03849326", "title": "Chronic Fatigue Etiology in Intensive Care Unit Survivors: the Role of Neuromuscular Function", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2023-12", "completion_date": "2025-04", "primary_completion_date": "2025-03", "last_updated": "2023-04-26" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Nexj Connected Wellness", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05019963", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Nexj%20Connected%20Wellness", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05019963", "title": "Enhancing COVID Rehabilitation With Technology", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-05-02", "completion_date": "2024-09", "primary_completion_date": "2024-08", "last_updated": "2024-07-03" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Nicotinamide Riboside", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Nicotinamide%20Riboside", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05703074", "title": "Mental Intervention and Nicotinamide Riboside Supplementation in Long Covid", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2023-01-30", "completion_date": "2025-06-23", "primary_completion_date": "2024-09-23", "last_updated": "2026-08-25" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Nivolumab And Ipilimumab", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05597800", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Nivolumab%20And%20Ipilimumab", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05597800", "title": "Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome", "status": "NOT_YET_RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2023-02-01", "completion_date": "2027-03-30", "primary_completion_date": "2026-12-31", "last_updated": "2022-10-28" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Nmn", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Nmn", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Isman 2024: Chalder fatigue 25.9→17.4 (p<0.0001) but combined with LDN (cannot isolate); dedicated NR RCT: no significant effect vs placebo; NAD+ depl", "pub_date": "", "excerpt": "Isman 2024: Chalder fatigue 25.9→17.4 (p<0.0001) but combined with LDN (cannot isolate); dedicated NR RCT: no significant effect vs placebo; NAD+ depletion well documented in PASC", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "No Physical Exercise", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Anti-inflammatory, Enrollment: Estimated, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07397910", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=No%20Physical%20Exercise", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07397910", "title": "Clinical Trial on a Natural Compound to Improve Chronic Inflammation After SARS-CoV-2 Infection", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-02-23", "completion_date": "2026-08-03", "primary_completion_date": "2026-07-06", "last_updated": "2026-02-09" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Anti-inflammatory", "Enrollment: Estimated", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Non-Invasive Neuromodulation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06456502", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Non-Invasive%20Neuromodulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06456502", "title": "Effectiveness of Non-invasive Neuromodulation in Patients With Long-COVID", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-06", "completion_date": "2026-06-30", "primary_completion_date": "2026-06-30", "last_updated": "2024-06-13" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Non-Invasive Vagus Nerve Stimulation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Non-Invasive%20Vagus%20Nerve%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05630040", "title": "VNS for Long-COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-11-11", "completion_date": "2024-10-03", "primary_completion_date": "2024-10-03", "last_updated": "2024-11-08" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Normal Saline", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT02854683", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Normal%20Saline", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02854683", "title": "Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients", "status": "UNKNOWN", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2016-02", "completion_date": "2021-12", "primary_completion_date": "2021-12", "last_updated": "2021-06-10" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Nortriptyline", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Nortriptyline", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT03844412", "title": "Vestibulodynia: Understanding Pathophysiology and Determining Appropriate Treatments", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2019-11-04", "completion_date": "2024-05-30", "primary_completion_date": "2024-03-13", "last_updated": "2026-03-19" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Nutraceutical Supplements", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Metabolic / Mitochondrial, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Nutraceutical%20Supplements", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01471652", "title": "Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder", "status": "WITHDRAWN", "phase": "PHASE2", "size_category": null, "start_date": "2012-03", "completion_date": "2013-02", "primary_completion_date": "2013-02", "last_updated": "2015-04-13" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Metabolic / Mitochondrial", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [] }, { "Therapeutic Agent": "Nutritional Blend (Immunerecov).", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Immunomodulatory, Sponsor Type: Other", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06166030", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Nutritional%20Blend", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06166030", "title": "IMMUNERECOV CONTRIBUTES TO IMPROVEMENT OF RESPIRATORY AND IMMUNOLOGICAL RESPONSE IN POST-COVID-19 PATIENTS.", "status": "UNKNOWN", "phase": "PHASE3", "size_category": "Medium (50-199 participants)", "start_date": "2023-12-10", "completion_date": "2024-12-15", "primary_completion_date": "2024-12-10", "last_updated": "2023-12-12" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Immunomodulatory", "Sponsor Type: Other" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Omega-3", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Omega-3", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05121766", "title": "Feasibility Pilot Clinical Trial of Omega-3 Supplement vs. Placebo for Post Covid-19 Recovery Among Health Care Workers", "status": "TERMINATED", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2022-01-10", "completion_date": "2023-04-21", "primary_completion_date": "2023-04-21", "last_updated": "2024-09-19" } ], "total_mentions": 1, "types": [ "Supplement / Nutraceutical" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "On Site Exercise Rehabilitation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=On%20Site%20Exercise%20Rehabilitation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05398692", "title": "Long COVID-19 Rehabilitation & Recovery Research Program", "status": "TERMINATED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-02-02", "completion_date": "2023-12-31", "primary_completion_date": "2023-12-31", "last_updated": "2025-09-22" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "One Day Course", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06085911", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=One%20Day%20Course", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06085911", "title": "RCT Long COVID-19 Rehabilitation", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-11-03", "completion_date": "2025-11", "primary_completion_date": "2025-02", "last_updated": "2024-06-11" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Online Visit", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07352254", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Online%20Visit", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07352254", "title": "OutreAch MediCal Care for HousEbound Patients With Post-COVID-19 Syndrome or ME/CFS of Any Cause (ACCESS)", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2026-01", "completion_date": "2028-12", "primary_completion_date": "2028-10", "last_updated": "2026-01-21" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Oral Rehydration Solution", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT02854683", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Oral%20Rehydration%20Solution", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02854683", "title": "Reducing Orthostatic Intolerance With Oral Rehydration in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients", "status": "UNKNOWN", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2016-02", "completion_date": "2021-12", "primary_completion_date": "2021-12", "last_updated": "2021-06-10" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Osteopathic Manipulative Therapy Long-Covid Protocol", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06883513", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Osteopathic%20Manipulative%20Therapy%20Long-Covid%20Protocol", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06883513", "title": "Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-05-01", "completion_date": "2025-07-03", "primary_completion_date": "2025-07-03", "last_updated": "2025-03-19" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Osteopathic Manipulative Therapy Not Long-Covid Treatment Protocol", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06883513", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Osteopathic%20Manipulative%20Therapy%20Not%20Long-Covid%20Treatment%20Protocol", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06883513", "title": "Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-05-01", "completion_date": "2025-07-03", "primary_completion_date": "2025-07-03", "last_updated": "2025-03-19" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Osteopathic Manipulative Treatment In Addition To Physiotherapy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05012826", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Osteopathic%20Manipulative%20Treatment%20In%20Addition%20To%20Physiotherapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05012826", "title": "Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-09-20", "completion_date": "2023-07-06", "primary_completion_date": "2023-06-06", "last_updated": "2023-05-10" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Otago Home Exercise Program", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06534164", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Otago%20Home%20Exercise%20Program", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06534164", "title": "Telerehabilitation of Balance Clinical and Economic Decision Support System", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2025-09-01", "completion_date": "2026-08-31", "primary_completion_date": "2026-06-30", "last_updated": "2025-07-10" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Outpatient Clinic With Multimodal Integrative Medicine And Naturopathy For Post-Covid-19 Patients", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Outpatient%20Clinic%20With%20Multimodal%20Integrative%20Medicine%20And%20Naturopathy%20For%20Post-Covid-19%20Patients", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05630378", "title": "Evaluation of an Integrative Medicine Outpatient Clinical Setting for Post-COVID-19 Patients", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-05-11", "completion_date": "2023-06-30", "primary_completion_date": "2023-02-01", "last_updated": "2023-12-04" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Pacing", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pacing", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01512342", "title": "Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2011-08", "completion_date": "2014-08", "primary_completion_date": "2014-06", "last_updated": "2015-12-17" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Pain Relaxation Techniques", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06235177", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pain%20Relaxation%20Techniques", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06235177", "title": "Psychoneuromentalism Disorder: A Medical Condition That Affects People With Psychological Impairments From Health Issues", "status": "UNKNOWN", "phase": "EARLY_PHASE1", "size_category": "Small (<50 participants)", "start_date": "2024-10-10", "completion_date": "2025-09-19", "primary_completion_date": "2025-06-29", "last_updated": "2024-08-12" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Paragon Novel Metabolic Regulator", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Metabolic / Mitochondrial, Sponsor Type: Industry", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07627815", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Paragon%20Novel%20Metabolic%20Regulator", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07627815", "title": "Evaluating the Safety and Efficacy of PNMR as Treatment for Long COVID", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2026-05-20", "completion_date": "2026-12-26", "primary_completion_date": "2026-08-26", "last_updated": "2026-06-04" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Metabolic / Mitochondrial", "Sponsor Type: Industry" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Parasym Device", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Parasym%20Device", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05225220", "title": "Multimodal Investigation of Post COVID-19 in Females", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-03-01", "completion_date": "2023-01-06", "primary_completion_date": "2023-01-06", "last_updated": "2023-07-07" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Pasc Core", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pasc%20Core", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05965739", "title": "RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2023-09-01", "completion_date": "2024-12-17", "primary_completion_date": "2024-09-19", "last_updated": "2026-08-11" }, { "nct_id": "NCT05965752", "title": "RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2023-09-01", "completion_date": "2024-06-10", "primary_completion_date": "2024-06-10", "last_updated": "2025-07-18" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Pascal Device", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pascal%20Device", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06739668", "title": "Humanity Neurotech Device Clinical Trial in Adults With Long COVID Cognitive Dysfunction", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-12-19", "completion_date": "2025-12-01", "primary_completion_date": "2025-12-01", "last_updated": "2026-02-02" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Patient-Partner Videotelephone-Delivered Cognitive Behavioral Stress Management Intervention", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Immunomodulatory, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Patient-Partner%20Videotelephone-Delivered%20Cognitive%20Behavioral%20Stress%20Management%20Intervention", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01650636", "title": "Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2010-10", "completion_date": "2017-05", "primary_completion_date": "2017-05", "last_updated": "2018-12-10" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Immunomodulatory", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Patient-Partner Videotelephone-Delivered Health Information", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Immunomodulatory, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Patient-Partner%20Videotelephone-Delivered%20Health%20Information", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01650636", "title": "Patient-Partner Stress Management Effects on Chronic Fatigue Syndrome Symptoms and Neuroimmune Process", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2010-10", "completion_date": "2017-05", "primary_completion_date": "2017-05", "last_updated": "2018-12-10" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Immunomodulatory", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Paxlovid (Nirmatrelvir + Ritonavir)", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Antiviral / Persistence, Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Network", "Evidence Level": "Moderate", "Key Studies / References": [ "PMID:42406565", "PMID:42402140" ], "Ongoing Research": "NCT07597902, NCT05852873, NCT06441955", "Clinical Notes": "Investigational for listed conditions. 5 associated trial(s) and 3 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Paxlovid", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [ "Paxlovid (Nirmatrelvir + Ritonavir)" ], "studies": [ { "pmid": "42406565", "title": "Evaluation of nirmatrelvir/ritonavir treatment for COVID-19 on health-related outcomes: a global economic value systematic literature review", "pub_date": "2026-07-06", "excerpt": "Nirmatrelvir/ritonavir (NMV/r) A systematic search of Embase, PubMed, Cochrane, and EconLit and of conference and health technology assessment agency websites was performed to identify economic analyses published between January 2022 and October 2025. Of the 33 included economic evaluations, most we...", "source_page": "long-covid" }, { "pmid": "42402140", "title": "[Long-COVID syndrome and lung-specific abnormalities following COVID-19].", "pub_date": "2026-07-05", "excerpt": "Following the acute phase of a SARS-CoV-2 infection, post-COVID - or long-COVID - syndrome may develop. This condition is characterized by unpleasant, persistent or new-onset symptoms following the acute phase of the infection. It might lead to an impaired health-related quality of life of affected ...", "source_page": "long-covid" }, { "title": "No significant symptom improvement in either trial; viral persistence as sole causal mechanism for established long COVID not supported by RCT evidenc", "pub_date": "", "excerpt": "No significant symptom improvement in either trial; viral persistence as sole causal mechanism for established long COVID not supported by RCT evidence", "source": "PACVS Evidence Map" } ], "trials": [ { "nct_id": "NCT07597902", "title": "SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction", "status": "NOT_YET_RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2026-06-01", "completion_date": "2028-06-30", "primary_completion_date": "2028-06-30", "last_updated": "2026-05-19" }, { "nct_id": "NCT05965726", "title": "RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2023-07-26", "completion_date": "2025-03-13", "primary_completion_date": "2024-12-05", "last_updated": "2026-03-27" }, { "nct_id": "NCT05595369", "title": "RECOVER-VITAL: Platform Protocol to Measure the Effects of Antiviral Therapies on Long COVID Symptoms", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2023-07-26", "completion_date": "2025-03-13", "primary_completion_date": "2024-08-06", "last_updated": "2025-12-02" }, { "nct_id": "NCT05852873", "title": "PAxlovid loNg cOvid-19 pRevention triAl With recruitMent In the Community in Norway", "status": "ACTIVE_NOT_RECRUITING", "phase": "PHASE3", "size_category": "Very Large (1000+ participants)", "start_date": "2023-05-12", "completion_date": "2027-06-11", "primary_completion_date": "2025-09-09", "last_updated": "2025-11-21" }, { "nct_id": "NCT05576662", "title": "Paxlovid for Treatment of Long Covid", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2022-11-08", "completion_date": "2023-09-12", "primary_completion_date": "2023-08-14", "last_updated": "2025-09-04" } ], "total_mentions": 11, "types": [ "Behavioral / Protocol / Exercise", "Drug (Pharmaceutical)", "Medical Device" ], "mechanisms": [ "Antiviral / Persistence", "Enrollment: Actual", "Enrollment: Estimated", "Sponsor Type: Network", "Sponsor Type: Other" ], "trial_types": [ "PHASE2", "PHASE3", "PHASE4" ], "trial_sizes": [ "Large (200-999 participants)", "Medium (50-199 participants)", "Very Large (1000+ participants)" ] }, { "Therapeutic Agent": "Peer Mentoring", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06095297", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Peer%20Mentoring", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06095297", "title": "Long COVID Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-04-25", "completion_date": "2027-12", "primary_completion_date": "2026-12", "last_updated": "2026-04-13" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Pentoxifylline", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pentoxifylline", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05513560", "title": "RECLAIM: Recovering From COVID-19 Lingering Symptoms Adaptive Integrative Medicine", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2023-05-31", "completion_date": "2025-12-31", "primary_completion_date": "2025-03-31", "last_updated": "2026-02-23" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Perceive-Outreach Disease Management Program", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07661862", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Perceive-Outreach%20Disease%20Management%20Program", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07661862", "title": "PERCEIVE-Outreach: A Scalable, Risk-Based Model for Managing Persistent Cardiovascular Impact in Long COVID", "status": "RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2026-04-01", "completion_date": "2029-04-01", "primary_completion_date": "2029-04-01", "last_updated": "2026-10-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Personalised Exercise Program", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Personalised%20Exercise%20Program", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06822179", "title": "Effectiveness of a Personalized In-home Telerehabilitation Program on Self-Care in Patients With Long COVID", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2025-03-01", "completion_date": "2026-09-01", "primary_completion_date": "2026-06-01", "last_updated": "2026-09-15" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Personalized Cardiopulmonary Rehabilitation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Personalized%20Cardiopulmonary%20Rehabilitation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06404060", "title": "RECOVER-ENERGIZE Platform Protocol_Appendix A (Exercise Intolerance)", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2024-07-17", "completion_date": "2026-05-05", "primary_completion_date": "2026-03-10", "last_updated": "2026-07-08" }, { "nct_id": "NCT06404047", "title": "RECOVER-ENERGIZE Platform Protocol", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2024-07-17", "completion_date": "2025-10-30", "primary_completion_date": "2025-10-30", "last_updated": "2025-11-14" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Pet Scan", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pet%20Scan", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05543590", "title": "Effect of Plasmapheresis on Clinical Improvement and Biological Parameters of Patients With Long-haul COVID", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2023-02", "completion_date": "2025-10", "primary_completion_date": "2025-02", "last_updated": "2023-08-14" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Pfizer-Biontech Mrna Covid-19 Vaccine", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pfizer-Biontech%20Mrna%20Covid-19%20Vaccine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05212610", "title": "Assessing Safety of Coronavirus Infection (COVID-19) Messenger RNA (mRNA) Vaccine Administration in the Setting of a Previous Adverse Reacti", "status": "COMPLETED", "phase": "PHASE4", "size_category": "Medium (50-199 participants)", "start_date": "2022-03-21", "completion_date": "2025-03-07", "primary_completion_date": "2025-03-07", "last_updated": "2026-03-27" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Pg2", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pg2", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00518869", "title": "Complementary Treatment of PG2 to Improve Clinical Benefit Response and Quality of Life in Fatigue", "status": "TERMINATED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2007-09", "completion_date": "2009-12", "primary_completion_date": "2008-06", "last_updated": "2025-06-04" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Phosphatidylcholine ± Computer-Assisted Cognitive Training", "Primary Conditions": [ "PACVS" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Phosphatidylcholine%20±%20Computer-Assisted%20Cognitive%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Both treatment groups improved vs control; PACVS patients explicitly included alongside PACS", "pub_date": "", "excerpt": "Both treatment groups improved vs control; PACVS patients explicitly included alongside PACS", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Phosphoserine Plus Vitamin C", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Phosphoserine%20Plus%20Vitamin%20C", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT03186027", "title": "Coenzyme Q10 Plus NADH Supplementation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2017-06-28", "completion_date": "2021-09-01", "primary_completion_date": "2020-05-28", "last_updated": "2022-09-21" } ], "total_mentions": 1, "types": [ "Supplement / Nutraceutical" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Photobiomodulation", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07546539", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Photobiomodulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07546539", "title": "Photobiomodulation in Chronic Fatigue Syndrome", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-06-15", "completion_date": "2026-09", "primary_completion_date": "2026-07-15", "last_updated": "2026-06-24" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Photobiomodulation Therapy", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06145867", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Photobiomodulation%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05760092", "title": "The Use of Photobiomodulation in the Treatment of Oral Complaints of Long COVID-19.A Randomized Controlled Trial.", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-03-01", "completion_date": "2024-03-08", "primary_completion_date": "2024-02-01", "last_updated": "2024-03-12" }, { "nct_id": "NCT06145867", "title": "A Feasibility Study: Assessing Photobiomodulation in Myalgic Encephalomyelitis", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-04-24", "completion_date": "2024-08-01", "primary_completion_date": "2024-08-01", "last_updated": "2024-04-29" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA", "PHASE2" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Physical Activity Behavioural Modification", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Physical%20Activity%20Behavioural%20Modification", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05752331", "title": "Feasibility of Personalised Health Behaviour Coaching to Support Symptoms and Activities of Daily Living in Those With Long COVID-19.", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-11-01", "completion_date": "2023-06-15", "primary_completion_date": "2023-05-31", "last_updated": "2023-08-04" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Physical Effort Stimulation", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Nih, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06472622", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Physical%20Effort%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06472622", "title": "Functional Neuroimaging to Detect the Neural Signatures of the Unpleasantness of Pain and Effort", "status": "RECRUITING", "phase": "EARLY_PHASE1", "size_category": "Small (<50 participants)", "start_date": "2025-04-09", "completion_date": "2034-06-30", "primary_completion_date": "2034-06-30", "last_updated": "2026-09-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Nih", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Physical Exercise", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Anti-inflammatory, Enrollment: Estimated, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07397910", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Physical%20Exercise", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07397910", "title": "Clinical Trial on a Natural Compound to Improve Chronic Inflammation After SARS-CoV-2 Infection", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-02-23", "completion_date": "2026-08-03", "primary_completion_date": "2026-07-06", "last_updated": "2026-02-09" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Anti-inflammatory", "Enrollment: Estimated", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Physical Exercise Program", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05094622", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Physical%20Exercise%20Program", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05094622", "title": "Physical Training in Patients With POTS After Covid-19", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-01-10", "completion_date": "2025-12", "primary_completion_date": "2023-12-31", "last_updated": "2025-04-06" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Physical Fatigue", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07278388", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Physical%20Fatigue", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07278388", "title": "Neural Mechanisms of Fatigue in Post-Acute Sequela of SARS-CoV-2", "status": "RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2025-07-16", "completion_date": "2029-12-31", "primary_completion_date": "2029-12-31", "last_updated": "2025-12-12" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Physical Rehabilitation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Physical%20Rehabilitation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07651371", "title": "Effects of a Physical Rehabilitation Program on Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-01-05", "completion_date": "2024-12-15", "primary_completion_date": "2023-12-15", "last_updated": "2026-06-16" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Physical Therapy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07254377", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Physical%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07254377", "title": "Design and Validation of Innovative Strategies Based on Dual-Task Approach", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-11-01", "completion_date": "2027-02-28", "primary_completion_date": "2026-03-30", "last_updated": "2025-12-11" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Physical Training Program", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Network, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07242573", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Physical%20Training%20Program", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07242573", "title": "Effect of Physical Exercise and Neuromodulation on Pain, Sleep and Fatigue in Patients With Fibromyalgia", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-11-01", "completion_date": "2027-12-15", "primary_completion_date": "2027-02-20", "last_updated": "2026-02-24" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Network", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Physical, Occupational, Speech Therapy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Physical,%20Occupational,%20Speech%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06234462", "title": "A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid", "status": "WITHDRAWN", "phase": "PHASE2", "size_category": null, "start_date": "2025-06", "completion_date": "2025-10-01", "primary_completion_date": "2025-09-01", "last_updated": "2025-08-26" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [] }, { "Therapeutic Agent": "Physiological Evaluation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Network, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06441955", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Physiological%20Evaluation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06441955", "title": "Covid-19 Long Haul Preventative and Health Promotion Care Clinical Trial Acceleration Program.", "status": "RECRUITING", "phase": "PHASE4", "size_category": "Medium (50-199 participants)", "start_date": "2024-03-01", "completion_date": "2030-09-30", "primary_completion_date": "2030-09-30", "last_updated": "2024-11-27" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Network", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Physiotherapy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05040893, NCT05012826", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Physiotherapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05040893", "title": "A Pilot Study of a PhysiOthErapy-based Tailored Intervention for Long COVID (COVID-19)", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-03-04", "completion_date": "2023-11-30", "primary_completion_date": "2023-08-09", "last_updated": "2023-08-29" }, { "nct_id": "NCT05012826", "title": "Osteopathy and Physiotherapy Compared to Physiotherapy Alone on Fatigue and Functional Status in Long COVID", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-09-20", "completion_date": "2023-07-06", "primary_completion_date": "2023-06-06", "last_updated": "2023-05-10" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise", "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Physiothreapy Protocol", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07046208", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Physiothreapy%20Protocol", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07046208", "title": "Effects os Physiotherapeutic Rehabilitation on Function Autonomic and Inflammatory in Patients With Long Covid", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-08-11", "completion_date": "2026-09-30", "primary_completion_date": "2026-08-10", "last_updated": "2025-07-01" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Pirfenidone", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Repurposed Drug, Sponsor Type: Other", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06928272", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pirfenidone", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06928272", "title": "Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study", "status": "RECRUITING", "phase": "PHASE3", "size_category": "Large (200-999 participants)", "start_date": "2025-09-10", "completion_date": "2027-12", "primary_completion_date": "2026-12", "last_updated": "2026-10-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Repurposed Drug", "Sponsor Type: Other" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Plasma Exchange Procedure", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Plasma%20Exchange%20Procedure", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05445674", "title": "Plasma Exchange Therapy for Post- COVID-19 Condition: A Pilot, Randomized Double-Blind Study", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2022-09-22", "completion_date": "2023-06-06", "primary_completion_date": "2023-06-06", "last_updated": "2023-06-07" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Plasmapheresis", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Plasmapheresis", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05543590", "title": "Effect of Plasmapheresis on Clinical Improvement and Biological Parameters of Patients With Long-haul COVID", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2023-02", "completion_date": "2025-10", "primary_completion_date": "2025-02", "last_updated": "2023-08-14" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Plitidepsin 1.5 Mg/Day", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06766825", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Plitidepsin%201.5%20Mg/Day", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06766825", "title": "Study to Evaluate the Efficacy and Safety of Plitidepsin in Adults With Post-COVID-19 Condition (PCC)", "status": "ACTIVE_NOT_RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2025-02-07", "completion_date": "2026-09-10", "primary_completion_date": "2026-09-10", "last_updated": "2026-07-14" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Portable Mask For Respiratory Gas Analysis", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Portable%20Mask%20For%20Respiratory%20Gas%20Analysis", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06933017", "title": "Feasibility of an Augmented Two-Day Step Test and Causal Modeling for Post-Exertional Symptom Exacerbation in Post Covid-19 Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-03-20", "completion_date": "2025-07-03", "primary_completion_date": "2025-07-03", "last_updated": "2025-07-08" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Posture Study, Autonomic Function Tests, And A Stress Test", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Posture%20Study,%20Autonomic%20Function%20Tests,%20And%20A%20Stress%20Test", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT03029377", "title": "Noradrenergic and Stress-Related Etiologies of Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2017-01", "completion_date": "2018-02-23", "primary_completion_date": "2018-02-23", "last_updated": "2018-04-26" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Prednisolone", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05619653", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Prednisolone", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05619653", "title": "Myocardial Protection in Patients With Post-acute Inflammatory Cardiac Involvement Due to COVID-19", "status": "ACTIVE_NOT_RECRUITING", "phase": "PHASE3", "size_category": "Large (200-999 participants)", "start_date": "2022-12-12", "completion_date": "2026-03-31", "primary_completion_date": "2025-08-08", "last_updated": "2025-12-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Prednisone", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Immunomodulatory, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06597682", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Prednisone", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06597682", "title": "Evaluating Immunomodulatory Interventions in Post-Acute Sequelae of SARS-CoV-2 InfEction", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2025-03", "completion_date": "2027-07", "primary_completion_date": "2027-07", "last_updated": "2025-03-06" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Immunomodulatory", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Pregabalin", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Network, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pregabalin", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05967052", "title": "Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation", "status": "TERMINATED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-10-24", "completion_date": "2025-09-11", "primary_completion_date": "2025-09-11", "last_updated": "2026-06-17" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Network", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Preprocessed Thawed Autologous Fmt", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Preprocessed%20Thawed%20Autologous%20Fmt", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT03691987", "title": "The Comeback Study", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2019-02-15", "completion_date": "2023-12-31", "primary_completion_date": "2023-03-01", "last_updated": "2024-02-23" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Preprocessed Thawed Donor Fmt", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Preprocessed%20Thawed%20Donor%20Fmt", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT03691987", "title": "The Comeback Study", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2019-02-15", "completion_date": "2023-12-31", "primary_completion_date": "2023-03-01", "last_updated": "2024-02-23" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Pressure Biofeedback Unit", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pressure%20Biofeedback%20Unit", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07397130", "title": "Inspiratory Muscle Pressure and Diaphragmatic Strength in Women With Long COVID-19: A Pressure Biofeedback-Guided Training Study", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-07-01", "completion_date": "2025-10-01", "primary_completion_date": "2025-08-01", "last_updated": "2026-02-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Pro2", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06091358", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pro2", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06091358", "title": "Inspiratory Muscle Training in People With Long COVID-19- A Pilot Investigation.", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-10-20", "completion_date": "2024-04-20", "primary_completion_date": "2024-03-29", "last_updated": "2023-11-30" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Probiotic", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05975034", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Probiotic", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05975034", "title": "Investigation of the Use of a Probiotic Supplement in People With Long COVID", "status": "UNKNOWN", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2023-06-12", "completion_date": "2023-12-11", "primary_completion_date": "2023-12-11", "last_updated": "2023-08-03" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Probiotic Agent", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Probiotic%20Agent", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06643299", "title": "Probiotic Use for Recovery Enhancement From Long COVID-19", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2025-05-13", "completion_date": "2026-07-02", "primary_completion_date": "2026-07-02", "last_updated": "2026-08-07" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Probiotics", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT03773003", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Probiotics", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05080244", "title": "WHO COVID-19 - Evaluation of the Efficacy of Probiotics to Reduce the Occurrence of Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2021-10-28", "completion_date": "2022-12-04", "primary_completion_date": "2022-12-04", "last_updated": "2023-11-07" }, { "nct_id": "NCT03773003", "title": "Research for Pathophysiology of Cancer Related Fatigue (CRF) and Chronic Fatigue (CFS/ME)", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-07-20", "completion_date": "2025-12-01", "primary_completion_date": "2025-07-01", "last_updated": "2025-05-29" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Processing Speed Training", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06095297, NCT07523113", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Processing%20Speed%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06095297", "title": "Long COVID Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-04-25", "completion_date": "2027-12", "primary_completion_date": "2026-12", "last_updated": "2026-04-13" }, { "nct_id": "NCT07523113", "title": "ME/CFS Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-06-23", "completion_date": "2028-06", "primary_completion_date": "2027-06", "last_updated": "2026-08-14" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Progressive Muscle Relaxation Protocol", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other Gov, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Progressive%20Muscle%20Relaxation%20Protocol", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06492577", "title": "Combined Pulmonary Rehabilitation and PMR for Long-Term COVID-19 Symptoms: A RCT", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-07-15", "completion_date": "2024-12-01", "primary_completion_date": "2024-10-06", "last_updated": "2024-12-03" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other Gov", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Prolonged Fasting", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Prolonged%20Fasting", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07418567", "title": "A Fasting Pilot Study for Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-05-01", "completion_date": "2025-12-01", "primary_completion_date": "2025-11-01", "last_updated": "2026-02-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Propranolol 20Mg", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Propranolol%2020Mg", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Significant HR reduction p=0.028; significant symptom burden reduction p=0.007; best pharmacological RCT evidence for POTS; applicable to post-COVID P", "pub_date": "", "excerpt": "Significant HR reduction p=0.028; significant symptom burden reduction p=0.007; best pharmacological RCT evidence for POTS; applicable to post-COVID POTS phenotype", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Provider Counseling", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Provider%20Counseling", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06234462", "title": "A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid", "status": "WITHDRAWN", "phase": "PHASE2", "size_category": null, "start_date": "2025-06", "completion_date": "2025-10-01", "primary_completion_date": "2025-09-01", "last_updated": "2025-08-26" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [] }, { "Therapeutic Agent": "Ps23 Heat-Treated", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ps23%20Heat-Treated", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05813899", "title": "Efficacy of Lactobacillus Paracasei PS23 for Patients With Post-COVID-19 Syndrome", "status": "TERMINATED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-01-16", "completion_date": "2024-04-30", "primary_completion_date": "2023-12-31", "last_updated": "2024-08-15" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Psychoeducation / Cbt For Cognitive Symptoms", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Psychoeducation%20/%20Cbt%20For%20Cognitive%20Symptoms", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Cognitive and affective psychoeducation interventions for long COVID cognitive complaints; results published 2025", "pub_date": "", "excerpt": "Cognitive and affective psychoeducation interventions for long COVID cognitive complaints; results published 2025", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Psychological Tests, Eeg, Magnetic Resonance", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06876948", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Psychological%20Tests,%20Eeg,%20Magnetic%20Resonance", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06876948", "title": "NENCA Study on Neurological Complications of Long COVID-19 in Children and Adolescents; Neurophysiological, Electroencephalographic and Neur", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-03-29", "completion_date": "2026-04-28", "primary_completion_date": "2025-03-29", "last_updated": "2025-03-14" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Psychology Interventions", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05705154", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Psychology%20Interventions", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05705154", "title": "Connecting Breath and Mind for CYP With Long COVID", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-04-30", "completion_date": "2024-03-30", "primary_completion_date": "2024-03-30", "last_updated": "2023-09-08" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Psychosocial Challenge Involving Socioevaluative Public Speaking", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Sponsor Type: Fed, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Psychosocial%20Challenge%20Involving%20Socioevaluative%20Public%20Speaking", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00100412", "title": "Hyporeactivity and Gulf War Illness", "status": "COMPLETED", "phase": "NA", "size_category": null, "start_date": "1999-10", "completion_date": "2002-09", "primary_completion_date": "Unknown", "last_updated": "2009-01-21" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Sponsor Type: Fed", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Psychotherapy", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Network, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Psychotherapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05967052", "title": "Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation", "status": "TERMINATED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-10-24", "completion_date": "2025-09-11", "primary_completion_date": "2025-09-11", "last_updated": "2026-06-17" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Network", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Pulley", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pulley", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07651371", "title": "Effects of a Physical Rehabilitation Program on Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-01-05", "completion_date": "2024-12-15", "primary_completion_date": "2023-12-15", "last_updated": "2026-06-16" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Pulmonary Rehabilitation In Primary Care", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pulmonary%20Rehabilitation%20In%20Primary%20Care", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05244044", "title": "Pulmonary Rehabilitation for Long COVID (Post COVID-19 Condition)", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-04-19", "completion_date": "2024-02-29", "primary_completion_date": "2023-12-18", "last_updated": "2024-10-01" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Pulmonary Rehabilitation Protocol", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other Gov, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pulmonary%20Rehabilitation%20Protocol", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06492577", "title": "Combined Pulmonary Rehabilitation and PMR for Long-Term COVID-19 Symptoms: A RCT", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-07-15", "completion_date": "2024-12-01", "primary_completion_date": "2024-10-06", "last_updated": "2024-12-03" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other Gov", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Pursed Lip Breathing", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pursed%20Lip%20Breathing", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05770193", "title": "Effect of Kinesio Tape Versus Diaphragmatic Breathing Exercise In Post COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-03-11", "completion_date": "2023-11-30", "primary_completion_date": "2023-08-30", "last_updated": "2023-12-05" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Pycnogenol®", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pycnogenol®", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05890534", "title": "Pycnogenol® in Post-COVID-19 Condition", "status": "COMPLETED", "phase": "PHASE3", "size_category": "Medium (50-199 participants)", "start_date": "2023-06-07", "completion_date": "2025-01-31", "primary_completion_date": "2024-11-05", "last_updated": "2026-04-29" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Pyridostigmine", "Primary Conditions": [ "Long COVID", "ME/CFS", "POTS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06366724", "Clinical Notes": "Crossover RCT + review supports hemodynamic benefit, esp hyperadrenergic POTS. 30-60mg TID. Cholinergic SE dose-limiting. Reasonable targeted option.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/compound/4991", "Safety": "Cholinergic side effects (GI cramping, diarrhea, salivation, sweating, bradycardia). Avoid in asthma, mechanical obstruction. Overdose risk cholinergic crisis.", "Dosing": "30–60 mg TID (sometimes 30 mg); titrate; study durations often 4–8 weeks for hemodynamic assessment.", "aliases": [], "studies": [ { "title": "Beneficial effect on hemodynamics in POTS; particularly relevant for hyperadrenergic phenotype; 21-RCT systematic review (2025)", "pub_date": "", "excerpt": "Beneficial effect on hemodynamics in POTS; particularly relevant for hyperadrenergic phenotype; 21-RCT systematic review (2025)", "source": "PACVS Evidence Map" } ], "trials": [ { "nct_id": "NCT06366724", "title": "LIFT: Life Improvement Trial", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2024-09-10", "completion_date": "2026-11", "primary_completion_date": "2026-09", "last_updated": "2025-10-22" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Pyridostigmine Bromide", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Acetylcholinesterase inhibitor. RCT support for hemodynamics in POTS. 30-60mg TID. Cholinergic SE dose-limiting. Targeted for hyperadrenergic POTS.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Pyridostigmine%20Bromide", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT03674541", "title": "The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2020-01-14", "completion_date": "2021-12-20", "primary_completion_date": "2021-12-05", "last_updated": "2022-11-08" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Qeeg-Neurofeedback", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Qeeg-Neurofeedback", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07005921", "title": "QEEG-NEUROFEEDBACK FOR COGNITIVE REHABILITATION IN LONG COVID-19 SURVIVORS WITH BRAIN FOG", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-06-10", "completion_date": "2026-08-14", "primary_completion_date": "2026-08-14", "last_updated": "2026-09-25" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Qigong", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Qigong", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05675995", "title": "Qigong for Post Acute Sequelae of COVID-19 Infection", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-01-04", "completion_date": "2024-05-15", "primary_completion_date": "2024-05-15", "last_updated": "2026-01-13" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Ramatroban", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05706454", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ramatroban", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05706454", "title": "Phase 2/Phase 3 Study To Evaluate The Efficacy And Safety Of Ramatroban Along With The Standard Of Care In Subjects Hospitalized For COVID P", "status": "UNKNOWN", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2022-11-10", "completion_date": "2026-05-31", "primary_completion_date": "2024-07-01", "last_updated": "2023-01-31" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Rauha® Digital Therapeutic Platform", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Industry", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Rauha®%20Digital%20Therapeutic%20Platform", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07714889", "title": "Development of an Accessible Cognitive Behavioral Therapy Digital Therapeutic for Individuals With Long COVID", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2026-07", "completion_date": "2026-09", "primary_completion_date": "2026-09", "last_updated": "2026-07-29" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Industry" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Rdx-19", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Rdx-19", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06113679", "title": "Pilot Randomized Study of RD-X19 Tx Device in Subjects With PCC (Long Covid) in the Outpatient Setting", "status": "TERMINATED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-10-30", "completion_date": "2024-06-21", "primary_completion_date": "2024-05-24", "last_updated": "2024-07-05" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Reaction Time Training", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06095297, NCT07523113", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Reaction%20Time%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06095297", "title": "Long COVID Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-04-25", "completion_date": "2027-12", "primary_completion_date": "2026-12", "last_updated": "2026-04-13" }, { "nct_id": "NCT07523113", "title": "ME/CFS Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-06-23", "completion_date": "2028-06", "primary_completion_date": "2027-06", "last_updated": "2026-08-14" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Real Transcranial Ultrasound Stimulation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07154199", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Real%20Transcranial%20Ultrasound%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07154199", "title": "Transcranial Ultrasound Stimulation for Cognitive Function Modulation in Patients With Post COVID-19 Brain Fog", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-01-06", "completion_date": "2027-12", "primary_completion_date": "2027-12", "last_updated": "2025-09-04" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Recover-Neuro", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Recover-Neuro", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "None of three cognitive rehabilitation interventions proved effective vs comparator; all five arms showed modest improvements over time; important nul", "pub_date": "", "excerpt": "None of three cognitive rehabilitation interventions proved effective vs comparator; all five arms showed modest improvements over time; important null result for cognitive rehabilitation in long COVID", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Recovery Factors", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Recovery%20Factors", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04381780", "title": "Treatment of Fibromyalgia With Recovery Factors", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2020-05-06", "completion_date": "2021-01-15", "primary_completion_date": "2020-12-01", "last_updated": "2021-10-11" }, { "nct_id": "NCT04381793", "title": "Treatment of CFS & Fibromyalgia With Recovery Factors", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2019-05-20", "completion_date": "2020-07-04", "primary_completion_date": "2020-07-04", "last_updated": "2020-10-19" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Recumbent Exercise Rehabilitation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Recumbent%20Exercise%20Rehabilitation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Improved lung function, physical activity, wellbeing in long COVID without PEM; must start recumbent (rowing/swimming/cycling); critical PEM caveat; K", "pub_date": "", "excerpt": "Improved lung function, physical activity, wellbeing in long COVID without PEM; must start recumbent (rowing/swimming/cycling); critical PEM caveat; Karolinska RCT results pending 2025", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Red Beetroot Juice", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Red%20Beetroot%20Juice", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06535165", "title": "Effect of Red Beetroot Juice Intake in Adults With Long COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2021-03-01", "completion_date": "2021-07-31", "primary_completion_date": "2021-07-31", "last_updated": "2024-08-05" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Red Ginseng Powder Capsule", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT02847845", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Red%20Ginseng%20Powder%20Capsule", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02847845", "title": "A Clinical Study About Improvement of Chronic Fatigue After Taking Red Ginseng", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2016-06", "completion_date": "2017-06", "primary_completion_date": "2017-06", "last_updated": "2016-07-28" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Regenecyte", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07184385", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Regenecyte", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07184385", "title": "A Study of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Post-COVID Condition", "status": "NOT_YET_RECRUITING", "phase": "PHASE3", "size_category": "Medium (50-199 participants)", "start_date": "2026-03-31", "completion_date": "2027-09-30", "primary_completion_date": "2027-06-30", "last_updated": "2025-09-23" }, { "nct_id": "NCT05682560", "title": "Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-05-04", "completion_date": "2025-02-27", "primary_completion_date": "2024-07-26", "last_updated": "2025-03-24" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2", "PHASE3" ], "trial_sizes": [ "Medium (50-199 participants)", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Rehabcovid_Immersivevr", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Rehabcovid_Immersivevr", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05846126", "title": "Digital Multimodal Rehabilitation for People With Post-acute COVID-19 Syndrome.", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-05-05", "completion_date": "2024-12-31", "primary_completion_date": "2024-12-20", "last_updated": "2026-04-30" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise", "Medical Device" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Rehabcovid_Telematic", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Rehabcovid_Telematic", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05846126", "title": "Digital Multimodal Rehabilitation for People With Post-acute COVID-19 Syndrome.", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-05-05", "completion_date": "2024-12-31", "primary_completion_date": "2024-12-20", "last_updated": "2026-04-30" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Rehabilitation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05855356", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Rehabilitation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05855356", "title": "Post Covid-19 Dysautonomia Rehabilitation Randomized Controlled Trial", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-02-01", "completion_date": "2024-03-27", "primary_completion_date": "2023-12-30", "last_updated": "2023-05-11" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Rehabilitation Program", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Rehabilitation%20Program", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06952127", "title": "Feasibility and Preliminary Efficacy of a Group-based Telerehabilitation Program in People With Post-COVID-19 Sequelae (TEPCO).", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-04-07", "completion_date": "2024-03-29", "primary_completion_date": "2024-03-29", "last_updated": "2025-04-30" }, { "nct_id": "NCT05848518", "title": "Exercise for Health in Patients With Post-acute Sequelae of COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-05-15", "completion_date": "2024-01-31", "primary_completion_date": "2023-09-30", "last_updated": "2024-03-19" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Reiki", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Reiki", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02075489", "title": "Acupressure for Pain Management and Fatigue Relief in Gulf War Veterans", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2012-09", "completion_date": "2017-10", "primary_completion_date": "2017-10", "last_updated": "2017-10-10" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Reimbursement Of 3 Long Consultations", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Reimbursement%20Of%203%20Long%20Consultations", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06082258", "title": "Education of Medical Staff to Post Acute Covid susTained sYmptoms", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2024-11", "completion_date": "2026-05", "primary_completion_date": "2025-12", "last_updated": "2026-07-01" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Relaxation Therapy", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Relaxation%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01512342", "title": "Pacing Activity Self-management for Patients With Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2011-08", "completion_date": "2014-08", "primary_completion_date": "2014-06", "last_updated": "2015-12-17" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Remdesivir", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Remdesivir", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05911906", "title": "An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.", "status": "COMPLETED", "phase": "PHASE4", "size_category": "Medium (50-199 participants)", "start_date": "2024-10-08", "completion_date": "2025-09-17", "primary_completion_date": "2025-09-17", "last_updated": "2026-02-20" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Repetitive Transcranial Magnetic Stimulation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07278206", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Repetitive%20Transcranial%20Magnetic%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07278206", "title": "Brain Stimulation in Long COVID", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-11-17", "completion_date": "2029-05-12", "primary_completion_date": "2028-11-17", "last_updated": "2025-12-19" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Resilience Building Exercises", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Resilience%20Building%20Exercises", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00468013", "title": "A Computer-Based Intervention for Medically Unexplained Physical Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2007-03", "completion_date": "2010-03", "primary_completion_date": "2010-03", "last_updated": "2015-02-09" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Resistance Exercise", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Resistance%20Exercise", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04900961", "title": "CISCO-21 Prevent and Treat Long COVID-19.", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2021-06-01", "completion_date": "2025-02-21", "primary_completion_date": "2024-08-30", "last_updated": "2025-02-25" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Resonance Breathing", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06379672", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Resonance%20Breathing", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06379672", "title": "Resonance Breathing Training for Long Covid-related Myocardial Injury", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-08-25", "completion_date": "2024-10-05", "primary_completion_date": "2024-09-25", "last_updated": "2024-07-30" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Respicure®", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Respicure®", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05601180", "title": "Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Lon", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2022-10-27", "completion_date": "2024-01-15", "primary_completion_date": "2024-01-15", "last_updated": "2024-03-19" } ], "total_mentions": 1, "types": [ "Supplement / Nutraceutical" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Restoring Energy With Sub-Symptom Threshold Aerobic Rehabilitation Exercise", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Metabolic / Mitochondrial, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Restoring%20Energy%20With%20Sub-Symptom%20Threshold%20Aerobic%20Rehabilitation%20Exercise", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06172803", "title": "Restoring Energy With Sub-symptom Threshold Optimized Rehabilitation Exercise for Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-10-01", "completion_date": "2024-01-15", "primary_completion_date": "2024-01-15", "last_updated": "2024-06-06" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Metabolic / Mitochondrial", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Ribose", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ribose", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01108549", "title": "Treatment of Chronic Fatigue Syndrome and Fibromyalgia With D-ribose- a Multicenter Study", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2009-04", "completion_date": "2009-09", "primary_completion_date": "2009-09", "last_updated": "2010-04-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Rice Protein Powder With Vitamin C", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Metabolic / Mitochondrial, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06967428", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Rice%20Protein%20Powder%20With%20Vitamin%20C", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06967428", "title": "Effect of Metabolic Modulation on a Post-acute COVID-19 Vaccination Syndrome (PACVS) Cohort", "status": "NOT_YET_RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2025-09-01", "completion_date": "2026-01", "primary_completion_date": "2026-01", "last_updated": "2025-05-13" } ], "total_mentions": 1, "types": [ "Supplement / Nutraceutical" ], "mechanisms": [ "Enrollment: Estimated", "Metabolic / Mitochondrial", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Rintatolimod", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Rintatolimod", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05592418", "title": "Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2023-06-30", "completion_date": "2023-11-30", "primary_completion_date": "2023-11-17", "last_updated": "2025-01-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Ritonavir", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Antiviral / Persistence, Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 3 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Ritonavir", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05965726", "title": "RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2023-07-26", "completion_date": "2025-03-13", "primary_completion_date": "2024-12-05", "last_updated": "2026-03-27" }, { "nct_id": "NCT05576662", "title": "Paxlovid for Treatment of Long Covid", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2022-11-08", "completion_date": "2023-09-12", "primary_completion_date": "2023-08-14", "last_updated": "2025-09-04" }, { "nct_id": "NCT05668091", "title": "A Decentralized, Randomized Phase 2 Efficacy and Safety Study of Nirmatrelvir/Ritonavir in Adults with Long COVID.", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2023-04-14", "completion_date": "2024-08-21", "primary_completion_date": "2024-04-09", "last_updated": "2024-12-02" } ], "total_mentions": 3, "types": [ "Drug (Pharmaceutical)", "Other / Unclassified" ], "mechanisms": [ "Antiviral / Persistence", "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)", "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Rituximab", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06952413", "Clinical Notes": "Anti-CD20 studied in ME/CFS (mixed prior). Several trials. Serious infection risk. Specialist use only for clear autoimmune subsets. 5 trial associations.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/compound/5104", "Safety": "Infusion reactions, serious infections (including PML risk), hepatitis B reactivation, hypogammaglobulinemia. Requires specialist oversight, screening, monitoring.", "Dosing": "Typical rheumatology regimens 1000 mg IV x2 (2 weeks apart) or 375 mg/m² weekly x4; ME/CFS trials used similar; repeat as needed.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06952413", "title": "Study of the Efficacy and Safety for Rituximab in Myalgia Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2025-04-09", "completion_date": "2027-10-31", "primary_completion_date": "2026-09-30", "last_updated": "2025-04-30" }, { "nct_id": "NCT01156922", "title": "B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Very Severe Chronic Fatigue Syndrome", "status": "TERMINATED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2010-06", "completion_date": "2016-04", "primary_completion_date": "2016-04", "last_updated": "2024-03-04" }, { "nct_id": "NCT02229942", "title": "B-lymphocyte Depletion Using Rituximab in Chronic Fatigue Syndrome/ Myalgic Encephalopathy (CFS/ME). A Randomized Phase-III Study.", "status": "COMPLETED", "phase": "PHASE3", "size_category": "Medium (50-199 participants)", "start_date": "2014-09", "completion_date": "2017-11", "primary_completion_date": "2017-09", "last_updated": "2021-05-11" }, { "nct_id": "NCT00848692", "title": "Drug Intervention in Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2008-06", "completion_date": "2010-06", "primary_completion_date": "2010-06", "last_updated": "2021-05-11" }, { "nct_id": "NCT01156909", "title": "B-cell Depletion Using the Monoclonal Anti-CD20 Antibody Rituximab in Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2010-10", "completion_date": "2014-02", "primary_completion_date": "2014-02", "last_updated": "2014-09-01" } ], "total_mentions": 5, "types": [ "Behavioral / Protocol / Exercise", "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2", "PHASE3" ], "trial_sizes": [ "Medium (50-199 participants)", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Rna Biomarker Blood Test", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06311435", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Rna%20Biomarker%20Blood%20Test", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06311435", "title": "Utilizing Novel Blood RNA Biomarkers as a Diagnostic Tool in the Identification of Long COVID-19", "status": "RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2024-03-15", "completion_date": "2026-03-15", "primary_completion_date": "2026-03-15", "last_updated": "2024-10-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Routine Daily Activity", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Routine%20Daily%20Activity", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05139979", "title": "Yogic Breathing and Guided Meditation for Long Covid Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-09-15", "completion_date": "2024-02-07", "primary_completion_date": "2024-02-07", "last_updated": "2025-02-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Rslv-132", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Rslv-132", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04944121", "title": "Phase 2 Study of RSLV-132 in Subjects With Long COVID", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2021-06-25", "completion_date": "2023-11-30", "primary_completion_date": "2023-10-31", "last_updated": "2024-05-29" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Rtms", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Rtms", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06586398", "title": "A Pilot rTMS Trial for Neuropsychiatric Symptoms of Long-COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-01-01", "completion_date": "2026-03-01", "primary_completion_date": "2026-03-01", "last_updated": "2026-07-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Rupatadine", "Primary Conditions": [ "MCAS" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Rupatadine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Significant improvements in itching, flushing, skin reactivity, headache, tachycardia, and quality of life vs placebo; mastocytosis population — appli", "pub_date": "", "excerpt": "Significant improvements in itching, flushing, skin reactivity, headache, tachycardia, and quality of life vs placebo; mastocytosis population — applicable to MCAS by shared mechanism", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Safflower Oil", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05705648", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Safflower%20Oil", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05705648", "title": "Nutritional Management of Post COVID-19 Cognitive Symptoms", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-10-01", "completion_date": "2027-03-01", "primary_completion_date": "2026-06-24", "last_updated": "2026-07-17" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Saline Infusion", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Saline%20Infusion", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04740736", "title": "Cardiovascular Analysis of PEM", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-08-31", "completion_date": "2025-07-11", "primary_completion_date": "2025-07-11", "last_updated": "2025-12-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Saline Infusions", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Saline%20Infusions", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00580619", "title": "Autonomic Nervous System and Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE1", "size_category": "Medium (50-199 participants)", "start_date": "2007-04", "completion_date": "2017-01", "primary_completion_date": "2017-01", "last_updated": "2017-01-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Seasonal Influenza Vaccination", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Immunomodulatory, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Seasonal%20Influenza%20Vaccination", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01651754", "title": "Humoral and Cellular Immune Responses After Influenza Vaccination in Patients With Postcancer Fatigue and in Patients With Chronic Fatigue S", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2010-09", "completion_date": "2012-06", "primary_completion_date": "2011-08", "last_updated": "2012-07-27" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Immunomodulatory", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Self- Applied Acupressure Plus Qigong Course Plus Advice Literature", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05289154", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Self-%20Applied%20Acupressure%20Plus%20Qigong%20Course%20Plus%20Advice%20Literature", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05289154", "title": "Acupressure and Qigong in Chronic Fatigue Post COVID-19.", "status": "UNKNOWN", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2022-06-14", "completion_date": "2023-10-01", "primary_completion_date": "2023-09-01", "last_updated": "2023-01-23" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Self-Administered Acupressure", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Self-Administered%20Acupressure", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00959998", "title": "Acupressure for Post-Treatment Cancer Fatigue", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2007-09", "completion_date": "2009-07", "primary_completion_date": "2009-07", "last_updated": "2012-06-26" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Selzentry", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Antiviral / Persistence, Enrollment: Estimated, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06511063", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Selzentry", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06511063", "title": "Antiviral Clinical Trial for Long Covid-19", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2024-10-01", "completion_date": "2026-12", "primary_completion_date": "2026-11", "last_updated": "2026-03-13" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Antiviral / Persistence", "Enrollment: Estimated", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Seraph® 100 Microbind® Affinity Blood Filter", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Seraph®%20100%20Microbind®%20Affinity%20Blood%20Filter", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06637800", "title": "Prospective, Open-label Study of Seraph 100 in Patients With Prolonged COVID (PC)", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2025-02-15", "completion_date": "2025-04", "primary_completion_date": "2025-04", "last_updated": "2026-04-20" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Shengmai Liquid", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06980636", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Shengmai%20Liquid", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06980636", "title": "A Trial of Shengmai Liquid for Long COVID Fatigue.", "status": "RECRUITING", "phase": "PHASE4", "size_category": "Medium (50-199 participants)", "start_date": "2025-12-01", "completion_date": "2026-11-30", "primary_completion_date": "2026-10-30", "last_updated": "2026-02-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Shenlingcao Oral Liquid", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05684952", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Shenlingcao%20Oral%20Liquid", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05684952", "title": "The Efficacy and Safety of a Chinese Herbal Medicine for Long COVID Associated Fatigue", "status": "UNKNOWN", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2023-05-30", "completion_date": "2024-02-01", "primary_completion_date": "2024-01-15", "last_updated": "2023-06-28" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Sildenafil", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Sildenafil", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00598585", "title": "Use of Sildenafil (Viagra) to Alter Fatigue, Functional Status and Impaired Cerebral Blood Flow in Patients With CFS", "status": "COMPLETED", "phase": "PHASE4", "size_category": "Small (<50 participants)", "start_date": "2002-07", "completion_date": "2010-12", "primary_completion_date": "2010-12", "last_updated": "2017-06-27" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Singstrong: Strong Lungs Through Song", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Singstrong:%20Strong%20Lungs%20Through%20Song", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04810065", "title": "SingStrong: Strong Lungs Through Song - Long COVID-19 Study", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2021-03-29", "completion_date": "2021-09-01", "primary_completion_date": "2021-07-29", "last_updated": "2021-09-28" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Sipavibart", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07021794", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Sipavibart", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07021794", "title": "SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2025-07-28", "completion_date": "2027-09-30", "primary_completion_date": "2027-09-30", "last_updated": "2026-09-29" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Sirolimus (low-dose Rapamycin)", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Immunomodulatory, Sponsor Type: Other", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06960928, NCT04948203", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Sirolimus", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06960928", "title": "Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19", "status": "RECRUITING", "phase": "PHASE3", "size_category": "Medium (50-199 participants)", "start_date": "2025-04-18", "completion_date": "2027-05-31", "primary_completion_date": "2026-12-31", "last_updated": "2026-05-18" }, { "nct_id": "NCT04948203", "title": "Assessing the Efficacy of Sirolimus in Patients With COVID-19 Pneumonia for Prevention of Post-COVID Fibrosis", "status": "ACTIVE_NOT_RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2021-07-09", "completion_date": "2026-12", "primary_completion_date": "2026-12", "last_updated": "2025-12-15" } ], "total_mentions": 2, "types": [ "Drug (Pharmaceutical)" ], "mechanisms": [ "Enrollment: Estimated", "Immunomodulatory", "Sponsor Type: Other" ], "trial_types": [ "PHASE2", "PHASE3" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Sodium Oxybate", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 3 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Sodium%20Oxybate", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT01584934", "title": "Sodium Oxybate in Patients With Chronic Fatigue Syndrome.", "status": "WITHDRAWN", "phase": "PHASE4", "size_category": null, "start_date": "2013-06", "completion_date": "2015-12", "primary_completion_date": "2015-06", "last_updated": "2022-12-15" }, { "nct_id": "NCT02055898", "title": "SWS And Daytime Functioning in Chronic FatiguE Syndrome (SAFFE)", "status": "COMPLETED", "phase": "PHASE4", "size_category": "Small (<50 participants)", "start_date": "2014-04", "completion_date": "2015-08", "primary_completion_date": "2015-08", "last_updated": "2020-11-18" }, { "nct_id": "NCT00498485", "title": "Use of Xyrem to Improve Sleep in Chronic Fatigue Syndrome", "status": "TERMINATED", "phase": "PHASE4", "size_category": "Small (<50 participants)", "start_date": "2007-05", "completion_date": "2008-12", "primary_completion_date": "2008-12", "last_updated": "2016-05-19" } ], "total_mentions": 3, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Solriamfetol", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Solriamfetol", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06404099", "title": "RECOVER-SLEEP: Platform Protocol, Appendix_A (Hypersomnia)", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2024-08-12", "completion_date": "2026-04-20", "primary_completion_date": "2026-03-24", "last_updated": "2026-06-03" }, { "nct_id": "NCT06404086", "title": "RECOVER-SLEEP: Platform Protocol", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2024-07-31", "completion_date": "2025-12-31", "primary_completion_date": "2025-12-31", "last_updated": "2026-01-22" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Solriamfetol Oral Tablet [Sunosi]", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Solriamfetol%20Oral%20Tablet%20[Sunosi]", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04622293", "title": "A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE4", "size_category": "Small (<50 participants)", "start_date": "2021-04-27", "completion_date": "2024-12-01", "primary_completion_date": "2024-09-01", "last_updated": "2025-04-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Somatropin", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Somatropin", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT03554265", "title": "Brain and Gut Plasticity in Mild TBI or Post-acute COVID Syndrome Following Growth Hormone Therapy", "status": "COMPLETED", "phase": "PHASE3", "size_category": "Medium (50-199 participants)", "start_date": "2018-08-06", "completion_date": "2023-10-04", "primary_completion_date": "2023-10-04", "last_updated": "2025-03-05" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Sonocea Sonic Augmentation Technology", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Sonocea%20Sonic%20Augmentation%20Technology", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07190105", "title": "Vagal Approaches on Long COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2025-10-27", "completion_date": "2025-12-11", "primary_completion_date": "2025-12-11", "last_updated": "2026-01-07" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Specialized Pro-Resolving Lipid Mediator", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other Gov, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Specialized%20Pro-Resolving%20Lipid%20Mediator", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07711444", "title": "The Efficacy of Long-Chain Fatty Acids, Eicosapentaenoic Acid (EPA) and Specialized Pro-Resolving Mediators (SPMs), in Treating Long COVID N", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-06-01", "completion_date": "2026-06-01", "primary_completion_date": "2025-12-01", "last_updated": "2026-07-21" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other Gov", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Specific Db Program/Diaphragmatic Manipulation Program", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Specific%20Db%20Program/Diaphragmatic%20Manipulation%20Program", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06330376", "title": "Diaphragmatic Breathing Exercises for Post-COVID-19 Diaphragmatic Dysfunction (DD)", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-03-01", "completion_date": "2025-08-15", "primary_completion_date": "2025-08-15", "last_updated": "2026-01-08" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Splenic Ultrasound", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Splenic%20Ultrasound", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06189066", "title": "Long COVID Ultrasound Trial", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-01-03", "completion_date": "2025-07-24", "primary_completion_date": "2024-07-24", "last_updated": "2026-01-07" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Standard Of Care", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Industry", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05855356", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Standard%20Of%20Care", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05601180", "title": "Evaluation of the Efficacy of Respicure® (Resveratrol / Quercetin) in the Management of Respiratory Conditions Including Asthma,COPD and Lon", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2022-10-27", "completion_date": "2024-01-15", "primary_completion_date": "2024-01-15", "last_updated": "2024-03-19" }, { "nct_id": "NCT05855356", "title": "Post Covid-19 Dysautonomia Rehabilitation Randomized Controlled Trial", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-02-01", "completion_date": "2024-03-27", "primary_completion_date": "2023-12-30", "last_updated": "2023-05-11" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise", "Supplement / Nutraceutical" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Industry", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Standard Rehabilitation Care", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05817032", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Standard%20Rehabilitation%20Care", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05817032", "title": "Effect of Telerehabilitation Practice in Long COVID-19 Patients", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-05", "completion_date": "2023-11", "primary_completion_date": "2023-10", "last_updated": "2023-04-18" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Standard Treatment / Treatment As Usual", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Standard%20Treatment%20/%20Treatment%20As%20Usual", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04177459", "title": "Rehabilitation of Adolescents Living With Chronic Fatigue", "status": "TERMINATED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2019-12-06", "completion_date": "2020-04-30", "primary_completion_date": "2020-04-30", "last_updated": "2020-06-25" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Steady State Plasma Glucose (Sspg) Test", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05833217", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Steady%20State%20Plasma%20Glucose", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05833217", "title": "Obesity, Insulin Resistance, and PASC: Persistent SARS-CoV-2", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-06-06", "completion_date": "2025-12-31", "primary_completion_date": "2025-05-02", "last_updated": "2024-12-04" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Stellate Ganglion Block", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07374562", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Stellate%20Ganglion%20Block", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07374562", "title": "Stellate Ganglion Block for Long COVID Symptoms: A Randomized Controlled Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-02-05", "completion_date": "2027-02", "primary_completion_date": "2027-02", "last_updated": "2026-02-09" }, { "nct_id": "NCT06253806", "title": "Stellate Ganglion Block for COVID-induced Parosmia", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-10-25", "completion_date": "2024-09-16", "primary_completion_date": "2024-09-16", "last_updated": "2025-11-10" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA", "PHASE2" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Stellate Ganglion Block With 0.5% Bupivacaine", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Stellate%20Ganglion%20Block%20With%200.5%%20Bupivacaine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05638620", "title": "Dual Sympathetic Blocks for Patients Experiencing Sympathetically-Mediated Symptoms From Long COVID", "status": "COMPLETED", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2023-01-03", "completion_date": "2023-12-30", "primary_completion_date": "2023-06-15", "last_updated": "2025-03-13" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Stem Cell", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06156241", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Stem%20Cell", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06156241", "title": "Stem Cell Study for Long COVID-19 Neurological Symptoms", "status": "UNKNOWN", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2024-01", "completion_date": "2026-02", "primary_completion_date": "2025-12", "last_updated": "2023-12-05" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Stimulate-Icp", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Stimulate-Icp", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "H1+H2 antihistamine RCT in long COVID; results pending publication", "pub_date": "", "excerpt": "H1+H2 antihistamine RCT in long COVID; results pending publication", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Stool Analysis", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Stool%20Analysis", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04363606", "title": "Chronic Fatigue Etiology and Recovery in Covid-19 Patients: the Role of Fatigability", "status": "TERMINATED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2020-05-27", "completion_date": "2022-03-01", "primary_completion_date": "2021-08-26", "last_updated": "2025-03-25" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Stool Samples", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Stool%20Samples", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05543590", "title": "Effect of Plasmapheresis on Clinical Improvement and Biological Parameters of Patients With Long-haul COVID", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2023-02", "completion_date": "2025-10", "primary_completion_date": "2025-02", "last_updated": "2023-08-14" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Structured Mindfulness Intervention", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07140094", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Structured%20Mindfulness%20Intervention", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07140094", "title": "Long-Covid-19 Alleviation Through Learning Mindfulness Study", "status": "RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2024-05-21", "completion_date": "2027-11-21", "primary_completion_date": "2027-05-21", "last_updated": "2026-08-31" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Submaximal Bicycle Exercise Stress Test On Days 1 And 2", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Submaximal%20Bicycle%20Exercise%20Stress%20Test%20On%20Days%201%20And%202", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT03567811", "title": "Exertional Exhaustion in Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2013-08-01", "completion_date": "2018-07-31", "primary_completion_date": "2018-07-31", "last_updated": "2019-06-20" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Swimming", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Swimming", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07454395", "title": "Is Swimming a More Tolerable Form of Movement for Individuals With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome?", "status": "SUSPENDED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2026-02-20", "completion_date": "2027-06", "primary_completion_date": "2027-01", "last_updated": "2026-03-30" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Symptom Monitoring", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Symptom%20Monitoring", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00997451", "title": "Fatigue Self-Management in Primary Care", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2009-02", "completion_date": "2011-12", "primary_completion_date": "2011-12", "last_updated": "2012-10-01" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Symptom-Focused Rehabilitation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Symptom-Focused%20Rehabilitation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05172206", "title": "Symptom-based Rehabilitation Compared to Usual Care in Post-COVID - a Randomized Controlled Trial", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-05-20", "completion_date": "2024-01-25", "primary_completion_date": "2024-01-25", "last_updated": "2025-03-28" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Synbiotic Ivs-1", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Synbiotic%20Ivs-1", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06620406", "title": "Synbiotic Therapy for NP-PASC", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-12-09", "completion_date": "2025-08-06", "primary_completion_date": "2025-08-06", "last_updated": "2025-08-26" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Tailored Lighting (Tl) Active", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Tailored%20Lighting", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06404112", "title": "RECOVER-SLEEP: Platform Protocol, Appendix_B (CPSD)", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2024-07-31", "completion_date": "2026-04-01", "primary_completion_date": "2026-02-26", "last_updated": "2026-07-08" }, { "nct_id": "NCT06404086", "title": "RECOVER-SLEEP: Platform Protocol", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2024-07-31", "completion_date": "2025-12-31", "primary_completion_date": "2025-12-31", "last_updated": "2026-01-22" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Targeted Wellness Formula C™ Sublingual Drops - 1200Mg - 30 Ml", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Targeted%20Wellness%20Formula%20C™%20Sublingual%20Drops%20-%201200Mg%20-%2030%20Ml", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04828668", "title": "Study to Evaluate Benefits & Safety of Endourage Formula C™ Oral Drops in People With Post-Acute COVID-19 Syndrome.", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2021-04-02", "completion_date": "2022-02-14", "primary_completion_date": "2022-01-31", "last_updated": "2025-08-07" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Tau + Multicomponent Treatment Virtual Sfcamina", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT04593225", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Tau%20+%20Multicomponent%20Treatment%20Virtual%20Sfcamina", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04593225", "title": "Effectiveness of VIRTUAL SFCAMINA STUDY", "status": "UNKNOWN", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2020-04-21", "completion_date": "2022-01-21", "primary_completion_date": "2021-12-21", "last_updated": "2021-12-30" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Taurine", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06721949, NCT07682402", "Clinical Notes": "Plasma levels inversely correlated with PASC severity. 1-3g/day raises levels. Mitochondrial + NF-kB rationale. Safe; may help energy/autonomic symptoms. Good mechanistic support, limited direct trials.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Taurine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Khoramjoo 2024: plasma taurine inversely correlated with PASC severity (148 vs 225 μM); 1.6g/day raised plasma 34μM; mitochondrial tRNA modification +", "pub_date": "", "excerpt": "Khoramjoo 2024: plasma taurine inversely correlated with PASC severity (148 vs 225 μM); 1.6g/day raised plasma 34μM; mitochondrial tRNA modification + NF-κB inhibition; no PASC intervention RCT", "source": "PACVS Evidence Map" } ], "trials": [ { "nct_id": "NCT06721949", "title": "Taurine Supplementation in Long COVID", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2025-11-18", "completion_date": "2028-12", "primary_completion_date": "2028-02", "last_updated": "2026-09-18" }, { "nct_id": "NCT07682402", "title": "Taurine Supplementation in Adolescents With Post-COVID Condition", "status": "NOT_YET_RECRUITING", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2026-09-30", "completion_date": "2028-12-31", "primary_completion_date": "2028-03-31", "last_updated": "2026-08-13" } ], "total_mentions": 3, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE1", "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Tdcs-Active", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Tdcs-Active", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05965739", "title": "RECOVER-NEURO: Platform Protocol, Appendix_A to Measure the Effects of BrainHQ, PASC CoRE and tDCS Interventions on Long COVID Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2023-09-01", "completion_date": "2024-12-17", "primary_completion_date": "2024-09-19", "last_updated": "2026-08-11" }, { "nct_id": "NCT05965752", "title": "RECOVER-NEURO: Platform Protocol to Measure the Effects of Cognitive Dysfunction Interventions on Long COVID Symptoms", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2023-09-01", "completion_date": "2024-06-10", "primary_completion_date": "2024-06-10", "last_updated": "2025-07-18" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Telehealth Exercise Training Program", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Telehealth%20Exercise%20Training%20Program", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07553897", "title": "Tele-exercise Training Program for Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-10-12", "completion_date": "2023-11-22", "primary_completion_date": "2023-11-08", "last_updated": "2026-04-28" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Telerehab Dss Pilot Test", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07079787", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Telerehab%20Dss%20Pilot%20Test", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07079787", "title": "Telerehabilitation Decision Support System: Pilot Testing Protocol", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-07-25", "completion_date": "2025-08-29", "primary_completion_date": "2025-08-18", "last_updated": "2025-07-23" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Telerehabilitation", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Network, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05817032", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Telerehabilitation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05967052", "title": "Investigation of Treating Chronic Fatigue Syndrome After COVID With Pharmacotherapy (Pregabalin) or Complex Rehabilitation", "status": "TERMINATED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-10-24", "completion_date": "2025-09-11", "primary_completion_date": "2025-09-11", "last_updated": "2026-06-17" }, { "nct_id": "NCT05817032", "title": "Effect of Telerehabilitation Practice in Long COVID-19 Patients", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-05", "completion_date": "2023-11", "primary_completion_date": "2023-10", "last_updated": "2023-04-18" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Sponsor Type: Network", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA", "PHASE2" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Telerehabilitation Program Based On Cardiorespiratory Principles", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Telerehabilitation%20Program%20Based%20On%20Cardiorespiratory%20Principles", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05973136", "title": "Telerehabilitation for Post COVID-19 Condition", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-04-01", "completion_date": "2022-08-08", "primary_completion_date": "2022-08-08", "last_updated": "2023-08-02" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Temelimab 54Mg/Kg", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Temelimab%2054Mg/Kg", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05497089", "title": "Temelimab as a Disease Modifying Therapy in Patients With Neuropsychiatric Symptoms in Post-COVID 19 or PASC Syndrome", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2022-08-29", "completion_date": "2024-05-10", "primary_completion_date": "2024-05-10", "last_updated": "2024-05-17" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Tenofovir Disoproxil/Emtricitabine", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Antiviral / Persistence, Enrollment: Estimated, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06511063", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Tenofovir%20Disoproxil/Emtricitabine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06511063", "title": "Antiviral Clinical Trial for Long Covid-19", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2024-10-01", "completion_date": "2026-12", "primary_completion_date": "2026-11", "last_updated": "2026-03-13" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Antiviral / Persistence", "Enrollment: Estimated", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Tens - High-Dose", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Tens%20-%20High-Dose", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05200858", "title": "Transcutaneous Electrical Nerve Stimulation (TENS) in Patients With Postacute Sequelae of Sars-CoV-2", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-03-01", "completion_date": "2023-12-01", "primary_completion_date": "2023-10-01", "last_updated": "2024-07-16" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Tens - Low-Dose", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Tens%20-%20Low-Dose", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05200858", "title": "Transcutaneous Electrical Nerve Stimulation (TENS) in Patients With Postacute Sequelae of Sars-CoV-2", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-03-01", "completion_date": "2023-12-01", "primary_completion_date": "2023-10-01", "last_updated": "2024-07-16" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Testofen", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Testofen", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05795816", "title": "Effectiveness of Testofen Compared to Placebo on Long COVID Symptoms", "status": "COMPLETED", "phase": "PHASE3", "size_category": "Medium (50-199 participants)", "start_date": "2023-10-25", "completion_date": "2025-01-31", "primary_completion_date": "2025-01-30", "last_updated": "2025-03-10" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "The Multi-Domain Tai Chi Digital Therapy Software Application", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05419219", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=The%20Multi-Domain%20Tai%20Chi%20Digital%20Therapy%20Software%20Application", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05419219", "title": "TaiChi-DTx for Treating Long Covid Symptoms", "status": "UNKNOWN", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2022-06-01", "completion_date": "2023-12-31", "primary_completion_date": "2023-05-31", "last_updated": "2023-02-15" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Thermal Pain Stimulation", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Nih, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06472622", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Thermal%20Pain%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06472622", "title": "Functional Neuroimaging to Detect the Neural Signatures of the Unpleasantness of Pain and Effort", "status": "RECRUITING", "phase": "EARLY_PHASE1", "size_category": "Small (<50 participants)", "start_date": "2025-04-09", "completion_date": "2034-06-30", "primary_completion_date": "2034-06-30", "last_updated": "2026-09-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Nih", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Thiamine (Vitamin B1)", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Thiamine", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05642923", "title": "Post-COVID-19 Chronic Fatigue Syndrome", "status": "COMPLETED", "phase": "PHASE4", "size_category": "Large (200-999 participants)", "start_date": "2023-01-08", "completion_date": "2025-03-05", "primary_completion_date": "2024-06-01", "last_updated": "2025-03-10" } ], "total_mentions": 1, "types": [ "Supplement / Nutraceutical" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE4" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Thunder-Fire Moxibustion Therapy", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT02964533", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Thunder-Fire%20Moxibustion%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT02964533", "title": "Thunder-Fire Moxibustion Therapy for Chronic Fatigue Syndrome on Shenque Acupoint: a Randomized Controlled Trial", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2016-11", "completion_date": "Unknown", "primary_completion_date": "2017-02", "last_updated": "2016-11-16" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Tirzepatide", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07128082", "Clinical Notes": "GLP-1/GIP agonist early Long COVID trials (metabolic/anti-inflammatory). Weekly titrated injection. GI side effects, cost. May benefit overweight subsets. Very early.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Tirzepatide", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07128082", "title": "The Long COVID Treatment Trial", "status": "ACTIVE_NOT_RECRUITING", "phase": "PHASE2", "size_category": "Very Large (1000+ participants)", "start_date": "2025-10-30", "completion_date": "2026-12", "primary_completion_date": "2026-12", "last_updated": "2025-12-23" } ], "total_mentions": 1, "types": [ "Drug (Pharmaceutical)" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Very Large (1000+ participants)" ] }, { "Therapeutic Agent": "Tnx-102 Sl", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Tnx-102%20Sl", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05472090", "title": "A Phase 2 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Patients With Multi-Site Pain Associated With Post-Acute Sequelae of SA", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2022-08-18", "completion_date": "2023-07-27", "primary_completion_date": "2023-07-12", "last_updated": "2024-11-26" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "To Measure Levels Of Circulating Monocyte/ T Cell Doublets After 28 Days Of 2 Hoba Treatment", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Immunomodulatory, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07189936", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=To%20Measure%20Levels%20Of%20Circulating%20Monocyte/%20T%20Cell%20Doublets%20After%2028%20Days%20Of%202%20Hoba%20Treatment", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07189936", "title": "Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2025-12-18", "completion_date": "2029-06-30", "primary_completion_date": "2028-06-30", "last_updated": "2026-01-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Immunomodulatory", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "To Measure Levels Of Circulating Monocyte/ T Cell Doublets At Baseline", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Immunomodulatory, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07189936", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=To%20Measure%20Levels%20Of%20Circulating%20Monocyte/%20T%20Cell%20Doublets%20At%20Baseline", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07189936", "title": "Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2025-12-18", "completion_date": "2029-06-30", "primary_completion_date": "2028-06-30", "last_updated": "2026-01-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Immunomodulatory", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "To Measure Orthostatic Tachycardia After 28 Days Of Treatment With 2Hoba", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Immunomodulatory, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07189936", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=To%20Measure%20Orthostatic%20Tachycardia%20After%2028%20Days%20Of%20Treatment%20With%202Hoba", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07189936", "title": "Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2025-12-18", "completion_date": "2029-06-30", "primary_completion_date": "2028-06-30", "last_updated": "2026-01-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Immunomodulatory", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "To Measure Splanchnic Venous Capacitance After 28 Days Of Treatment With 2Hoba", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Immunomodulatory, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07189936", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=To%20Measure%20Splanchnic%20Venous%20Capacitance%20After%2028%20Days%20Of%20Treatment%20With%202Hoba", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07189936", "title": "Effect of 2-HOBA in Persistent Immune Activation in Long COVID POTS", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2025-12-18", "completion_date": "2029-06-30", "primary_completion_date": "2028-06-30", "last_updated": "2026-01-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Immunomodulatory", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Tonabersat", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Tonabersat", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06437223", "title": "Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2024-03-12", "completion_date": "2025-09-30", "primary_completion_date": "2025-09-30", "last_updated": "2026-03-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Traditional Chinese Medicine Treatment", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06095258", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Traditional%20Chinese%20Medicine%20Treatment", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06095258", "title": "A Practical RCT of TCM in the Treatment of LCOVID and Analysis of Syndrome Types and Medication Characteristics.", "status": "UNKNOWN", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2023-12-01", "completion_date": "2026-02-28", "primary_completion_date": "2025-11-30", "last_updated": "2023-10-26" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Training In The Management Of Functional Disorders", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Training%20In%20The%20Management%20Of%20Functional%20Disorders", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06082258", "title": "Education of Medical Staff to Post Acute Covid susTained sYmptoms", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2024-11", "completion_date": "2026-05", "primary_completion_date": "2025-12", "last_updated": "2026-07-01" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Training: Intermittent Hypoxic Exposure", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06614309", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Training:%20Intermittent%20Hypoxic%20Exposure", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06614309", "title": "Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-09-24", "completion_date": "2026-12", "primary_completion_date": "2026-12", "last_updated": "2026-06-05" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Training: Progressive Carbon Dioxide Ramping", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06614309", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Training:%20Progressive%20Carbon%20Dioxide%20Ramping", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06614309", "title": "Non-invasive Treatment for Long COVID (Post COVID-19 Condition) Brain Fog", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-09-24", "completion_date": "2026-12", "primary_completion_date": "2026-12", "last_updated": "2026-06-05" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Trans-Auricular Vagus Nerve Stimulation: High Intensity", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06095297, NCT07523113", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Trans-Auricular%20Vagus%20Nerve%20Stimulation:%20High%20Intensity", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06095297", "title": "Long COVID Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-04-25", "completion_date": "2027-12", "primary_completion_date": "2026-12", "last_updated": "2026-04-13" }, { "nct_id": "NCT07523113", "title": "ME/CFS Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-06-23", "completion_date": "2028-06", "primary_completion_date": "2027-06", "last_updated": "2026-08-14" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise", "Medical Device" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Trans-Auricular Vagus Nerve Stimulation: Low Intensity", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06095297, NCT07523113", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Trans-Auricular%20Vagus%20Nerve%20Stimulation:%20Low%20Intensity", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06095297", "title": "Long COVID Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-04-25", "completion_date": "2027-12", "primary_completion_date": "2026-12", "last_updated": "2026-04-13" }, { "nct_id": "NCT07523113", "title": "ME/CFS Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-06-23", "completion_date": "2028-06", "primary_completion_date": "2027-06", "last_updated": "2026-08-14" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise", "Medical Device" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Transcraneal Direct Current Electric Stimulation", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Transcraneal%20Direct%20Current%20Electric%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07573709", "title": "Functional and Affective Effects of a Brief tDCS Intervention in Fibromyalgia and Chronic Fatigue Syndrome", "status": "TERMINATED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-01-01", "completion_date": "2025-05-30", "primary_completion_date": "2025-05-01", "last_updated": "2026-05-07" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Transcranial Direct Current Electric Stimulation", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Transcranial%20Direct%20Current%20Electric%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07573709", "title": "Functional and Affective Effects of a Brief tDCS Intervention in Fibromyalgia and Chronic Fatigue Syndrome", "status": "TERMINATED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-01-01", "completion_date": "2025-05-30", "primary_completion_date": "2025-05-01", "last_updated": "2026-05-07" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Transcranial Direct Current Stimulation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07709234, NCT06074848", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Transcranial%20Direct%20Current%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07709234", "title": "Transcranial Direct Current Stimulation for Long COVID Brain Fog and Fatigue", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-09-15", "completion_date": "2028-03-01", "primary_completion_date": "2027-12-22", "last_updated": "2026-07-22" }, { "nct_id": "NCT06074848", "title": "tDCS in the Management of Post-COVID Disorders", "status": "UNKNOWN", "phase": "PHASE2", "size_category": "Small (<50 participants)", "start_date": "2023-08-25", "completion_date": "2024-09-28", "primary_completion_date": "2024-07-01", "last_updated": "2024-04-24" } ], "total_mentions": 2, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA", "PHASE2" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Transcranial Direct Current Therapy", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05780450", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Transcranial%20Direct%20Current%20Therapy", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05780450", "title": "Effectiveness of Transcranial Direct Current in Patients With Persistent COVID-19 With Headaches and Chronic Pain.", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-04-01", "completion_date": "2023-07", "primary_completion_date": "2023-07", "last_updated": "2023-06-13" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Transcutaneous Electrical Vagal Neurostimulation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05918965", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Transcutaneous%20Electrical%20Vagal%20Neurostimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05918965", "title": "Vagus Stimulation in Female Long COVID Patients.", "status": "UNKNOWN", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-03-22", "completion_date": "2025-03-01", "primary_completion_date": "2025-03-01", "last_updated": "2023-06-26" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Transcutaneous Non-Invasive Vagus Nerve Stimulation", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Transcutaneous%20Non-Invasive%20Vagus%20Nerve%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05608629", "title": "Vagus Nerve Stimulation as Treatment for Long Covid", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-06-06", "completion_date": "2022-12-05", "primary_completion_date": "2022-12-05", "last_updated": "2024-01-08" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Transcutaneous Vagus Nerve Stimulation", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06968104", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Transcutaneous%20Vagus%20Nerve%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06968104", "title": "Vagus Nerve Stimulation to the Ear to Improve Symptoms in Post-COVID-19 and ME/CFS", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2025-07-18", "completion_date": "2026-10", "primary_completion_date": "2026-10", "last_updated": "2025-08-08" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Transcutaneous Vagus Nerve Stimulator", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06585254", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Transcutaneous%20Vagus%20Nerve%20Stimulator", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06585254", "title": "tVNS in Long COVID-19", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-11-01", "completion_date": "2027-02-01", "primary_completion_date": "2026-12-31", "last_updated": "2026-08-03" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Transfer Package", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06095297, NCT07523113", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Transfer%20Package", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06095297", "title": "Long COVID Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-04-25", "completion_date": "2027-12", "primary_completion_date": "2026-12", "last_updated": "2026-04-13" }, { "nct_id": "NCT07523113", "title": "ME/CFS Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-06-23", "completion_date": "2028-06", "primary_completion_date": "2027-06", "last_updated": "2026-08-14" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Treadmill Ergometer", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Treadmill%20Ergometer", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07651371", "title": "Effects of a Physical Rehabilitation Program on Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2021-01-05", "completion_date": "2024-12-15", "primary_completion_date": "2023-12-15", "last_updated": "2026-06-16" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Treatment A: Treatment By A Homeopath Prescribing A Specific Homeopathic Remedy For Long Covid", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07694232", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Treatment%20A:%20Treatment%20By%20A%20Homeopath%20Prescribing%20A%20Specific%20Homeopathic%20Remedy%20For%20Long%20Covid", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07694232", "title": "A Pilot Randomized Controlled Trial of Homeopathic Treatment for Long COVID", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2026-07-15", "completion_date": "2028-12-01", "primary_completion_date": "2028-07-01", "last_updated": "2026-07-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Treatment As Usual", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06928480, NCT04593225", "Clinical Notes": "Investigational for listed conditions. 3 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Treatment%20As%20Usual", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06928480", "title": "Effectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-1", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-05-01", "completion_date": "2026-12-31", "primary_completion_date": "2026-12-31", "last_updated": "2025-05-22" }, { "nct_id": "NCT05793736", "title": "Prevention of Long Covid Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-02-02", "completion_date": "2023-10-30", "primary_completion_date": "2023-10-30", "last_updated": "2024-05-13" }, { "nct_id": "NCT04593225", "title": "Effectiveness of VIRTUAL SFCAMINA STUDY", "status": "UNKNOWN", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2020-04-21", "completion_date": "2022-01-21", "primary_completion_date": "2021-12-21", "last_updated": "2021-12-30" } ], "total_mentions": 3, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "Medium (50-199 participants)", "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Triflow", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05813873", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Triflow", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05813873", "title": "The Use of Incentive Spirometry in Adult Patients Hospitalised in a Rehabilitation Center With Long-covid Syndrome", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-12-21", "completion_date": "2026-12-31", "primary_completion_date": "2025-12-23", "last_updated": "2025-08-14" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Trigeminal Nerve Stimulation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05855369", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Trigeminal%20Nerve%20Stimulation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05855369", "title": "Study of Chemosensory Enhancement Through Neuromodulation Training (SCENT for Long COVID)", "status": "RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2023-10-02", "completion_date": "2028-05-31", "primary_completion_date": "2028-05-31", "last_updated": "2026-04-02" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Truvaga Electrical Vagus Nerve Stimulator", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Industry", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Truvaga%20Electrical%20Vagus%20Nerve%20Stimulator", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07190105", "title": "Vagal Approaches on Long COVID-19", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2025-10-27", "completion_date": "2025-12-11", "primary_completion_date": "2025-12-11", "last_updated": "2026-01-07" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Industry" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Tvns + Slow-Paced Breathing", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06996314", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Tvns%20+%20Slow-Paced%20Breathing", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06996314", "title": "Effects of Auricular Vagus Nerve Stimulation Combined With Slow-paced Breathing on Individuals With Postural Orthostatic Tachycardia Syndrom", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-09-01", "completion_date": "2028-08-31", "primary_completion_date": "2028-03-01", "last_updated": "2025-06-04" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Tvns Without Breathing Training", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06996314", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Tvns%20Without%20Breathing%20Training", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06996314", "title": "Effects of Auricular Vagus Nerve Stimulation Combined With Slow-paced Breathing on Individuals With Postural Orthostatic Tachycardia Syndrom", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-09-01", "completion_date": "2028-08-31", "primary_completion_date": "2028-03-01", "last_updated": "2025-06-04" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Two-Day Cardiopulmonary Exercise Test", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Two-Day%20Cardiopulmonary%20Exercise%20Test", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04026425", "title": "Analysis of Post-exertional Malaise Using a Two-day CPET in People With ME/CFS", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2018-08-01", "completion_date": "2023-03-31", "primary_completion_date": "2022-03-15", "last_updated": "2023-07-07" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Uc-Mscs", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Uc-Mscs", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05719012", "title": "Efficacy and Safety of Umbilical Cord Mesenchymal Stem Cells in the Treatment of Long COVID-19", "status": "WITHDRAWN", "phase": "PHASE2", "size_category": null, "start_date": "2023-04-01", "completion_date": "2024-03-30", "primary_completion_date": "2023-12-01", "last_updated": "2023-11-21" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [] }, { "Therapeutic Agent": "Umbilical Cord Mesenchymal Stem Cell", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06492798", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Umbilical%20Cord%20Mesenchymal%20Stem%20Cell", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06492798", "title": "Effectiveness and Safety of Mesenchymal Stem Cell Therapy in Long COVID Patients", "status": "UNKNOWN", "phase": "PHASE1", "size_category": "Medium (50-199 participants)", "start_date": "2023-09-01", "completion_date": "2026-08-31", "primary_completion_date": "2025-07-01", "last_updated": "2024-07-09" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Unfractionated Heparin", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Unfractionated%20Heparin", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05204550", "title": "Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Large (200-999 participants)", "start_date": "2023-01-30", "completion_date": "2026-04-01", "primary_completion_date": "2024-12-09", "last_updated": "2026-05-05" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Unified Protocol For The Transdiagnostic Treatment Of Emotional Disorders", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06928480", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Unified%20Protocol%20For%20The%20Transdiagnostic%20Treatment%20Of%20Emotional%20Disorders", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06928480", "title": "Effectiveness and Acceptability of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in People With Long COVID-1", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-05-01", "completion_date": "2026-12-31", "primary_completion_date": "2026-12-31", "last_updated": "2025-05-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Upadacitinib", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Repurposed Drug, Sponsor Type: Other", "Evidence Level": "Moderate", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06928272", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Upadacitinib", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06928272", "title": "Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study", "status": "RECRUITING", "phase": "PHASE3", "size_category": "Large (200-999 participants)", "start_date": "2025-09-10", "completion_date": "2027-12", "primary_completion_date": "2026-12", "last_updated": "2026-10-06" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Repurposed Drug", "Sponsor Type: Other" ], "trial_types": [ "PHASE3" ], "trial_sizes": [ "Large (200-999 participants)" ] }, { "Therapeutic Agent": "Valacyclovir", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07597902", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Valacyclovir", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07597902", "title": "SARS-CoV-2 and Herpesvirus Inhibition for Ending Long COVID Dysfunction", "status": "NOT_YET_RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2026-06-01", "completion_date": "2028-06-30", "primary_completion_date": "2028-06-30", "last_updated": "2026-05-19" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Valacyclovir Celecoxib Dose 1", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Valacyclovir%20Celecoxib%20Dose%201", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06316843", "title": "Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2023-10-15", "completion_date": "2024-10-31", "primary_completion_date": "2024-10-31", "last_updated": "2025-01-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Valacyclovir Celecoxib Dose 2", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Valacyclovir%20Celecoxib%20Dose%202", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06316843", "title": "Valacyclovir Plus Celecoxib for Post-Acute Sequelae of SARS-CoV-2", "status": "COMPLETED", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2023-10-15", "completion_date": "2024-10-31", "primary_completion_date": "2024-10-31", "last_updated": "2025-01-22" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Valganciclovir", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Valganciclovir", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT00478465", "title": "Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Eps", "status": "COMPLETED", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2007-05", "completion_date": "2007-08", "primary_completion_date": "2007-08", "last_updated": "2022-05-27" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Vaxtherapy Protocol", "Primary Conditions": [ "PACVS" ], "Proposed Mechanism": "Not specified", "Evidence Level": "Anecdotal", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 0 associated trial(s) and 1 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Vaxtherapy%20Protocol", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [ { "title": "Four-stage protocol anchored in pathophysiology; stage 4 (mitochondrial supplements) directly overlaps with VitalScan4PACVS protocol", "pub_date": "", "excerpt": "Four-stage protocol anchored in pathophysiology; stage 4 (mitochondrial supplements) directly overlaps with VitalScan4PACVS protocol", "source": "PACVS Evidence Map" } ], "trials": [], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Unknown / General" ], "trial_types": [], "trial_sizes": [] }, { "Therapeutic Agent": "Vericiguat Oral Tablet", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05697640", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Vericiguat%20Oral%20Tablet", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05697640", "title": "Study to Investigate Improvement in Physical Function in SF-36 With Vericiguat Compared With Placebo in Participants With Post-COVID-19 Synd", "status": "ACTIVE_NOT_RECRUITING", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2023-06-22", "completion_date": "2026-12-31", "primary_completion_date": "2026-04-01", "last_updated": "2026-01-28" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "Vestibular Rehabilitation Program", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06534164", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Vestibular%20Rehabilitation%20Program", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06534164", "title": "Telerehabilitation of Balance Clinical and Economic Decision Support System", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2025-09-01", "completion_date": "2026-08-31", "primary_completion_date": "2026-06-30", "last_updated": "2025-07-10" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Vielight Neuro Rx Gamma Active Device", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Neurological / Autonomic, Sponsor Type: Industry", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Vielight%20Neuro%20Rx%20Gamma%20Active%20Device", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05857124", "title": "A Study Evaluating the Efficacy of the Vielight Neuro RX Gamma in the Treatment of Post COVID-19 Cognitive Impairment", "status": "COMPLETED", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2023-04-01", "completion_date": "2025-01-16", "primary_completion_date": "2024-09-01", "last_updated": "2025-06-15" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Actual", "Neurological / Autonomic", "Sponsor Type: Industry" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Vimida", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06251518", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Vimida", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06251518", "title": "Investigating the Effectiveness of Vimida", "status": "ACTIVE_NOT_RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-02-13", "completion_date": "2025-12", "primary_completion_date": "2025-09", "last_updated": "2025-06-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Virtual Reality", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06374446", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Virtual%20Reality", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06374446", "title": "Effect of Virtual Reality in Patients With Long Covid-19", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-04-20", "completion_date": "2024-06-30", "primary_completion_date": "2024-06-15", "last_updated": "2024-04-18" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Virtual Reality Combined With Classical Treatment", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06374446", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Virtual%20Reality%20Combined%20With%20Classical%20Treatment", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06374446", "title": "Effect of Virtual Reality in Patients With Long Covid-19", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-04-20", "completion_date": "2024-06-30", "primary_completion_date": "2024-06-15", "last_updated": "2024-04-18" } ], "total_mentions": 1, "types": [ "Medical Device" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Vitamin And Trace Elements", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Vitamin%20And%20Trace%20Elements", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT04751669", "title": "Efficacy of a Dietary Supplementation in Reducing Hospital Admissions for COVID-19. Randomized Clinical Trial", "status": "COMPLETED", "phase": "NA", "size_category": "Large (200-999 participants)", "start_date": "2021-08-09", "completion_date": "2023-10-26", "primary_completion_date": "2023-10-26", "last_updated": "2024-03-25" } ], "total_mentions": 1, "types": [ "Supplement / Nutraceutical" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Large (200-999 participants)", "NA" ] }, { "Therapeutic Agent": "Vitamin D", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Sponsor Type: Other Gov, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Vitamin%20D", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05633472", "title": "The Roles of Vitamin D and Microbiome in Children With Post-acute COVID-19 Syndromes (PACS) and Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-10-18", "completion_date": "2024-08-23", "primary_completion_date": "2024-08-23", "last_updated": "2025-04-17" }, { "nct_id": "NCT05630339", "title": "Magnesium and Vitamin D Combination for Post-COVID Syndrome", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-01-30", "completion_date": "2023-09-01", "primary_completion_date": "2023-05-01", "last_updated": "2023-09-28" } ], "total_mentions": 2, "types": [ "Supplement / Nutraceutical" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Sponsor Type: Other Gov", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Vitamin D3", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Vitamin%20D3", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05356936", "title": "Pilot Study of Vitamin K2 (MK-7) and Vitamin D3 Supplementation and the Effects on PASC Symptomatology and Inflammatory Biomarkers", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-06-01", "completion_date": "2024-08-01", "primary_completion_date": "2024-04-01", "last_updated": "2024-09-27" } ], "total_mentions": 1, "types": [ "Supplement / Nutraceutical" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Vitamin K2", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Vitamin%20K2", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05356936", "title": "Pilot Study of Vitamin K2 (MK-7) and Vitamin D3 Supplementation and the Effects on PASC Symptomatology and Inflammatory Biomarkers", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-06-01", "completion_date": "2024-08-01", "primary_completion_date": "2024-04-01", "last_updated": "2024-09-27" } ], "total_mentions": 1, "types": [ "Supplement / Nutraceutical" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Vix001", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05947617", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Vix001", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05947617", "title": "Safety, Efficacy, and Dosing of VIX001 in Patients With Neurological Symptoms of Post Acute COVID-19 Syndrome (PACS).", "status": "UNKNOWN", "phase": "PHASE1", "size_category": "Small (<50 participants)", "start_date": "2023-10-01", "completion_date": "2025-09-01", "primary_completion_date": "2025-04-01", "last_updated": "2023-07-17" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "Vocational Rehabilitation", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Neurological / Autonomic, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06095297", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Vocational%20Rehabilitation", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06095297", "title": "Long COVID Brain Fog: Cognitive Rehabilitation Trial", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2024-04-25", "completion_date": "2027-12", "primary_completion_date": "2026-12", "last_updated": "2026-04-13" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Estimated", "Neurological / Autonomic", "Sponsor Type: Other" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Vsl#3®", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05874089", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Vsl#3®", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05874089", "title": "VSL#3® vs Placebo in the Treatment of Fatigue and Other Symptoms in Long Covid (DELong#3)", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-11-03", "completion_date": "2023-11-03", "primary_completion_date": "2023-09-03", "last_updated": "2023-05-24" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Waiting Group", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Waiting%20Group", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05630378", "title": "Evaluation of an Integrative Medicine Outpatient Clinical Setting for Post-COVID-19 Patients", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2022-05-11", "completion_date": "2023-06-30", "primary_completion_date": "2023-02-01", "last_updated": "2023-12-04" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Waiting List", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05236465", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Waiting%20List", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05236465", "title": "A 3-day Course for CFS/ME", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2022-03-21", "completion_date": "2028-12-01", "primary_completion_date": "2027-01-01", "last_updated": "2025-11-26" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Walking", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06928116", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Walking", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06928116", "title": "Heat thErapy And mobiLity in COVID-19 Survivors", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2025-01-16", "completion_date": "2029-08", "primary_completion_date": "2028-08-31", "last_updated": "2026-09-28" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Water+Ct", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Fed, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06142253", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Water+Ct", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06142253", "title": "Water-based Activity to Enhance Recovery in Long COVID-19", "status": "RECRUITING", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2024-12-01", "completion_date": "2026-12-31", "primary_completion_date": "2026-12-31", "last_updated": "2026-06-18" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Fed", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Wearable Device", "Primary Conditions": [ "Long COVID", "ME/CFS" ], "Proposed Mechanism": "Enrollment: Actual, Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05741112", "Clinical Notes": "Investigational for listed conditions. 2 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Wearable%20Device", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06840873", "title": "Tele-Rehabilitative Exercise Training Program in Nurses With Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-11-02", "completion_date": "2024-11-01", "primary_completion_date": "2024-06-30", "last_updated": "2025-10-07" }, { "nct_id": "NCT05741112", "title": "The Long COVID-19 Wearable Device Study", "status": "RECRUITING", "phase": "NA", "size_category": "Very Large (1000+ participants)", "start_date": "2023-11-16", "completion_date": "2025-12-01", "primary_completion_date": "2025-12-01", "last_updated": "2025-05-11" } ], "total_mentions": 2, "types": [ "Behavioral / Protocol / Exercise", "Medical Device" ], "mechanisms": [ "Enrollment: Actual", "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA", "Very Large (1000+ participants)" ] }, { "Therapeutic Agent": "Web-Based Platform.", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Web-Based%20Platform.", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05422924", "title": "A Web-based Platform to Improve Physical Function, Nutrition, and Mindfulness in Patients With Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2023-08-25", "completion_date": "2025-01-31", "primary_completion_date": "2023-10-31", "last_updated": "2025-03-06" } ], "total_mentions": 1, "types": [ "Behavioral / Protocol / Exercise" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Western Medicine Treatment", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT06095258", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Western%20Medicine%20Treatment", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06095258", "title": "A Practical RCT of TCM in the Treatment of LCOVID and Analysis of Syndrome Types and Medication Characteristics.", "status": "UNKNOWN", "phase": "PHASE2", "size_category": "Medium (50-199 participants)", "start_date": "2023-12-01", "completion_date": "2026-02-28", "primary_completion_date": "2025-11-30", "last_updated": "2023-10-26" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "PHASE2" ], "trial_sizes": [ "Medium (50-199 participants)" ] }, { "Therapeutic Agent": "White Rice Flour", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Industry, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=White%20Rice%20Flour", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05840237", "title": "REGAIN: RCT of Oxaloacetate for Fatigue in Long COVID", "status": "COMPLETED", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2023-06-01", "completion_date": "2025-01-30", "primary_completion_date": "2025-01-30", "last_updated": "2025-02-04" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Industry", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "Whole Body Hyperthermia", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT05931497", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Whole%20Body%20Hyperthermia", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05931497", "title": "Sauna for Long Covid", "status": "RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-08-01", "completion_date": "2026-12-01", "primary_completion_date": "2026-09-30", "last_updated": "2025-11-13" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Whole-Body Electromyostimulation Suit", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT07312357", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Whole-Body%20Electromyostimulation%20Suit", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT07312357", "title": "Whole-Body Electrostimulation for Functional Recovery in Post-COVID Syndrome", "status": "NOT_YET_RECRUITING", "phase": "NA", "size_category": "Small (<50 participants)", "start_date": "2026-03", "completion_date": "2026-12", "primary_completion_date": "2026-09", "last_updated": "2025-12-31" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA", "Small (<50 participants)" ] }, { "Therapeutic Agent": "Xltranplus, Xltran", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Xltranplus,%20Xltran", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT05467904", "title": "Double-Blind Randomized Placebo-Controlled Trial of a Proprietary Full Hemp Flower Formulation for Long COVID", "status": "WITHDRAWN", "phase": "NA", "size_category": null, "start_date": "2024-08", "completion_date": "2025-12", "primary_completion_date": "2025-05", "last_updated": "2025-07-17" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "NA" ] }, { "Therapeutic Agent": "Yan Nian Jiu Zhuan Fa", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "NCT03496961", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=Yan%20Nian%20Jiu%20Zhuan%20Fa", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT03496961", "title": "Yan Nian Jiu Zhuan Fa Improve Chronic Fatigue Syndromes", "status": "UNKNOWN", "phase": "NA", "size_category": "Medium (50-199 participants)", "start_date": "2018-12-01", "completion_date": "2021-12-01", "primary_completion_date": "2021-06-01", "last_updated": "2021-03-17" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "NA" ], "trial_sizes": [ "Medium (50-199 participants)", "NA" ] }, { "Therapeutic Agent": "[11C]Cppc Injection", "Primary Conditions": [ "Long COVID" ], "Proposed Mechanism": "Enrollment: Actual, Sponsor Type: Other, Unknown / General", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=[11C]Cppc%20Injection", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT06223971", "title": "Long COVID-19 [11C]CPPC Study", "status": "COMPLETED", "phase": "EARLY_PHASE1", "size_category": "Small (<50 participants)", "start_date": "2024-08-06", "completion_date": "2026-03-31", "primary_completion_date": "2025-04-30", "last_updated": "2026-04-30" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Actual", "Sponsor Type: Other", "Unknown / General" ], "trial_types": [ "EARLY_PHASE1" ], "trial_sizes": [ "Small (<50 participants)" ] }, { "Therapeutic Agent": "[Zr-89]Oxine-Labeled Leukocytes Pet/Mri", "Primary Conditions": [ "ME/CFS" ], "Proposed Mechanism": "Enrollment: Estimated, Immunomodulatory, Sponsor Type: Other", "Evidence Level": "Preliminary", "Key Studies / References": [ "See linked studies" ], "Ongoing Research": "None currently listed", "Clinical Notes": "Investigational for listed conditions. 1 associated trial(s) and 0 study reference(s) in current data. Review primary sources and consult specialists before use.", "Last Updated": "2026-10-07", "PubChem": "https://pubchem.ncbi.nlm.nih.gov/#query=[Zr-89]Oxine-Labeled%20Leukocytes%20Pet/Mri", "Safety": "Limited specific safety data in these populations. Review full prescribing information and consult specialist. Many agents used off-label or investigational.", "Dosing": "See linked studies/trials for reported doses and durations; typical protocols vary widely.", "aliases": [], "studies": [], "trials": [ { "nct_id": "NCT03807973", "title": "Tracking Peripheral Immune Cell Infiltration of the Brain in Central Inflammatory Disorders Using [Zr-89]Oxinate-4-labeled Leukocytes.", "status": "SUSPENDED", "phase": "PHASE1", "size_category": "Medium (50-199 participants)", "start_date": "2021-10-05", "completion_date": "2028-10", "primary_completion_date": "2028-10", "last_updated": "2026-06-02" } ], "total_mentions": 1, "types": [ "Other / Unclassified" ], "mechanisms": [ "Enrollment: Estimated", "Immunomodulatory", "Sponsor Type: Other" ], "trial_types": [ "PHASE1" ], "trial_sizes": [ "Medium (50-199 participants)" ] } ] }